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Development And Validation Of A Novel E2f1 Mouse Model To Evaluate The CellType Specific Contribution Of E2f1 To Age-Associated Neurodegeneration
Abstract
Increased expression of cell cycle proteins, including the transcription factor E2F1, is observed in a variety
of aging-associated neurodegenerative diseases. E2F1 modulates the G1-S phase transition of the cell
cycle, apoptosis, and inflammation, and its upregulation in neurodegenerative diseases may contribute to
pathology by promoting all of these processes, leading to neuronal dysfunction/death. Thus, reducing
E2F1 levels in neurons may mitigate the progression of neurodegeneration. However, E2F1tm1/tm1 mice
exhibit central nervous system (CNS) pathology, with contradictory studies suggesting that E2F1 loss
impairs or improves memory as measured by novel object recognition assays. Given that neuronal and
synaptic function are affected by inherent neuronal processes and that neuroimmune interactions are
regulated by CNS-resident innate immune cells, specifically microglia, we generated a conditional floxed
E2F1 mouse (E2F1fx/fx) to study cell-type specific roles of E2F1. We then developed a novel constitutive
E2F1 knockout (E2F1-/-) mouse to 1) reevaluate E2F1-mediated CNS pathology and neurocognitive
behaviors to confirm the presence of CNS-associated phenotypes in our E2F1-/- mouse and 2)
characterize inflammatory mediator release from E2F1-/- macrophages in response to differing doses of
lipopolysaccharide (LPS) with and without priming to acquire a better understanding of E2F1’s role in
inflammation. We found that E2F1 loss in E2F1-/- mice did not cause some of the reported E2F1tm1/
tm1-associated CNS and peripheral pathologies, while discovering a novel E2F1-/- related phenotype:
megakaryocytic hyperplasia. We also found that E2F1-/- macrophages exhibited anti-inflammatory
(reduced IL-6 and TNF-alpha release) and pro-inflammatory (increased CCL-2 release) responses
dependent on LPS dose and priming condition. These results suggest that aspects of mouse model
design may account for altered neuron/synapse health observed in E2F1tm1/tm1 mice which may not be
dependent on E2F1 loss alone, and that E2F1 has beneficial and detrimental functions in inflammation
depending on its roles in initiation and resolution of inflammation. Further exploration of E2F1’s role in
neuronal health and neuroinflammatory response should provide insight into not only the cell-type
specific therapeutic development for neurodegenerative diseases but also the novel roles of E2F1 in
innate immune memory.
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ABSTRACT

DEVELOPMENT AND VALIDATION OF A NOVEL E2F1 MOUSE MODEL TO
EVALUATE THE CELL-TYPE SPECIFIC CONTRIBUTION OF E2F1 TO AGEASSOCIATED NEURODEGENERATION
Claire Meurice
Kelly L. Jordan-Sciutto

Increased expression of cell cycle proteins, including the transcription factor
E2F1, is observed in a variety of aging-associated neurodegenerative diseases.
E2F1 modulates the G1-S phase transition of the cell cycle, apoptosis, and
inflammation, and its upregulation in neurodegenerative diseases may contribute
to pathology by promoting all of these processes, leading to neuronal
dysfunction/death. Thus, reducing E2F1 levels in neurons may mitigate the
progression of neurodegeneration. However, E2F1tm1/tm1 mice exhibit central
nervous system (CNS) pathology, with contradictory studies suggesting that
E2F1 loss impairs or improves memory as measured by novel object recognition
assays. Given that neuronal and synaptic function are affected by inherent
neuronal processes and that neuroimmune interactions are regulated by CNSresident innate immune cells, specifically microglia, we generated a conditional
floxed E2F1 mouse (E2F1fx/fx) to study cell-type specific roles of E2F1. We then
developed a novel constitutive E2F1 knockout (E2F1-/-) mouse to 1) reevaluate
E2F1-mediated CNS pathology and neurocognitive behaviors to confirm the
v

presence of CNS-associated phenotypes in our E2F1-/- mouse and 2)
characterize inflammatory mediator release from E2F1-/- macrophages in
response to differing doses of lipopolysaccharide (LPS) with and without priming
to acquire a better understanding of E2F1’s role in inflammation. We found that
E2F1 loss in E2F1-/- mice did not cause some of the reported E2F1tm1/tm1associated CNS and peripheral pathologies, while discovering a novel E2F1-/related phenotype: megakaryocytic hyperplasia. We also found that E2F1 -/macrophages exhibited anti-inflammatory (reduced IL-6 and TNF- release) and
pro-inflammatory (increased CCL-2 release) responses dependent on LPS dose
and priming condition. These results suggest that aspects of mouse model
design may account for altered neuron/synapse health observed in E2F1tm1/tm1
mice which may not be dependent on E2F1 loss alone, and that E2F1 has
beneficial and detrimental functions in inflammation depending on its roles in
initiation and resolution of inflammation. Further exploration of E2F1’s role in
neuronal health and neuroinflammatory response should provide insight into not
only the cell-type specific therapeutic development for neurodegenerative
diseases but also the novel roles of E2F1 in innate immune memory.
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CHAPTER 1: INTRODUCTION

Cells contributing to neuroinflammation and their roles in homeostasis and
disease in the central nervous system

Inflammation is mediated by reactive oxygen species (ROS) and second
messengers, such as cytokines and chemokines, produced by specialized cells
in response to pathogens, stimuli, and injury. Inflammation in the central nervous
system (CNS) is termed neuroinflammation, and microglia and astrocytes are the
primary regulators of immune responses in the CNS; however,
neuroinflammation can also be induced or exacerbated by endothelial cells and
peripherally derived immune cells, such as perivascular macrophages, choroid
plexus macrophages, and cerebrospinal fluid (CSF)-resident T cells [85, 115,
236]. The extent of neuroinflammation depends on the context, duration, and
strength of insult. There are two sides to neuroinflammation. In certain contexts,
such as neurodevelopment, synaptic plasticity, tissue repair or neuroprotection,
neuroinflammation has positive outcomes [76, 288, 375], whereas in other
contexts, such as traumatic brain injury, anxiety, depression, cognitive
impairment/reduced synaptic plasticity and neuronal damage,
neuroinflammation-associated outcomes may have a negative impact [82, 199].
Chronic inflammation has been linked to the development of cognitive
impairment and neurodegenerative diseases [82]. Thus, a thorough
1

understanding of the regulation of neuroinflammation and the response of
resident CNS cells to neuroinflammation is critical for the treatment of
neurodegenerative diseases.

Microglia: Within the brain, microglia are considered to be the central players in
neuroimmune interactions [267, 289]. Microglia, which participate in
macrophage-like activities within the CNS [268], inhabit CNS white and gray
matter and comprise between 0.5%-16.6% of the entire CNS cell population
depending on the brain region [217]. Early in embryogenesis, microglia develop
from the embryonic yolk sac myeloid precursor cells and migrate to the CNS
around embryonic day 8.5 [109]. Once established, microglia have limited
turnover from bone marrow-derived myeloid cells [4, 109], although recent
evidence suggests that microglia turnover is dependent on a different progenitor
source located within the CNS [90]. Microglia are the first responders during
innate immune response to injury or infection and play important housekeeping
roles including phagocytosis-driven elimination of debris and harmful factors,
regulation of synapse number, and synaptic plasticity [230].

Albeit its negative connotation, neuroinflammation can be beneficial and
necessary. For example, cytokine release from microglia allows for the
necessary coordinated initiation and resolution of immune response to noxious
stimuli by limiting nerve damage, providing trophic support, spurring synaptic
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pruning of nonfunctional synapses, and suppressing further neuroinflammation
with the aim to protect nerve tissue [16, 289, 294]. Further, transient immune
activation can promote immune conditioning. In these cases, transient immune
activation before injury or infection reduced inflammatory cytokine secretion in
response to insult and promoted neuroprotection [346].

While microglial activity is required to maintain a well-functioning neuronal
network, microglia are also implicated in amplifying neurodegenerative processes
due to unremitting neuroinflammation and/or frequent exposure to misfolded
proteins or neuronal debris that exist in aging or neurodegenerative diseases
[253, 350]. Microglia can exhibit stronger responses to proinflammatory stimuli
during aging and neurodegenerative diseases than in a young or healthy brain, a
process referred to as microglial priming [79, 350]. Heightened response to
proinflammatory stimuli is not restricted to CNS-derived neuroinflammation, as
primed microglia exhibit an augmented response to peripheral inflammatory
stimuli as well [346, 350]. Primed microglia exhibit enhanced or prolonged
response to homeostatic disturbances, which are recognized by altered
morphology (enlarged soma or shorter dendritic arbors), increased expression of
surface markers (MHC-II, Axl, Lgals3, and CD11c), and increased release of
proinflammatory cytokines (TNF-, IL-1, and IL-6), as well as increased release
of anti-inflammatory cytokines (IL-10 and TGF-) [135, 235, 253]. Experiments
utilizing LPS-induced proinflammatory activity in aged brains indicate that IL-10,
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TGF-, and IL-4 are unable to suppress proinflammatory cytokine activity,
suggesting that priming renders microglia less sensitive to anti-inflammatory
regulation. In that context, microglial priming is expected to lead to increased
neuronal death and dysfunction, accelerating the progression of
neurodegeneration [350].

Astrocytes: Similar to microglia, astrocytes can have beneficial as well as
unfavorable roles in neuroinflammation [60]. Astrocytes are the most abundant
glial cell type in the CNS and are necessary for the maintenance of CNS
homeostasis. Astrocytes support synapse formation and plasticity by providing
metabolites and growth factors to neurons and by regulating extracellular
glutamate concentrations and ion balance [252, 299]. Depending on the timing
and context, astrocyte activity can promote immunosuppression and tissue repair
or exacerbate inflammatory response leading to tissue damage. CNS injury leads
to astrogliosis, and glial scar formation which is aimed to confine inflammatory
and neurotoxic mediators to the injury site. Upregulation of cytoskeletal glial
fibrillary acidic protein (GFAP), commonly used for the in vivo and in vitro
detection of astrocytes, is a typical hallmark of a wide variety of CNS pathologies
[273]. The contribution of astrocytes to pathological neuroinflammation is
mediated primarily through the release of toxic mediators and reduced trophic
support. In response to microglial activation, astrocytes increase proinflammatory
cytokine and chemokine production, further amplifying and sustaining
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inflammation. Additionally, increased release of vascular endothelial growth
factor (VEGF) from activated astrocytes leads to pathological vascular
permeability, compromising the selectively permeable blood brain barrier that
normally restricts peripheral immune cell infiltration [160, 188, 289].
Blood-Brain Barrier: In the healthy CNS, the blood brain barrier, blood-meningeal
barrier, and parenchymal microenvironment limit macrophage- and T cell-driven
neuroinflammation. In addition to other mechanisms, these limitations mediated
by these barriers underlie the immune-privileged status of the CNS — antigens,
i.e., foreign substances that elicit an immune response, can evade immunological
recognition in the brain parenchyma. However, immune privilege of the CNS is
not an absolute; CNS immune privilege is relative to other organ antigen-induced
immune response. In addition, immune privilege does not extend to the
ventricles, choroid plexus, meninges, and circumventricular organs, where
immune reactivity is similar to that observed in the periphery [105]. CSF, choroid
plexus, meninges, and circumventricular organs can house peripheral immune
cells that are able to release cytokines which can cross the blood-brain barrier,
when present, to alter glial or epithelial cell function [48]. Although a minimal
number of T cells reside in the brain, they can also migrate to the CSF, affecting
neuroinflammation in the CNS by interacting with glial or epithelial cells lining the
ventricles and choroid plexus [229]. Meningeal dendritic cells and perivascular
and choroid plexus macrophages release soluble chemical messengers,
including cytokines and chemokines, that exert effects in the CNS in response to
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peripheral stimuli [37]. However, once inflammation is established, the immune
privilege of the CNS is undermined, which can occur due to the breakdown of the
blood-brain barrier, with consequent attenuation of the immunosuppressive
effects of the CNS microenvironment, increased local immunostimulatory
effectsof proinflammatory cytokines and chemokines, and the facilitation of
immune cell infiltration [48, 105].

A well-functioning immune system is necessary to combat infection and eliminate
pathogens, and neuroimmune signaling contributes to the organization and
functioning of the CNS. However, neurodegenerative diseases and aging are
associated with aberrant microglial reactivity as well as the overproduction or
exaggerated release of cytokines [334]. Therefore, it is important to evaluate how
alterations in signaling pathways which can be beneficial in limiting chronic
neuroinflammation may impact CNS homeostasis.

Calcium hypothesis of neurodegeneration, select mechanisms involved in
calcium regulation, and barriers to drug development

The calcium hypothesis of neurodegeneration states that prolonged alterations in
molecular mechanisms regulating calcium homeostasis outside of the normal
modulation of cellular/intracellular calcium concentrations during the
physiological depolarization/repolarization cycle in healthy neurons contribute to
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and is necessary for the development of neuronal dysfunction characteristic of
neurodegenerative diseases and aging-associated memory impairment [352].
Compromised calcium homeostasis occurs through the hyperactivation of certain
membrane receptors; metabolic, oxidative, and proteotoxic stress; alteration of
subcellular components that regulate calcium homeostasis such as ion channels,
buffers, adenosine triphosphate-dependent ion pumps; and/or other regulatory
mechanisms. The outcome of failure to maintain homeostatic calcium
concentrations include the induction of pathological processes that are
characteristic of neurodegenerative diseases, such as the accumulation of
amyloid beta peptide (A) and phospho-tau, dendrite pruning, synaptic loss,
mitochondrial dysfunction, oxidative stress, inflammation, and cell death, some of
which also occur with aging [331, 341, 349, 352].

Intracellular calcium concentrations rise in response to a wide range of stimuli,
and the amplitude and coordination between adjacent cells (neurons and glia)
determine whether calcium influx will be beneficial or detrimental in the context of
learning and memory [36]. The excitatory neurotransmitter glutamate can
activate ionotropic and glutamatergic metabotropic receptors (mGluRs), leading
to increased intracellular calcium levels. Calcium signaling mediated by
glutamate occurs primarily through the activation of ionotropic membrane
receptors, namely, N-methyl-D-aspartic acid (NMDA), B-amino-3-hydroxy-5methylsoxazole (AMPA), and kainate receptors [331, 341]. NMDA receptors
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(NMDARs), which are composed of NR1 and NR2A-D subunits, are pivotal in the
regulation of learning and memory [81, 331]. Following AMPA receptor activation
and consequential membrane depolarization, the voltage-dependent magnesium
block is removed, which allows subsequent calcium influx through the NMDA
channel that serves as a trigger for synaptic plasticity mediated by calmodulindependent kinase-II. Uncoordinated or insufficient calcium influx through
NMDARs can inhibit long-term potentiation (LTP) or promote long-term
depression mediated by calcineurin, both of which impair learning and memory
[341, 349]. While most studies on learning and memory focus on NMDARmediated LTP and promotion of long-term depression, there are important
calcium regulating mGluRs as well. Of the three identified mGluRs, the most
relevant to this discussion are group I mGluRs, i.e., mGluR1 and mGluR5.
mGluR1 and mGluR5 are coupled to Gq proteins that when stimulated result in
calcium influx through TRP channels and/or calcium release from ER stores via
the activation of phospholipase C and inositol-1,4,5-triphosphate, which are
critical to LTP generation in hippocampal interneurons. Both ionotropic receptors
and group I mGluRs contribute to synaptic plasticity; inhibition of receptor
activation and extracellular or intracellular calcium influx impair LTP and the
associated protein production and neuritogenesis, all of which are necessary for
memory consolidation [323, 331].

8

While the inhibition of calcium influx can impair learning and memory, excess
calcium influx can be just as or more detrimental to neuronal function.
Excitotoxicity is defined by excessive and prolonged calcium influx through
glutamate-mediated NMDAR activation which impairs learning and memory
through the activation of catabolic enzymes that trigger a cascade of events,
which culminate in the generation of ROS and cellular toxicity [97, 234]. This can
occur through primary or secondary activation of NMDA receptors. Primary
activation of NMDA receptors in the absence of glutamate can occur through
their interaction with A [318]; however secondary activation is more common.
Secondary activation of NMDA receptors can occur in a mechanism similar to
that necessary for synaptic plasticity. Activation of AMPA, kainate, and group I
mGluRs can contribute to altered membrane potential, which relieves the
magnesium block and facilitates NMDAR-mediated calcium influx [29, 59, 93,
175, 341, 349] . An increase in intracellular calcium activates calcium-dependent
enzymes and protein kinases and potentially leads to the generation of
neurotoxic ROS [331].

Once calcium enters the cell, it is sensed by an abundance of calcium-binding
proteins, most of which contain helix-loop-helix motifs termed EF-hands. The
proteins containing EF-hands that are involved in sensing and transmitting
calcium signals in neurons include S100 proteins, neuronal calcium sensors, and
calmyrins. Most pertinent to this discussion are calcium signals transmitted by
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calmodulin and calpains [349]. During glutamate-induced hyperactivation of
NMDARs, excess calcium influx stimulates neuronal nitric oxide synthase (NOS)
activity and translocation to the cell membrane through its interaction with
postsynaptic density protein-95 (PSD-95), a scaffolding protein that binds to
NMDARs [152]. The activation of NOS is followed by the production of nitric
oxide which reacts with superoxide anion to form peroxynitrite, resulting in
neuronal damage through lipid peroxidation, direct DNA damage, and
mitochondrial dysfunction [226, 262–264, 283, 341]. Calmodulin-dependent
kinase-II, while beneficial for synaptic strengthening, also contributes to signaling
mechanisms that lead to excitotoxicity in cortical neurons, although the exact
mechanisms are not clear [67].

Calpains, calcium-dependent proteases, have beneficial as well as detrimental
roles in mediating excitotoxicity. LTP is blocked by calpain inhibitors and the
disruption of calpain-1 or calpain-2 function, suggesting that calpains may be
necessary for learning and memory [6, 75, 238, 303]. Calpains can (1) contribute
to delayed, irreversible excitotoxic calcium elevation by cleaving Na/Ca
exchanger isoform 3, thereby impairing calcium extrusion from the cell [22], (2)
cleave AMPARs, NMDARs, and the important synaptic scaffold protein PSD-95,
thereby reducing the number of functional synapses [30, 83, 157, 200, 353], and
(3) negatively regulate caspase-3/9 activation, resulting in caspase-independent
neuronal death [32, 177, 341]. Calpains also cleave select apoptosis-regulatory
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proteins, including apoptotic protease-activating factor-1 (APAF-1), BAX, BID,
E2F1, and p53 [17, 51, 57, 106, 108, 208, 269, 341, 377]. Some calpaindependent cleavage products gain neurotoxic function, such as that occurs with
the p35 cleavage product p25 and the 18-kDa fragment of BAX [106, 173, 250],
whereas other calpain-dependent cleavage events serve an anti-apoptotic role,
such as the calpain-mediated degradation of p53 and APAF-1 [341]. However,
the effect of the stable calpain cleavage product of E2F1, a major apoptosis
mediator, on neuronal health remains unknown [377]. Altogether, this discussion
of dual beneficial and negative roles of glutamate receptors and calciumdependent enzymes highlights the challenges involved in identifying druggable
targets that can be utilized to inhibit excitotoxicity-mediated damage without
impairing synaptic health.

In vitro, excitotoxicity often results in either irreversible disruption of ion
homeostasis and cellular integrity leading to necrotic cell death or in delayed
calcium deregulation and apoptotic cell death [9, 177, 330]. However, extrinsic
factors can improve the chances of neuronal survival [8]. Surviving neurons may
still suffer long-term consequences, including DNA damage or cell cycle
reactivation, as a result of the excitotoxic insult [52, 210, 247], Since neurons are
postmitotic, the necessity of cell cycle proteins in neurons after differentiation has
been an enduring, albeit unanswered, question. However, it is clear that some of
these proteins that are typically ascribed cell cycle roles are necessary for CNS
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organization and synapse health [131]. Therefore, targeting redundant cell cycle
proteins to prevent aberrant cell cycle reentry has been explored as an intriguing
strategy to prevent and/or alleviate neuronal loss or dysfunction in
neurodegenerative diseases characterized by mild excitotoxicity and cell cycle
reactivation [332]. Since cell cycle proteins are also increased in many
neurodegenerative diseases, the next sections will focus on the cell cycle and the
known roles of select cell cycle proteins in neurons.

Regulation of cell cycle proteins

Phases of the cell cycle: Numerous mechanisms are in place to regulate the cell
cycle to ensure proper cell division. Cell division requires two consecutive
processes, DNA replication and segregation of duplicate chromosomes into
separate daughter cells. Before either of these processes can occur, the cell
must upregulate protein production required for DNA synthesis during the G1
(growth) phase before proceeding to synthesize DNA in the S phase. Following
DNA synthesis, the cell synthesizes proteins responsible for cell division in the
G2 (preparation) phase before entering mitosis (M phase) during which duplicate
DNA separates into two sets and divides, forming two daughter cells. Cells that
have exited the cell cycle, such as neurons and other differentiated cells, remain
in G0. Neurons that have entered G0 can reenter the cell cycle at G1; however,
most neurons in the mammalian CNS stay in an extended G0 phase [100, 101].

12

Regulation of cell cycle transition: Transitions between different phases of the
cell cycle are regulated by a combination of cyclins that bind to specific cyclindependent kinases (CDKs) and bypassing of the checkpoint inhibition mediated
by CDKs. At the beginning of G1, cells synthesize cyclin D, which activates
CDK4/6 upon binding. Cyclin D:CDK4/6 phosphorylates retinoblastoma protein
(pRb), causing the disassociation of histone deacetylases and derepression of
the cyclin E gene. Binding of cyclin E to CDK2 results in further phosphorylation
of pRb and the subsequent release of the transcription factor E2F1, which is
necessary for the production of proteins required for DNA replication, such as
DNA polymerase-, dihydrofolate reductase, and proliferating cell nuclear
antigen (PCNA) [98, 194]. G1 phase includes two checkpoints, i.e., defectdetecting points, which, when triggered, prevent cell cycle progression by
inhibiting phase-specific CDKs. The first checkpoint the cell must bypass occurs
early in G1, when the cell checks for the availability of growth factors [98].
Transforming growth factor  (TGF-) is one of these growth factors that, when
sufficiently available, induces the expression and activation of some CDK
inhibitors (CKI), the Ink family member p15Ink4b and the Kip family member
p27Kip1, which inhibit CDK4/6 and CDK2 kinase activity and subsequently prevent
the phosphorylation of pRb, the release of E2F1, and the progression to the S
phase [98, 270]. The second checkpoint occurs late in G1, when the cell
establishes whether it is receiving enough nutrients or has reached the proper
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size to start DNA replication, which is largely regulated by mTOR [98]. After G1
checkpoints are bypassed, progression into the S phase and DNA synthesis are
driven by CDK2 binding by cyclin A instead of cyclin E [243]. A third checkpoint
within the S phase serves to check the presence of DNA damage, which is either
due to an insult occurring prior to the S phase or that is produced during DNA
synthesis [284]. In the presence of DNA damage, the tumor suppressor gene p53
is activated, which prevents cell cycle progression by the upregulation of the CKI
p21Cip1, a Cip family member, which can inhibit DNA synthesis by binding to
PCNA until DNA repair is completed. In the case of irreparable damage,
apoptosis is induced to prevent the transmission of damaged DNA to daughter
cells [73, 100]. During the late S phase, p21Cip1 can also inhibit the formation of
cyclin A:CDK1 complex, which is required to activate late replication origins,
thereby inhibiting DNA synthesis in the late S phase. If no defect is detected, the
formation of cyclin A:CDK1 complex, which has started in the late S phase,
continues into the late G2 phase, where chromosome condensation begins [117,
162]. Regulation of the G2/M transition occurs through the association of cyclin
B:CDK1 complexes [118, 124]. Checkpoints at this stage monitor for the failure of
DNA synthesis or chromosome organization, which can result in cancer [207,
348]. After entry to the M phase, additional checkpoints monitor mitotic spindle
position and chromosome separation in cells [100, 184, 261].
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Cell cycle regulation by protein localization: In addition to the coordinated
activation of different cyclin/CDK complexes, modulation of the protein
expression and checkpoint regulation, intracellular localization of different cell
cycle-regulating proteins adds an additional layer to the regulation to the cell
cycle [333]. Since the spatiotemporal context determines the biological functions
of proteins within a cell, cell cycle progression relies on fine-tuning of protein
transport [141]. During the G1 phase, cyclin D1 accumulates in the nucleus.
When the cell enters the S phase, glycogen synthase kinase 3-mediated
phosphorylation of cyclin D1 and subsequent binding to the nuclear exportin
CRM1 causes the cytoplasmic translocation of cyclin D1, which is targeted for
cytoplasmic proteolysis to prevent further activity [5, 78, 311]. At the beginning of
mitosis, cyclin B, which contains a nuclear exclusion signal, is actively exported
to the cytoplasm [127]. The 14-3-3 group proteins mediate the intracellular
trafficking of the cyclin B:CDK1 complex and the CDK-activating enzyme Cdc25
to prevent inappropriate S- or M-phase progression [285, 368]. Intriguingly, cell
cycle proteins in neurons are also located in pre-synaptic and post-synaptic
compartments, implying that they may play additional roles in neurite outgrowth,
synaptic scaling, and synaptic plasticity [100, 131]. While the role of cell cycle
proteins in dividing cells is well-characterized, the roles and complex interplay of
cell cycle proteins with other molecules in the context of a cell type that does not
divide adds an additional layer of complexity to understanding the functions of
these critical proteins. In the next section, the role of select cell cycle proteins in
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neurons after differentiation, particularly their roles in neuronal migration,
maturation, and synaptic plasticity, are examined.

Cell cycle regulators and their roles in CNS organization and function

Organization of the CNS initially depends on neurogenesis and differentiation of
neuroprogenitor cells into postmitotic neurons. These neurons become polarized
and extend processes, i.e., neurites, through cytoskeletal rearrangements, which
result in one neurite that eventually becomes an axon whereas the other neurites
become dendrites. This process occurs in combination with neuronal migration
during which radial or tangential migration of immature neurons toward the
cortical plate or from the ganglionic eminence form the multilayered cerebral
cortex [18]. The formation of synapses depends on immature neuron axonal
migration, axonal guidance, synapse formation, maturation, and maintenance.
The development of functional synapses involves local reorganization of the actin
cytoskeleton and activity-dependent synaptic scaling [26] . A subset of cell cycle
regulators in adult neurons play important roles in neuronal migration,
maturation, and synaptic plasticity. Cell cycle regulators such as CDKs, CKIs,
pRb, E2F1, E2F3, and S- and M-phase complexes have indispensable roles
during healthy CNS development and/or synapse maintenance.
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Among the cell cycle proteins that have been examined for their involvement in
neuronal migration are the Cip/Kip family of CKIs, pRb, and E2F3. P27Kip1 is
expressed in all layers of the developing cerebral cortex, and its loss of function
impairs neuronal differentiation and migration, resulting in decreased
neurogenesis and an accumulation of cells in the ventricular/subventricular zone
of the developing cortex. Independent from its classic cell-cycle related function,
p27Kip1’s ability to stabilize the proneural transcription factor neurogenin-2 is a
suggested mechanism by which it promotes neuronal migration, as neurogenin-2
overexpression rescues neuronal migration defects caused by p27Kip1 loss of
function [233]. P27Kip1 also intersects with the major neuronal migration signaling
pathway controlled by Cdk5, a neuron specific atypical cyclin-dependent kinase
[77]. Unlike that which occurs with other cyclin:CDK complexes, p27Kip1 fails to
inhibit CDK5 activity as it cannot bind to the CDK5 activator protein p35 [180]. In
neurons, CDK5 stabilizes p27Kip1, leading to the phosphorylation of cofilin and
reduced levels of F-actin in neurites, where p27Kip1 contributes to CDK5mediated cell motility through the regulation of microtubules and actin
cytoskeleton [164]. P57Kip2, which is only expressed in the cortical plate [233],
also regulates cytoskeleton through the modulation of the RhoA-cofilin pathway
[366]. Unlike that observed with p27Kip1 knockdown, p57Kip2 knockdown leads to a
neuronal migratory defect without a neurogenesis defect, underscoring both the
overlapping as well as the distinct roles of CKIs in neuronal differentiation and
migration [148].
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Importantly, while E2F1 is the primary member of the E2F family of cell cycle
proteins that play important roles in regulating G1/S transition during cell cycle,
the functional interaction between pRb and the E2F family member E2F3, and
not pRb and E2F1, is imperative for tangential interneuron migration. The
ganglionic eminence cellular genes, which are regulated by pRb, suggested to
play roles in neuronal migration include neogenin, SEMA3d, VLDLR, ApoE, CCK,
TWIST1, and TWIST neighbor; however, whether these genes are transcriptional
targets of E2F3 has not been established [101, 212]. Similar to the Cip/Kip family
CKIs, the E2F family members, of which there are 8, may have overlapping
functions in certain contexts [281]; however, E2F3 plays a distinct role in
neuronal migration [212]. Although E2F1 plays no known roles in neuronal
migration, E2F1 is suggested to maintain the postmitotic state of mature neurons
[339] and may play additional roles in synapse maintenance based on several
lines of evidence. E2F1 was reported to localize to the synaptosome and to
increase with age. Also, in mice lacking E2F1 DNA-binding activity (E2F1tm1/tm1),
E2F1 loss of function was associated with reduced synaptic protein expression at
1 year of age, including NMDA receptor subunits NR1 and NR2A, AMPA
receptor subunit 2 (GluR2), synaptic RAS GTPase-activating protein (synGAP),
and PSD-95 [321]. E2F1 is able to bind RNA [147] and therefore, like other RNAbinding proteins, may support synaptic maintenance by regulating mRNA
transport or translation at the synapse [291]. Similar to p57Kip1 and p57Kip2
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family members, E2Fs may have overlapping and distinct roles in neuronal
health, wherein E2F3 may be more integral to neurodevelopment and E2F1 may
be required for synapse maintenance.

Degradation and replication machinery associated with the S and M phases of
the cell cycle also participate in regulation of axonal growth, dendrite
morphogenesis, pruning, postsynaptic local translation and homeostatic plasticity
[125]. This includes the origin of replication complexes and aurora kinases;
however, this discussion will focus on the roles of anaphase-promoting
complex/cyclosome (APC/C) [336]. APC/C, which consists of at least 11 different
subunits, degrades proteins during mitosis and G1. Association with the
activating subunits Cdh1 and Cdc20 regulates the activity and substrate
specificity of APC/C [254]. During the cell cycle, Cdh1 and Cdc20 recognize
specific degradation motifs on APC/C’s substrates; these subunits also regulate
mitotic progression, sister chromatid separation, and mitotic exit [101, 255, 256].
In neurons, APC/CCdh1 and APC/CCdc20 play roles in axonal growth, dendrite
morphogenesis, and synaptic plasticity. APC/CCdh1 degrades DNA binding 2 (Id2)
protein and transcriptional corepressor SnoN, both of which increase axonal
growth when stabilized [179, 305]. In the context of neuronal regeneration, Cdh1
knockdown or Id2 stabilization overcomes the inhibitory effect of myelin on
axonal growth, indicating that targeting this pathway may be beneficial in the
context of axonal regeneration following injury [170, 179]. However, albeit the
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potential benefit of Cdh1 knockdown for the promotion of axonal regeneration,
heterozygous Cdh1 knockout mice have impaired LTP in the hippocampal CA1
region with an accompanying defect in fear conditioning [185]. APC/CCdc20,
although also degrading Id2, has no effect on axon growth; it instead promotes
dendritic growth through the interaction of Cdc20 with HDAC6 at the centrosome
[166]. Similar to Cdh1, Cdc20 may also regulate synaptic function [61]; however,
the available evidence is correlative at best. Again, as with the calcium signaling
pathway, targeting the “outgrown” roles of cell cycle proteins becomes difficult as
some are integral to mature neuronal synaptodendritic health.

Cell cycle reactivation in neurodegenerative disease

Unlike most cell types, neurons typically maintain a G0 state with permanently
blocked capacity to proliferate after differentiation in the adult CNS. However, cell
cycle reactivation in adult neurons can be an indication of neurodegeneration and
CNS injury [43, 44, 102, 153, 213, 224, 265, 364]. Aberrant cell cycle reentry or
protein expression has been observed in Alzheimer’s disease (AD) [11, 12, 129,
130, 167], amyotrophic lateral sclerosis (ALS) [265, 266], Parkinson’s disease
(PD) [133, 153, 183], Huntington’s disease (HD) [94, 251], HIV-associated
encephalitis (HIVE) [155], and HIV-associated neurocognitive disorder (HAND)
[296]. The participation of the cell cycle in pathology has been most documented
for AD. The examination of brain specimens of patients with AD reveals
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increased expression of numerous cell cycle proteins including E2F1, CDK1,
CDK4, cyclin B, cyclin D, PCNA, p16, and Ki-67 [14, 43, 154, 298, 335]. Cell
cycle reentry is presumed to precede neuronal death in AD since increased cell
cycle protein expression is observed in early disease stages [365]. While the
postmortem analysis of cell cycle proteins in ALS motor neurons has been
limited, the spinal cord ventral horn tissue exhibits increased nuclear expression
of phosphorylated pRb, cyclin D1, and E2F1 [265]. Additionally, the postmortem
analysis of brains from patients with PD reveals increased nuclear
phosphorylated pRb, E2F1, and PCNA in substantia nigra, frontal cortex, and
hippocampus [133]. Also, CNS specimens of patients with HD exhibited
increased cyclin D1 and E2F1 [251]. Finally, cortical and hippocampal neurons in
brain specimens of HIV-infected patients with neurocognitive impairment exhibit
increased phosphorylated pRb and E2F1 expression [155, 296].

There are multiple mechanisms that can lead to cell cycle reactivation in these
conditions, and they may differ depending on the neurodegenerative conditions’
predominant pathological mechanisms. For specific neuronal types, including
sympathetic and cortical neurons, upregulation of cell cycle markers and
attempts to reactivate the cell cycle are observed in response to acute insults
including neurotrophic factor deprivation [244], DNA damage [246], oxidative
stress [168], and excitotoxicity [52]. A [63, 112, 197], 3-nitroproprionic acid
[251], 6-hydroxydopamine [89, 272] or 1-methyl-4-phenylpyridinium [133], and
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gp120 [296], which are used to study AD, HD, PD, and HIV-related neurotoxicity,
respectively, also induce cell cycle protein expression. Usually, neurons exposed
to these insults in cell culture conditions die before entering the DNA synthesis
stage of the cell cycle, a process referred to as abortive cell cycle reentry which
often results in apoptosis [27, 191]. This process is characterized by the
upregulation of G1/S-phase cell cycle mediators, namely cyclin D:CDK4/6 and
E2F transcription factors [52, 191, 242, 244, 245]. However, some neurons that
reenter the cell cycle are able to replicate their DNA and exist as tetraploid
neurons, a phenomenon best characterized in AD and aging [100, 198, 220].
Tetraploid neurons are more vulnerable to noxious stimuli and may therefore
contribute to the progression and severity of AD [13, 24, 99, 100]. Several in vitro
studies aimed to determine the mechanism underlying de novo tetraploidy in
neurodegenerative diseases. One such study indicates that cell cycle reentry in
AD may be regulated by miR-26b, a microRNA whose levels are elevated in
relevant pathological areas early in the course of AD. MiR-26b induced cell cycle
reentry through an pRb/E2F dependent mechanism that led to upregulation of
cyclin E and downregulation of p27Kip1 [1].

While cell cycle reactivation may appear to be merely a downstream
consequence of a toxic neuronal environment, oncogene expression in
postmitotic hippocampal and cortical neurons in transgenic mouse models
caused neuronal cell cycle reentry, with AD-like pathological changes including
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intracellular tau hyperphosphorylation and extracellular A accumulation [100,
214, 248]. In vitro, A treatment affected APC/CCdh1 and its substrates,
downregulating Cdh1, resulting in reduced degradation of cyclin B as well as
glutaminase — the enzyme responsible for converting glutamine into glutamate
— emphasizing how alterations in certain cell cycle machinery can also promote
excitotoxicity [104]. The contribution of inappropriate cell cycle reactivation to AD
and PD has been further bolstered by the demonstration that the cell cycle
protein inhibitor flavopiridol improves memory and reduces neuron death in AD
and PD mouse models [182, 297]. Consistently, in vitro and in vivo studies on
E2F1 have also demonstrated that E2F1 knockdown and knockout lead to
reduced cell death in response to excitotoxic and A treatments [111, 297, 377],
reduced dopaminergic cell death in a mouse model of PD [133], and reduced de
novo tetraploidy accompanied with improved long-term memory in aging mouse
brain [198]. These multiple lines of evidence highlight E2F1 as a potential target
for the development of therapies for neurodegenerative diseases.

Evaluating the potential for E2F1 therapy in mitigation of
neurodegenerative disease

E2F structure and function: E2F transcription factors were first identified as a
result of their ability to bind to the adenoviral gene E2 promoter [171]. At present,
there are eight E2F genes (E2F1-8), classified by their cell cycle activities:
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activators (E2F1-3a) and repressors (E2F3b-8) [33, 50, 103]. Activator E2Fs
share a high level of structural homology, including a nuclear localization signal
(NLS), cyclin A-binding domain, DNA-binding domain, dimerization domain, and
transactivation domain [69, 327]. Within the transactivation domain is a pocket
protein-binding site, which canonically binds pRb in E2F activators [50, 87, 128,
159]. Situated downstream of growth-factor signaling cascades, E2F proteins are
required for the expression of proteins involved in DNA synthesis and cell cycle
progression to the S phase [70, 91, 140, 186, 259]. The regulation of E2F activity
is accomplished through cell cycle-dependent and independent protein-protein
interactions and/or post-translational modifications, which can derepress or alter
DNA binding activity, as well as interactions with other transcription factors bound
to neighboring regulatory elements [69, 315, 327]. Canonically,
hyperphosphorylation of pRb by CDK4/6 and CDK2 results in the release of E2F
activators from the pRb:E2F repressor complex and binding to E2F-binding sites
on promoters while associated with differentiation regulated transcription factor
polypeptide (DP) 1/2, activating gene transcription required for cell cycle
progression. While E2Fs are bound to pRb, E2F-DP dimers are unable to recruit
the basal transcription factor TFIID and other transcriptional co-activators,
preventing E2F-dependent gene transcription [176, 275, 317, 329]. However,
pRb can also convert activators to repressors by recruiting chromatin-modifying
factors such as histone deacetylases to promoters of E2F-inducible genes. The
specific co-repressor complex recruited is dependent on the gene promoter and
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cellular context [3, 21, 370]. In addition to pRb, cyclin A:CDK2 can bind to and
phosphorylate activator E2Fs, thereby inhibiting their DNA-binding and
transactivation functions [126].

Compensation by E2F family members: Studies aimed to delineate specific
functions of activator E2Fs illustrate that activator E2Fs may compensate for the
loss of another. For example, elimination of any single activator E2F does not
markedly affect cell cycle progression and cellular proliferation; however, double
knockouts are impaired and triple knockouts cannot proliferate [69, 355].
Although it is clear that the functions of activator E2Fs can overlap, it is also
evident that, in certain contexts, activator E2F family members have distinct
functions as well [70, 140, 345]. Additionally, knockout experiments may be
flawed in the aspect of studying specific roles of activator E2Fs, as both E2F1
knockout and E2F3 knockout cells exhibit the compensatory upregulation of the
other E2F, indicating that the apparent dispensable functions of one E2F may not
remain dispensable in the context of delivering a targeted therapy. As evidence
for this argument, while knockout of E2F1 or E2F3 does not alter proliferation,
E2F1 or E2F3 shRNA-transfected cells severely reduce proliferation [169].
Keeping this caveat in mind, some distinct roles of E2F1 in vivo are indicated
through the characterization of E2F1 knockout models.

25

Suggested roles of E2F1 in specific tissues: Despite the clear role of E2F1 in cell
proliferation, E2F1-mutant and knockout mice are fertile and undergo normal
development. However, these animals present with exocrine gland dysplasia,
testicular atrophy, thymic hyperplasia, increased thymocyte count, impaired
wound healing, reduced neuroprogenitor cell proliferation, and tumors in various
tissues, indicating that E2F1 plays a vital role in multiple organs and processes,
including but not limited to, pancreatic beta cell differentiation, spermatogonial
cell maturation, thymocyte apoptosis, local inflammatory response, reepithelialization, neurogenesis, and tumor suppression [62, 84, 95, 361].
Historically, E2F1 has been viewed as an oncogene given its role in the
progression of cell cycle and that increased E2F1 expression is present in a
variety of cancers including breast, cervical, ovarian, esophageal, lung, and
gastrointestinal stromal cancers, gastric adenocarcinoma, glioblastoma,
hepatocellular carcinoma, small cell lung carcinoma, melanoma, oral squamous
cell carcinoma, and pancreatic ductal carcinoma [215]. However, E2F1’s tumor
suppressive function may be a result of its important apoptotic roles or due to its
repression of cancer-related genes in specific organs [274, 320, 361]. After
decades of in vivo and in vitro studies, it has become clear that E2F1 plays a part
in multiple processes dependent and/or independent of its cell cycle regulatory
roles. Genome-wide association studies indicate that E2F1 may play important
roles in countless cellular pathways, since it binds to hundreds of promoter
regions [31, 72, 241, 316]. The functions of E2F1 eventually are determined by
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its protein levels, interaction partners, and posttranslational modifications [280].
Altered levels of E2F1 affect apoptosis [110], DNA damage response [306],
inflammation [189], and senescence [80], all of which can contribute to
development of a neurodegenerative phenotype [55, 174, 204, 211].

E2F1 in apoptosis: E2F1 induces apoptosis in the presence of irreparable DNA
damage and other stimuli through (1) the direct transcriptional activation of
apoptotic proteins APAF-1 [219], PUMA, BIM, NOXA, Hrk/DP5 [132],
Smac/Diablo [358], caspases 3, 7, 8, and 9 [225], and p14ARF [234], (2)
transactivation of the p53 homolog p73 [146, 307], (3) the stabilization of p53 [25,
260], (4) the activation of calpains [308], and (5) reduction of the inhibitor of
death receptor-mediated apoptosis TRAF2 [258]. Although the contribution of
neuronal apoptosis to the development of neurodegenerative disease is
controversial due to contradictory results in postmortem tissues [165], activation
of calpains is commonly observed [2, 45, 337]. Reduced apoptosis and/or
reduced activation of calpains may preserve vital synaptic proteins, such as
PSD-95, that are important for maintaining healthy neuronal networks and
preserving learning and memory [152]. E2F1 deficiency prevents neuronal death
associated with insults linked to neurodegenerative diseases in vitro [111, 297,
377] and reduces dopaminergic neuron death in PD mouse models in vivo [133],
thus, E2F1 appears to be a potential target for a variety of aging-related
neurodegenerative diseases. However, while E2F1 deletion may reduce
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neurodegeneration by attenuating neuronal apoptosis, the beneficial roles of
E2F1 in DNA repair may complicate the development of therapeutics targeting
E2F1 in neurons.

E2F1 in DNA damage: Given the well-defined contribution of E2F1 to the repair
of double-strand DNA breaks, the loss of E2F1 may impair DNA repair processes
through the reduction of homologous recombination factors RAD54 and RAD51
[56]. Whether a deficiency in RAD54 or RAD51 affects neuron health and
function in vivo is not known; however, RAD54 disruption did not alter cortical
development in vivo [279]. Since the mature nervous system consists largely of
postmitotic cells, homologous recombination, which is primarily restricted to late
S and G2/M phases of the cell cycle, is important only for the early proliferative
stages of embryonic nervous system development and for other mitotic cells
outside the nervous system [239]. The other double-strand break repair pathway,
non-homologous end-joining (NHEJ), is consider the predominant DNA repair
pathway for double-strand breaks in the post-natal brain [181]. Overall, the
potential benefits of reduced E2F1-mediated apoptosis and reduced calpain
activation may outweigh the risk of impaired homologous recombinationmediated DNA double-strand break repair, since DNA repair processes
commonly required for neuronal health are those involved in the repair of singlestrand DNA breaks and NHEJ-mediated repair of double strand breaks [150].
Conversely, E2F1 was shown to occupy genomic regions associated with DNA
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repair in cortical neurons treated with camptothecin, which inhibits topoisomerase
I and leads to the accumulation of unrepairable DNA damage and neuronal
apoptosis [370]. Since E2F1 inhibition increased DNA damage and apoptosis in
that study, it remains possible that E2F1 plays an important role in DNA repair in
aging neurons.[203]

E2F1 in inflammation: E2F1’s role in inflammation is a double-edged sword, with
studies suggesting that E2F1 plays either proinflammatory or anti-inflammatory
roles. The translocation of E2F1 to the NF-B promotors of inflammatory genes
has been shown to potentiate the production of proinflammatory cytokines,
whereas the loss of E2F1 has been shown to impair the production of
proinflammatory cytokines, specifically TNF-, CCL-3, IL-23A, and IL-1 [189].
Yet, E2F1 has also been shown to inhibit the formation of active NF-B
complexes, indicating that E2F1 levels or cellular context may alter its overall role
in inflammation [10, 313, 324]. Various studies in cells involved in inflammation,
such as dendritic cells and macrophages, capture the complexities of E2F1’s role
in inflammatory processes.

Evidence for the proinflammatory role of E2F1 is provided by Warg et al., who
showed that the levels of proinflammatory cytokines (TNF-, IL-6, and IL1)
produced in response to the systemic bacterial endotoxin LPS exposure were
lower in E2f1-mutant mice than in wildtype mice [343]. In cell culture, this
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phenomenon has been observed in response to highly efficient E2F1 knockdown
and knockout experiments [189, 362]. On the other hand, the anti-inflammatory
role of E2F1 is supported by a study of induced pluripotent stem cell-derived
human macrophages, where reducing E2F1 levels using shRNA induced a gene
signature indicative of a proinflammatory M1-like phenotype in macrophages,
also known as classically activated macrophages, with increased expression of
the M1-like cell surface markers MHCII and CD86 [136]. At the opposite end of
the functional spectrum, M2-like macrophages, also termed alternately activated
macrophages, have immunosuppressive functions and promote wound healing
[222]. Theoretically, increased M1 polarization of macrophages might contribute
to impaired wound healing observed in the study on E2F1-mutant mice by
D’souza et al.; however, the M1- and M2-like phenotypes of macrophages were
not examined in that study [84]. On the other hand, Wang et al. reported the
opposite finding; E2F1 expression impaired wound healing and that E2F1-mutant
mouse macrophages recruited to the wound site in E2F1 knockout mice
exhibited higher expression levels of M2-like markers (Arg-1, IL-10, and TGF-)
compared to wildtype E2F1 macrophages, resulting in accelerated wound
healing [340]. In dendritic cells, E2F1 expression suppresses dendritic cell
maturation and proinflammatory cytokine release both in the absence of
exogenous treatment and following LPS treatment. E2F1-mutant monocytederived dendritic cells exhibit increased cellular maturation markers (MHCII,
CD86, CD83) at baseline and 24 hours after LPS treatment, and E2F1
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knockdown increases proinflammatory cytokine and chemokine release (TNF-,
RANTES, MDC, IL-12) in response to LPS [92]. Whether E2F1 loss affects
microglia is unknown. However, double E2F1/E2F2 knockout reduces microglial
activation associated with spinal cord injury [354]. This outcome could be due to
reduced cell death and microglia-activating factors or due to cell-specific roles of
E2F1 and E2F2 in microglia. Altogether, it is not clear how E2F1 promotes or
inhibits inflammatory phenotypes or why E2F1 is proinflammatory in one context
and not another. Further investigation into the roles of E2F1 in inflammation in
microglia could identify new treatment avenues or specific therapeutic pathways
that should be avoided.

E2F1 in cellular senescence: One final consideration regarding the role of E2F1
in the CNS is its dual roles in cellular senescence, a state of irreversible terminal
arrest of cell proliferation, which is hypothesized to contribute to aging by altering
normal cellular function, changing the behavior of neighboring cells, degrading
structural components, and accelerating the loss of tissue regenerative capacity
by reducing stem and progenitor cells [42]. The CDK inhibitors p21Cip1 and
p16Ink4a maintain pRb in a hypophosphorylated state [47, 227], suppressing E2F1
and other E2Fs and irreversibly blocking cell cycle progression [113]. Senescent
cells are resistant to cell death and display significant changes in their secretory
phenotype, termed the senescence-associated secretory phenotype [65]. The
increased expression levels of the proinflammatory cytokines, namely, IL-1, IL-
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1, IL-6, IL-8, and TNF- [64, 216], as well as matrix metalloproteinases, which
degrade extracellular matrix proteins such as collagen and elastin [286], are
commonly associated with this phenotype and can induce senescence in
neighboring cells, alter tissue homeostasis, and induce tumorigenesis and
malignant progression of nearby premalignant cells [46, 47, 64, 231]. Although
the loss of E2F1 is theorized to promote senescence due to the inability to
activate E2F target genes [227], some studies have shown that embryonic
fibroblasts from E2F1 knockout mice have reduced senescence and ROS levels,
mediated through the increased FOXO3-dependent transcription of two
antioxidant enzymes: manganese superoxide dismutase and catalase [357].
However, yet again, whether targeting E2F1 in immune cells promotes
detrimental senescence and associated inflammation remains unclear.

Rationale and Objectives:

During the development of therapies, it is important to establish all possible
undesirable effects due to alteration in the activity of the target of interest. In the
context of neurodegeneration, reduced apoptosis and impaired cell cycle
progression would be considered beneficial; however, impaired pancreatic
function, impaired DNA damage response, increased proinflammatory cytokine
release associated with immune cell activation or senescence, and increased risk
of cancer would alter the safety profile, rendering a global E2F1 therapy an
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unlikely boon. However, advances in gene therapy provide the ability to deliver a
transgene to a particular brain region or cell type, in essence circumventing
unwanted side effects caused by genetic manipulation in undesired cells/organs
[309]. To date, studies investigating the impact of E2F1 loss on learning and
memory have reported contradictory results. In one study, E2F1 loss resulted in
reduced levels of synaptic proteins, impaired novel object recognition, and
development of anosmia [321]. Another study found that E2F1 loss improved
novel object recognition and spatial memory [198]. The underlying cause of these
contradictory results is not clear as both studies used the same genetic mouse
model. However, the mice were bred onto different backgrounds in these studies.
To more clearly understand the impact of E2F1 loss on learning and memory and
to elucidate cell-type specific functions of E2F1, we developed a conditional
E2F1 mouse (1) to evaluate whether E2F1 loss in neurons causes behavioral
impairment, since cell cycle proteins are known to affect post-synaptic local
translation and homeostatic plasticity, and (2) to characterize the inflammatory
profile caused by E2F1 loss with the aim to identify whether E2F1 loss in immune
cells of the brain or the periphery might contribute to neurological deficits
reported in aging E2F1-mutant mice. Before establishing whether neuron-specific
E2F1 knockout mice exhibited behavioral or synaptic deficits, we first developed
and validated our conditional E2F1 mouse-derived full body E2F1 knockout
model, described in Chapter 2. Evaluation of this new full body knockout mouse
line was necessary given the contradictory findings of E2F1’s role in learning and
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memory, as previously discussed [198, 321]. To our surprise, we found that E2F1
knockout did not produce the expected behavioral deficits or alter synaptic
protein expression in mice. In fact, all behavioral and mature neuronal
phenotypes previously reported in E2F1-mutant mice were either absent or
muted. In Chapter 3, we present our findings on the characterization of cytokine,
chemokine, and growth factor release from E2F1 knockout macrophages in
response to LPS at early and late timepoints, with and without priming, to identify
proinflammatory and anti-inflammatory roles of E2F1 that may influence
neurocognition and neurodegeneration. Our results suggest that E2F1 has proand anti-inflammatory roles in bone-marrow-derived macrophages. In Chapter 4,
we discuss our findings and suggest future directions to further clarify the role of
E2F1 in the CNS and in the context of inflammation. Taken together, the findings
of this thesis work suggests that E2F1’s roles in mature neurons may be less
integral than previously suggested and that model differences and technical
difficulties may account for the disconnect between studies investigating CNSrelated functions of E2F1.
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CHAPTER 2: DEVELOPMENT AND VALIDATION OF A NOVEL
E2F1 MOUSE REVEALS DIFFERENCES IN E2F1-RELATED
PHENOTYPES

Introduction

E2 promotor binding factor 1 (E2F1) is one of eight E2F transcription factors,
classically characterized as activators (E2F1-3a) and repressors (E2F3b-8) of
transcription [33, 50, 103, 171]. All E2F members share a highly homologous
DNA-binding domain and bind to E2F promoter sequences to regulate
transcription that depends on the availability of binding partners including
dimerization proteins and retinoblastoma (pRb) family proteins [34, 87, 103].
Although E2F1-3 exhibit extensive functional redundancy in vivo, distinct roles for
specific transcription factors have been characterized [33, 70]. While E2F1 is
widely recognized for its regulatory role in the progression of G1/S phase of the
cell cycle [70, 259, 319, 355], it has become evident that E2F1 also regulates
apoptosis [70, 110, 132, 219], senescence [80, 357], DNA damage response [56,
306, 370], differentiation [205, 338, 373], inflammation [10, 84, 138, 343], and
metabolism [35, 71] through transcription-dependent and transcriptionindependent mechanisms.
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Following neuronal differentiation, at which time neurons exit the cell cycle, E2F1
expression is downregulated but maintained [321, 369], suggesting that E2F1
may be required for normal neuronal function. Although contrary to the maxim
that E2F activators promote cell cycle progression, E2F1-3 act as repressors in
differentiated cells [58]. The repressor roles of neuronal E2F1 in apoptosis and
cell cycle regulation were identified through the use of transcription-deficient
E2F1 mutants, which suggest that E2F1 exists in a repressive complex with
necdin or pRb to maintain a post-differentiated state or inhibit apoptotic gene
transcription and cell cycle reentry [315, 339]. However, reduced aberrant cell
cycle reentry and reduced cell death have been reported in E2F1-deficient
neurons responding to various toxic stimuli [111, 297, 377], indicating that E2F1’s
role in regulating these processes is context-dependent. Concordant with other
studies reporting a predominantly cytoplasmic E2F1 localization [321, 342, 354],
Ting et al. found that E2F1 was expressed in synaptosomes [321], raising the
possibility that it may play a role in synaptic plasticity. In that study, E2F1 mutant
mice (E2F1tm1/tm1) exhibited age-dependent novel object recognition impairment
and perturbed synaptic protein expression that started on postnatal day (P) 270
and remained detectable through P365 [321]. Still, the ability of E2F1 to regulate
memory remains unclear. In contrast, Lopez-Sanchez at al. reported that E2F1
tm1/tm1

mice displayed improved novel object recognition and reduced de novo

age-associated neuronal tetraploidy [198]. The functional outcome of E2F1 loss
is important as a variety of neurodegenerative diseases exhibit E2F1
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dysregulation [133, 155, 251, 265, 296]. Given that a conglomerate of in vitro and
in vivo studies indicate that E2F1 deficiency and cell cycle inhibitors can improve
neuronal survival and behavioral outcomes in response to neurodegenerative
disease-associated insults [111, 133, 182, 297, 377], a more precise dissection
of the role of E2F1 in neuronal health and function in in vivo models would guide
efforts on therapeutic development.

Transgenic mice are useful tools for delineating the contribution of genes and
proteins to physiological processes [19]. Studies using the E2F1tm1/tm1 mouse
model, in which the DNA binding and dimerization domains of E2F1 are
disrupted by the insertion of a PGK-neocassette to abolish E2F1-mediated
transcription [95], suggests that E2F1 is indispensable for a variety of processes,
including but not limited to, controlled thymocyte replication [95]; testicular,
exocrine, and neuronal health [143, 156, 278, 321, 339]; neurogenesis [62];
olfaction [321]; anxiety [198, 321]; and potentially memory [198, 321]. In some
cases, the mRNA message of a gene that is supposed to be eliminated in a
knockout mouse line is retained and translated into a mutant or partial protein
[221]. In addition, the retention of selection markers used for transgenic mouse
generation, such as the PGK-neocassette, are known to cause unexpected
phenotypes in knockout mice due to the disrupted expression of neighboring
genes up to distances of 100kb from the site of mutation [257, 287]. Given that
RNA transcripts are detected in E2F1tm1/tm1 mice which exhibit detrimental neural
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and behavioral phenotypes [321] and based on the strong in vitro and in vivo
evidence for benefits associated with E2F1 loss in neurodegeneration [111, 133,
297, 377], it is important to determine whether E2F1-related phenotypes are
present in mice lacking all E2F1 functional domains and if any of the CNS-related
phenotypes are mediated by the loss of neuronal E2F1.

Therefore, we aimed to determine the contribution of neuron-specific E2F1 loss
to aging-dependent synaptic health, learning, and memory in a conditional
mouse model that lacked all E2F1 functional domains. Using a Cre-lox breeding
strategy, we generated constitutive E2F1 knockout mice (E2F1-/-) to assess
previously reported CNS phenotypes observed in E2F1tm1/tm1 mice. Here, we
show that E2F1-/- mice exhibit few of the reported CNS phenotypes and
recapitulate some but not all tissue pathologies observed in E2F1 tm1/tm1 mice.

Methods

Animals

Generation of E2F1fx/fx mice: E2F1fx/fx mice were designed and generated by the
Gene Targeting Core and Laboratory (Fig. 1A) and the Transgenic and Chimeric
Mouse Facility at the University of Pennsylvania. Approximately 500-nucleotidelong homology arms flanking exons 3-7 of E2F1 were cloned into the multiple
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cloning site of PL253 [195]. The resulting plasmid was transfected into bacteria
allowing recombineering of an approximately 15-kB-long genomic region with
exons 2-7 and the 3’ untranslated region (UTR) of E2F1 from a BAC clone
(BACPAC Genomics) with the mouse E2F1 genomic DNA [195]. The PL452
[195] was used to construct a plasmid with approximately 500-nt-long homology
arms homologous to areas located about 100 nt upstream of exon 2 and 100 nt
downstream of the 3’ UTR of E2F1. This construct was then inserted by
recombineering into the modified PL253 plasmid with the wildtype E2F1
sequence to produce the final targeting vector for E2F1 fx/fx, which contained loxp
sites flanking exon 2 of E2F1, 3’ UTR of E2F1, and a FLT-flanked neocassette.
The final targeting vector sequence was verified and electroporated into V6.5
mouse embryonic stem (ES) cells [271]. ES clones that successfully integrated
the construct were identified by positive selection using 50 µg/ml kanamycin,
followed by confirmation using Southern blot and chromosome counting.
Southern blot was performed by cutting genomic DNA either with XbaI (15-kB
band in wildtype animals and a 17-kB band in mutant animals) or KpnI (14-kB
band in wildtype animals and 16-kb band in mutant animals) using appropriate
Southern probes. These ES clones were used by the Transgenic Core for
blastocyte injection to produce chimera, which were confirmed by Southern
blotting (Fig. 1B). Heterozygous breeding produced wildtype (E2F1+/+),
heterozygous (E2F1+/fx), and homozygous floxed (E2F1fx/fx) mice, which were
confirmed using the following primers that recognized a 336-bp band in wildtype
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animals and a 434-bp band in mutant animals: 5’TTGGGAGGTTAGTGGCAGGAAG-3’ and 5’AGGTGTGCGAGCAGAGACAGATTC-3’.

Generation of E2F1-/- mice: E2F1-/- mice were generated by mating E2F1fx/fx mice
with B6.129-Gt(ROSA)26Sortm1(cre/ERT2)Tyj/J (Stock No. 008463) purchased from
Jackson Laboratories (Bar Harbor, ME), until double homozygous
E2F1fx/fx:CreERT2++ mice were obtained. Genotyping for CreERT2 was achieved
using the following primers: 5’-AGGGGAGCTGCAGTGGAGTA-3’, 5’CCGAAAATCTGTGGGAAGTC-3’, and 5’CGGTTATTCAACTTGCACCAA-3’.
Male mice were injected with 75 mg/kg tamoxifen dissolved in corn oil once a day
for five consecutive days before setting up double homozygous male and female
breeding cages. On 12 days post coitus (dpc), dams were injected once with 1.5
mg tamoxifen. Tail samples from the resulting pups were used to determine if
Cre recombination had occurred in utero using the following primers: 5’TTGGGAGGTTAGTGGCAGGAAG-3’ and 5’AGAAGTCACTGGCAATGACATCT-3’. A male and female mouse that were
positive for Cre recombination in the tail sample were mated with each other.
Again, on 12 dpc, the pregnant dam was injected once with 1.5 mg tamoxifen
and the resulting pups were genotyped and Cre recombination was confirmed in
tail samples. Next, the male was bred with a B6.129 hybrid wildtype female that
had been generated during E2F1fx/+ mating, to start the process of removing the
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CreERT2 alleles. An E2F1+/-; CreERT2+ mouse was then bred again with another
B6.129 hybrid mouse. Male and female E2F1+/- mice that lacked the CreERT2
allele were bred with each other to produce wildtype (E2F1+/+), heterozygous
(E2F1+/-), and homozygous E2F1 knockout (E2F1-/-) mice. The genotypes were
confirmed using the following three primers that detected the wildtype and Crerecombined alleles based on the presence of a 336-bp band in wildtype animals
and a 425-bp band in mutant animals: 5’-TTGGGAGGTTAGTGGCAGGAAG-3’,
5’-AGGTGTGCGAGCAGAGACAGATTC-3’, 5’AGAAGTCACTGGCAATGACATCT-3’.

E2F1tm1/tm1 mice: E2F1tm1/tm1 (B6;129S4-E2F1tm1Meg/J; strain # 002785) mice
and wildtype F2 hybrid (B6129SF2/J; strain #101045) mice were purchased from
Jackson Laboratories.

All mice were kept on a 12-h light/dark cycle and provided water ad libitum in the
University of Pennsylvania animal facilities. Male and female mice were used for
all experiments except those involving E2F1tm1/tm1 mice, which were only males
that were part of the colony used in experiments reported by Ting et al. [321].

Quantitative reverse transcription-polymerase chain reaction
For quantitative reverse transcription-polymerase chain reaction (qPCR), total
RNA was extracted from brain, heart, kidney, liver, spleen, and lung tissues of
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P42 E2F1+/+ and E2F1-/- mice using RNeasy mini kit (Qiagen). RNA was
quantified using Nanodrop (Thermo Fisher Scientific). For each organ sample,
equal amounts of RNA (200 ng-1 µg) were reverse transcribed using RT2 First
Strand kit (Qiagen). qPCR was performed using Fast SYBR Green® Master mix
(Thermo Fisher Scientific) with primer pairs for mouse E2F1 (forward, 5’GCGCATCTATGACATCACCA-3’; reverse, 5’-GCTTACCAATCCCCACCAT-3’),
mouse Necab3 (forward, 5’-GACTACTTCTCCACACACCTG-3’; reverse,5’GCAGAAATCGTGTGACAAACTG-3’), and mouse GAPDH (forward 5’AATGGTGAAGGTCGGTGTG-3’; reverse 5’GTGGAGTCATACTGGAACATGTAG-3’) using the 7300 Real-Time PCR system
(Thermo Fisher Scientific). Data were analyzed using the comparative Ct (Ct)
method, and the results were expressed as fold change in gene expression. All
primers were Primetime Primers (IDT Technologies) with efficiency ranging
between 80% and 110%.

Immunoprecipitation of E2F1
Brains from P42 E2F1+/+ and E2F1-/- mice were homogenized in 1x RIPA buffer
(Cell Signaling Technology) supplemented with a protease inhibitor cocktail using
a Dounce homogenizer, followed by sonication and centrifugation at 14,000 g for
10 mins at 4oC. The protein concentrations were quantified using the BCA assay
(Thermo Fisher Scientific). Epoxy Dynabeads (Thermo Fisher Scientific) were
conjugated to normal Rabbit IgG or a monoclonal rabbit antibody raised against
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the E2F1 C-terminus (EPR3818(3); Abcam) according to the manufacturer
protocol. Next, 500 µg lysates were incubated in immunoprecipitation columns for
24 hours at 4oC. Following three washes with phosphate-buffered saline (PBS),
bound complexes were eluted with 0.1 M glycine-HCl (pH 2.5-3). The bound
complexes were analyzed by immunoblotting with a monoclonal mouse E2F1
antibody (KH95; Thermo Fisher Scientific).

Immunoblotting
Hippocampi, cortex, and cerebella isolated from 12- to 13-month-old mice were
homogenized in 1x RIPA buffer supplemented with a protease inhibitor cocktail
using a Dounce homogenizer, followed by sonication and centrifugation at
14,000 g for 10 mins at 4oC. Protein concentrations were determined using the
BCA assay (Thermo Fisher Scientific). Equal amounts of protein (3, 7, or 15 µg)
were loaded onto 4-12% Bis-Tris gels for immunoblotting. PVDF membranes
were probed with antibodies against GluR2 (E1L8U, Cell Signaling Technology,
1:2000), NR1 (D65B7, Cell Signaling Technology, 1:1000), NR2A (#4205, Cell
Signaling Technology, 1:1000), NR2B (D15B3, Cell Signaling Technology,
1:4000), PSD-95 (MAB1598, Millipore, 1:2000), synapsin (D12G5 XP, Cell
Signaling Technology, 1:3000), synaptophysin (SY38, Abcam, 1:2000), Syngap
(PA1-046, Thermo Fisher Scientific,1:2000), PCNA (PC10, Cell Signaling
Technology, 1:2000), and actin (8H10D10, Cell Signaling Technology, 1:10,000).
Detection was achieved using goat anti-mouse or anti-rabbit HRP-conjugated
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secondary antibodies and enhanced chemiluminescence and visualized using a
ChemiDoc imager (Bio-Rad). Densitometric analysis was performed using the
Bio-Rad Image Lab software. All results were normalized to the membranes
stained with Fast Green FCF dye. Immunoblots in figures are representative of
four of eight independent biological replicates for each genotype.

Tissue processing for CNS in situ hybridization and immunofluorescence
Animals at 14-months-old were transcardially perfused with 30 ml PBS, followed
by perfusion with 30 ml 4% paraformaldehyde in PBS (pH 7.4). The brains were
post-fixed in 4% paraformaldehyde for 20-24 hours at 4oC. After fixation, brains
were washed with PBS before dehydration and paraffin embedding. Sections
were cut into 5-µm-thick sections.

RNAscope in situ hybridization
RNAscope in situ hybridization (ISH) was performed by the Pathology Core
Laboratory at Children’s Hospital of Philadelphia Research Institute. Briefly,
tissue sections were deparaffinized and rehydrated. RNAscope probes for mouse
E2F1 encompassing nucleotides 631-1513 and mouse PPIB encompassing
nucleotides 98-856 as control were purchased from Advanced Cell Diagnostics.
Amplification of the probes were detected using RNAscope 2.5 (LS)-Red
Reagent kit with the BOND RX System (Advanced Cell Diagnostics). The kit
protocol was followed aside from an adjustment to pretreatment times to maintain
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tissue integrity. Pretreatment times were 15 minutes for target antigen retrieval
and 10 minutes for protease treatment. Following amplification of the target
probes, the tissues were counterstained using hematoxylin.

Immunofluorescence
Tissue sections were deparaffinized and rehydrated, followed by antigen retrieval
by incubating tissue-mounted slides in citrate buffer (pH 6.0) at 95oC for 40
minutes. Tissues were blocked using the Mouse-on-Mouse blocking reagent
(Vectashield) and incubated in antibodies against PCNA (PC10, Cell Signaling
Technology, 1:3000) and GFAP (Dako, 1:1000) or those against DCX (#4604,
Cell Signaling Technology, 1:200) and GFAP (GA5, Cell Signaling Technology,
1:1000) overnight at 4oC. Cy3-conjugated goat anti-mouse and goat anti-rabbit
antibodies were used to detect PCNA and DCX, respectively. FITC-conjugated
goat anti-rabbit and goat anti-mouse antibodies were used to detect GFAP
(Dako) and GFAP (Cell Signaling Technology), respectively. DAPI was used to
label nuclei, and coverslips were mounted and sealed using Prolong Gold
antifade mounting media (Thermo Fisher Scientific).

Behavioral phenotyping

Light/dark box assay: The light/dark box test was performed between 7:00 A.M.
and 12:00 PM following protocols validated by the Neurobehavior Testing Core at
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University of Pennsylvania. A two-chambered plexiglass box (16” x 16” x 14”),
divided into a light (clear-sided) and dark (lidded with black wall) side, was setup
with an approximately 700-lux high-intensity lamp placed above the light side. A
2” x 2” opening between the sides allowed for mice to travel between the two
chambers (Stoelting). Before each trial, 12-month-old mice were habituated to
the room for 30 minutes. The mice were placed in the dark side of the box and
allowed to explore both chambers for 300 seconds. All trials were recorded using
a webcam for offline grading. Anxiety-like behavior was evaluated by scoring the
amount of time spent in the light side of the apparatus. Before and after each
trial, the apparatus was wiped down with 70% ethanol.

Open field assay: The open field assay was performed between 7:00 A.M. and
1:00 P.M. following protocols validated by the Neurobehavior Testing Core at
University of Pennsylvania. Before each trial, 12-month-old mice were habituated
to the room for 30 minutes. Mice were placed into the center of a clear Plexiglass
arena (14” x 14” x 18’) fitted with infrared emitters and photosensors to detect
beam breaks as peripheral, center, and rearing activity. Locomotor activity was
measured using the PAS-Open Field system (San Diego Instruments). Anxietylike behavior was measured based on the percentage of centrally located beam
breaks (central/total beam breaks x 100). Before and after each trial, the
apparatus was wiped down with 70% ethanol.
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Novel object recognition assay: Novel object recognition assay was performed
between 7:00 A.M. and 12:00 P.M. following protocols validated by the
Neurobehavior Testing Core at University of Pennsylvania. The novel object
recognition procedure is a twelve-day assay comprising handling, habituation,
training (familiarization), and testing (recall) phases. On days 1–5, P365+ mice
were handled by the experimenter for two minutes. On days 6–10, mice were
habituated to the empty arena (12” x 15” x 15”) for 5 minutes. On day 11, mice
were trained for 15 minutes to recognize a pair of identical objects [filled glass
bottles (1.5” dia x 6”) or metal towers (1.5” x 1.5” x 5”) mounted on square plastic
bases] that were placed 3.5” away from the long wall and 3” away from the short
wall so that the mouse must extend from the walls to explore. 24 hours later, on
day 12, mice were reintroduced to the arena for 15 minutes, with one of the
familiar objects replaced with a novel object. Habituation, training, and testing
sessions were recorded using a webcam, and total time exploring each object
was analyzed offline using the ANY-maze software (Stoelting). The mouse was
considered to be exploring the object if its head was oriented toward the object
and located within a 2-cm perimeter. Object preference was measured as
follows: computing time spent exploring one object / time spent exploring both
objects x 100. Increased percent of time investigating the novel object over the
familiar object was identified as novelty preference. Discrimination index was
quantified as follows: discrimination index = (time spent exploring the novel
object – time spent exploring the familiar object) / (time spent exploring the novel
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object + time spent exploring the familiar object). Discrimination index was used
to confirm any observed genotype differences in novelty preference. To be
considered for statistical analysis, mice had to explore the familiar or novel object
for at least 3 seconds during testing and reach a total of 10 seconds of
exploration in both the training and testing phases. Before and after each trial,
the apparatus and trial objects were wiped down with 70% ethanol.

Habituation/dishabituation assay: The habituation/dishabituation assay was
performed between 7:00 A.M. and 12:00 P.M. at the Neurobehavior Testing Core
at University of Pennsylvania. 12- to 13-month-old mice were habituated to the
room for 30 minutes prior to following the previously published protocol [363].
The procedure was performed in dim light (5-10 lux) to spur exploration and
recorded with an infrared compatible camera for offline grading. Mice were
placed into a clean bedded cage with a modified cage top to allow the
suspension of a cotton-tipped wooden applicator from above. Cotton tips were
dipped in water, almond extract (1:100), or vanilla extract (1:100) or were
exposed to same- and opposite-sex odors by wiping the bottom of cages housing
adult C57BL6 male or female mice. During the test, mice were presented each
odor three times each for 2 minutes with 1-minute breaks. Exploration of the
scented cues was recorded using an infrared camera setting, and time spent
exploring each scent was scored later. Prolonged gnawing behaviors caused
data to be excluded in occasional scent trials. Time exploring scents was
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counted if the mouse was within 1 cm of the cotton tip with its nose oriented in
the cue’s direction.

Necropsy and histopathology
All necropsies and histopathological analyses were performed by the
Comparative Pathology Core at University of Pennsylvania. 15- to 18-month-old
E2F1+/+ and E2F1-/- mice underwent necropsy. Tissues were weighed, formalinfixed, dehydrated, and embedded in paraffin according to standard protocols.
Sections were cut into 5-µm-thick sections, stained with hematoxylin/eosin, and
examined under a microscope.

Statistical analysis
All data were analyzed using GraphPad Prism 9. All data were presented as
means ± standard error of the mean (SEM) unless otherwise indicated. Data
from two groups were analyzed using independent Student’s t test. Data from
three groups with only one independent variable were analyzed using one-way
analysis of variance (ANOVA) with Tukey’s post hoc test. For behavioral
experiments where sex and genotype were included as independent variables,
two-way ANOVA with Tukey’s post-hoc was used to determine significance. For
novel object recognition assay and odor habituation/discrimination, where three
variables (sex, genotype, object/scent) were present, three-way ANOVA was
used to identify significant interactions followed by two-way ANOVA with Tukey’s
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post hoc test to determine if the observed effects differed when data were
separated by sex or when male and female data were combined within the same
analysis. For habituation experiments where the same animal was assessed over
time, the results were analyzed using repeated-measures or mixed two-way
ANOVA with Tukey’s post hoc test to detect habituation in analyses where sexes
were kept separate as well as combined. Genotype differences in habituation
assays were assessed using Sidak’s post hoc test. Dishabituation to a novel
scent was also assessed using Sidak’s post hoc test. Three-way ANOVA was
also used to analyze body weight over time to identify significant interactions
followed by two-way ANOVA with Tukey’s post hoc test to determine if the
observed effects differed between sexes or animals at different ages.
Significance was defined as a p value of <0.05.

Results

Insertion of flanking loxP sites and heritable Cre-mediated inactivation of
E2F1 locus
To inactivate the E2F1 locus by Cre/lox breeding, we first generated the
conditional E2F1 mice (E2F1fx/fx) by homologous recombination [195]. Our
targeting vector contained a mutated E2F1 with the first loxp site located 208 bp
upstream of exon 2, and a genomic assembly containing flippase recognition
targets flanking the neocassette followed closely by the second loxp site located
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315 bp downstream of the 3’ UTR of E2F1 (Fig. 2.1A). After electroporation and
drug selection of ES cells, Southern blot analysis confirmed that homologous
recombination occurred in 14 of the 196 clones. Male chimaeras generated from
two E2F1+/fx clones transmitted the mutated E2F1 allele through the germline to
produce E2F1+/fx mice from a mixed B6.129 background. Genotyping by
Southern blot analysis (Fig. 2.1B) confirmed that the E2F1 mutation was present
in F1 B6.129 mice. Interbreeding of F1 male and female E2F1+/fx mice produced
E2F1+/+, E2F1+/fx, and E2F1fx/fx mice, which were confirmed by genomic PCR
(Fig. 2.1C). Then, we establish a homozygous E2F1fx/fx line for the derivation of a
novel constitutive E2F1 knockout mouse using the Cre/lox technology.

As a first step for the production of constitutive E2F1 knockout mice (E2F1-/-),
E2F1fx/fx mice were bred with B6.129 mice homozygous for tamoxifen-inducible
Cre under the control of the ubiquitous ROSA26 promoter (CreERT2++) for two
generations to produce double homozygous mice (E2F1 fx/fx;CreERT2++). Using
tamoxifen injection at specific times, we aimed to increase Cre efficiency in
gametes to produce chimaeras that could transmit a knockout allele to their
offspring without the need for Cre expression later. Specifically, we injected F2
E2F1fx/fx; CreERT2++ adult males for five consecutive days with 75mg/kg
tamoxifen before breeding with naïve E2F1fx/fx; CreERT2++ females. We waited
12 days post coitus (dpc) to inject pregnant female mice with 1.5 mg of
tamoxifen. We chose this amount as it appears to maximize embryonic
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recombination efficiency while minimizing tamoxifen-induced embryo lethality [68,
125]. Next, we interbred the resulting F3 pups that were positive for a Crerecombined allele by PCR and subjected them to the abovementioned injection
procedure. Following the generation of an F4 E2F1-/-; CreERT2++ male, we
mated it and it’s E2F1+/- progeny with female E2F1+/+ B6.129 mice across two
generations. Breeding of F6 pups containing the E2F1 mutation produced
E2F1+/+, E2F1+/-, and E2F1-/- littermates (Fig. 2.2A). These E2F1-/- mice lacked
E2F1 genomic DNA as evidenced by DNA sequencing of the knockout allele,
which revealed the retention of one loxp site but no E2F1 (nucleotides 516510493) (Fig. 2.2B), and by PCR (Fig. 2.2D) of the tail samples. Genotyping
confirmed that heterozygous breeding produced mice near the expected
mendelian ratio of 1:2:1. We identified 97 E2F1+/+, 188 E2F1+/-, and 109 E2F1-/mice from a total of 394 mice. As expected, we did not detect E2F1 RNA in a
variety of organs from E2F1-/- mice by qPCR (Fig. 2.2C) or E2F1 protein in the
brain of E2F1-/- mice by immunoprecipitation (Fig. 2.2E).

Off-target effects of the targeting strategy
Since approximately 5.3 kb of the E2F1 DNA (approximately 7.5 kb including the
FRT-flanked neocassette) was excised from the genome, we next determined if
deletion of this large segment adversely affected the gene expression of nearby
genes. Necab3 is the closest gene to E2F1; the 5’ UTR of Necab3 is located only
547 bp downstream of E2F1 (UCSC Genome Browser). Our analysis revealed
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that there was no change in the CNS expression levels of Necab3 among the
E2F1+/+, E2F1+/-, and E2F1-/- mice. However, the expression of Necab3 in the
liver was significantly altered by our targeting strategy [F(2,9)=13.65, p=0.0019].
The mean (±SEM) fold changes in the expression levels of Necab3 were 19.81 ±
0.89 and 55.60 ± 6.44 in the E2F1+/- and E2F1-/- mice, respectively, compared
with the E2F1+/+ mice. Post hoc analysis indicated that the liver Necab3
expression was significantly different between the E2F1-/-and E2F1+/+ mice
(p=0.0203) (Fig. 2.2F).

Residual C-terminal E2F1 RNA is detected in E2F1tm1/tm1 mice
The E2F1-/- mice were generated as a tool to further characterize the roles of
E2F1 in the CNS; thus, we next compared E2F1 RNA expression between our
novel E2F1-/- mice and the E2F1tm1/tm1 mice. Our analyses using an RNAscope
probe that spanned the E2F1 nucleotides 631-1513 revealed that E2F1 RNA was
not detectable in the brains of E2F1-/- mice. Tissue integrity was not
compromised since the control probe PPIB was able to detect its target RNA in
the E2F1-/- brains (Fig. 2.3A). In contrast, E2F1 RNA was still detected in the
E2F1tm1/tm1 mice (Fig. 2.3B), as previously reported [321]. Since the RNAscope
probe detects nucleotides that are associated with the transactivation domain
and Rb-binding activities of E2F1 [86, 128, 159, 172, 293, 359], the E2F1tm1/tm1
mice may retain functional E2F1 domains or a mutant protein that exhibits
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functions unrelated to E2F1, since the neocassette was inserted prior to the
transactivation domain [95].

Effect of E2F1 loss on body weight
E2F1tm1/tm1 mice exhibit 17%-20% reduction in body weight during the first 8
months of life [62, 95]; therefore, we recorded the weight of mice at adolescence
(6 weeks), adulthood (3 months), and middle-age (12 months). As there were three
variables (age, sex, and genotype), we analyzed the data using three-way ANOVA
with Tukey’s post hoc test. All mice gained weight as they aged, independent of
genotype (main effect of age, F(2,126)=108.1, p<0.0001). Sex had a significant
effect on body weight [F(1,126) = 52.45, p<0.0001], and E2F1 loss also
significantly reduced weight [F(1,126)=4.364, p=0.0387]. There was no significant
interaction between genotype and age or sex, and there was no three-way
interaction among age, sex, and genotype, indicating that genotype did not affect
weight substantially more in one sex or at one age. However, Tukey’s post hoc
test indicated that there was no significant difference in weight between the E2F1+/+
and the sex-matched E2F1-/- mice (n=11-12 per group) (Fig. 2.4A). To minimize
the effect of sex when grouping the data together, we represented E2F1 -/- as a
percent of average E2F1+/+ weights by each sex. This also minimized the effect of
age [ F(2,132)=0.1987, p=0.82]. Again, we detected a main effect of genotype on
weight [F(1,132)=5.273, p=0.0232]. On average, the mean (±SEM) weights of the
E2F1-/- mice at 6 weeks, 3 months, and 12 months of age were 2.93% ± 0.37%,
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5.57% ± 0.40%, and 5.85% ± 0.68% less than those of the E2F1+/+ mice,
respectively (n=22-24 per group); however, there was no significant difference
between the genotypes at any age by Tukey’s post hoc analysis (Fig. 2.4B).

Effect of E2F1 loss on brain weight
E2F1tm1/tm1 brains weigh approximately 10% less than E2F1+/+ brains at 3 months
of age [62]. Therefore, we measured wet brain weight of the E2F1-/- mice. Twoway ANOVA indicated that there was no genotype effect [F(1,26)=0.1898,
p=0.6666] and no interaction between sex and genotype [F(1,26)=0.4680,
p=0.4999]. There was a trend toward a difference in brain weight by sex
[F(1,26)=3.375, p=0.0776] (Fig. 2.4C). When brain weight was transformed into a
percentage of sex-matched E2F1+/+ mouse brain weight, there was still no
significant difference in brain weight by independent t test. The brain weights
(mean ± SEM) of the E2F1-/- mice were 99.40% ± 0.27% of those of the E2F1+/+
mice (n=15 per genotype, comprising of 7 males and 8 females each) (Fig. 2.4D).

Anxiety-like behavior, locomotor activity, novel object recognition, and
olfaction in middle-aged E2F1-/- mice
Anxiety-like behavior: Since E2F1tm1/tm1 mice exhibit novel object recognition
impairment at 12 months of age on a F2 B6x129 background [321] and not a
C57B6 background [198], we evaluated the behavioral characteristics of our
novel E2F1-/- mice at this age. 12-month-old E2F1tm1/tm1 mice on a F2 B6x129
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background also exhibited anxiety-like behavior in light/dark box [321] and in
elevated plus maze on a C57B6 background [198]. Therefore, we hypothesized
that E2F1-/- mice would exhibit anxiety-like behavior. To address this hypothesis,
we assessed anxiety-like behaviors using two different assays: light/dark box and
open field assays. Two-way ANOVA analyzing the time mice spent in the light
chamber of the light/dark box revealed a significant interaction between sex and
genotype [F(1,42)=5.192, p=0.0279], indicating that genotype likely affected
results obtained from one sex differently than the other. There was no significant
effect of genotype or sex alone [F(1,42)=2.733, p=0.1058; F(1,42)=0.03104,
p=0.8610]. Female E2F1-/- mice exhibited significant anxiety-like behavior
(p=0.0443, n=11-12), whereas male E2F1-/- did not (p=0.9690, n=12-13) (Fig.
2.5A). When sexes were combined, there was no significant difference by
independent t test (p=0.2150, n=22-25 per genotype), corroborating the lack of a
genotype effect on time spent in the light chamber observed in our two-way
ANOVA (Fig. 2.5B). Two-way ANOVA analyzing the percent of beam breaks that
occurred in the center of the open-field found an effect of sex [F(1,42)=5.722,
p=0.0213] but no significant interaction [F(1,42)=0.02312,p=0.8799] and no effect
of genotype [F(1,42)=1.539, p=0.2216]. Tukey’s post hoc analysis revealed no
significant difference between the sexes of any genotype (Fig. 2.5C). When
sexes were combined, there was no significant difference by independent t test
(p=0.1674, n=22-25 per genotype), corroborating the lack of a genotype effect on
open field center activity observed in our two-way ANOVA (Fig. 2.5D).
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Locomotor Activity: We also used the open field assay to quantify locomotor
activity, which we expected to be unaffected by the loss of E2F1, since 12month-old E2F1tm1/tm1 mice did not exhibit locomotor deficits [321]. Two-way
ANOVA analyzing total beam breaks (horizontal and vertical) identified no effects
of sex or genotype [F(1,43)=1.631, p=0.2084; F(1,43)=0.5496, p=0.4625];
however, there was a trend toward an interaction between the sex and genotype
[F(1,43)=2.952, p=0.0930]. The analysis of horizontal beam breaks alone also
identified that there was no effect of sex or genotype [F(1,43)=1.367, p=0.2488 ;
F(1,43)=0.5445, p=0.4646] and that there was a trend toward an interaction
between the two [F(1,43)=2.886, p=0.0966]. The analysis of vertical beam breaks
revealed a significant effect of sex [F(1,43)=9.691, p=0.0033], no significant
effect of genotype [F(1,43)=0.2189, p=0.6422], and no interaction between sex
and genotype [F(1,43)=1.789, p=0.1880]. Tukey’s post hoc test confirmed that
there were no significant differences between genotypes for any sex. Vertical
activity was significantly increased in the E2F1-/- males compared to the E2F1-/females (p=0.0141, n=11-13 per group) (Fig. 2.6).

Novel Object Recognition: Previous assessments of E2F1tm1/tm1 novel object
recognition used both standard (15 minutes) [198] and demanding (5 minutes)
[198, 321] novel object recognition assay protocols. Both studies also varied in
the sexes analyzed and the habituation procedures, and neither study evaluated
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intersession habituation. Therefore, we focused on the assessment of male and
female E2F1-/- mice using a modified standard 15-minute novel object recognition
assay to ensure that middle-aged E2F1+/+ B6.129 mice exhibited novelty
preference. This included extensive intersession habituation to the area to
increase the saliency of objects presented during the assay’s training phase.

Habituation: In our studies, analyzing distance travelled across five preexposure
sessions (PEs) using three-way repeated-measures ANOVA indicated that all
mice habituated to the arena [F (2.608, 104.3) = 20.87, p<0.0001]. There was no
effect of genotype or sex [F (1,40) = 0.1632, p=0.6884 ; F (1,40) = 0.1632,
p=0.6469]. There were interactions between genotype and preexposure and
between sex and preexposure [F(4,160)=2.563, p=0.0405; F(4,160)=2.890,
p=0.0241], indicating that genotype and sex altered the distance traveled across
PEs. There were no interactions between sex and gene or among the three
variables [F(1,40)=0.006738, p=0.0.9350 ; F(4, 160)=1.322, p=0.2642]. The
assessment of the male and female behavior separately using two-way ANOVA
to exclude sex as a variable indicated that, while there was a significant effect of
preexposure on distance traveled for both sexes [Male: F(2.615,52.30)=7.335,
p=0.0006; Female: F(2.390,47.80)=15.54, p<0.0001], the comparison of only the
female E2F1+/+ and E2F1-/- indicated that there was a significant interaction
between preexposure and genotype [F(4,80)=2.936, p=0.0255]. Furthermore,
genotype appeared to affect distance traveled across preexposure intervals only
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in female mice. In both analyses, there was no effect of genotype alone [Male:
F(1,20)=0.1186, p=0.7342; Female: F(1,20)=0.05163, p=0.8226]. While Tukey’s
post hoc test of the data from the males indicated that both the E2F1+/+ and
E2F1-/- males habituated to the arena by PE5 (PE1 vs PE5: p=0.0290, p=0.0325,
n=10-12) and not before (Fig. 2.7A and 2.7D), Tukey’s post hoc test of the data
from the females indicated that, while the E2F1+/+ females also habituated by
PE5 (PE1 vs PE5: p=0.0193, n=12), the E2F1-/- females habituated earlier,
exhibiting significantly reduced distance traveled by PE3 (PE1 vs PE3: p=0.0236,
n=10). Distance traveled significantly decreased between PE3 and PE5 in the
E2F1+/+ females (p=0.0370, n=12), indicating that while the E2F1-/- had finished
habituating by PE3 (PE3 vs PE5: p=0.9386, n=10), the E2F1+/+ females were still
habituating to the arena (Fig. 2.7B and 2.7E). When the data from both sexes
were combined, two-way ANOVA detected a significant trend toward an
interaction between preexposure and genotype [F(4,168)=2.129, p=0.0793], in
addition to a main effect of preexposure [F(2.400, 100.8)=19.33, p<0.0001]. A
genotype effect was still absent [F(1,42)=0.1380, p=0.7121]. Again, both the
E2F1+/+ and E2F1-/- mice habituated to the arena by PE5 (p=0.0002, p=0.004).
However, the E2F1-/- mice appeared to habituate earlier, exhibiting significantly
reduced distance traveled by PE3 (PE1 vs PE3: p=0.0168, n=22). By
comparison, the E2F1+/+ mice did not exhibit significant reduction in movement
by PE3 (PE1 vs PE3: p=0.3528, n=22) but did by PE4 (PE1 vs PE4: p=0.0140,
n=22). While the activity of E2F1-/- mice did not change between PE3 and PE5
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(p=0.9929, n=22), the distance traveled was significantly reduced between PE3
and PE4 in the E2F1+/+ mice (p=0.0073, n=22). Given the results of the male-only
and female-only analyses, it is likely that the differences between the E2F1+/+ and
E2F1-/- females were driving the observed genotype differences (Fig. 2.7C and
2.7F). For all analyses, there were no significant differences in distance traveled
between the genotypes at any of the preexposure trials.

Object familiarization/training: During object training, mice did not exhibit
differences in object exploration time by two-way ANOVA at any of the measured
timepoint intervals between the genotypes or the sexes. The analysis of 5-minute
bins for object preference using three-way ANOVA indicated that there was no
significant preference for either identical object/location. There was a trend for a
three-way interaction among gene, sex and object location at 5 minutes [F(1,66)
= 3.179, p=0.0792] and 10 minutes [F(1,80)=2.789, p=0.0988], which did not
exist at 15 minutes [F(1,82)=0.6469, p=0.4236] (Fig. 2.8A-C). Combining sexes
for analysis indicated that there was no preference for object location or
interactions. Before beginning the novel object recognition phase of testing, the
mean (±SEM) exploration time for the entire training phase was 82.081 ± 7.321
seconds for the E2F1+/+ mice (n=21) and 75.563 ± 8.594 for the E2F1-/- mice
(n=24). There were no differences in exploration time in genotypes by sex either
(E2F1+/+ male, 87.5 ± 11.580 seconds, n=10; E2F1-/- male, 78 ± 13.841 seconds,
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n=13; E2F1+/+ female 77.155 ± 9.478 seconds, n=11; E2F1-/- female, 71.973 ±
9.826 seconds, n=11).

Object Recognition Test: We assessed object exploration (seconds), object
preference (%), and discrimination index in 5-minute bins. Two-way ANOVA
indicated that the total object exploration time did not differ for any time intervals
among the genotypes or between the sexes. For all bins, we included analyses
that kept sexes separate as well as in combination since previous studies
examining the E2F1tm1/tm1 model assessed only male mice or examined sexmixed populations with power too low to identify potential sex differences.

At the 5-minute timepoint, we excluded two E2F1+/+ males, two E2F1-/- males,
one E2F1+/+ female, and three E2F1-/- females that did not fulfill the novel object
recognition analysis requirements. Three-way ANOVA indicated that there was a
significant three-way interaction among gene, sex, and novel object preference
[F(1,66)=22.80, p<0.0001] and a significant interaction between gene and novel
object preference [F(1,66)=7.663, p=0.0073]. There was also a significant effect
of novel object preference [F(1,66)=61.05, p=<0.0001]. There was no interaction
between sex and novelty and no main effect of sex. Together, these results
suggested that genotype alone might alter novel object recognition, and that the
effect of E2F1 loss in novel object recognition for one sex might be different from
the other. Using two-way ANOVA to analyze male mouse behavior separately
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indicated that there was a trend toward an interaction between genotype and
novel object preference [F (1,34) = 3.319, p=0.0773] in addition to a main effect
of novel object preference [F(1,34)=45.44, p<0.0001]. The E2F1+/+ males
interacted more with the novel object than the familiar object (p=0.0138, n=8), as
did the E2F1-/- males (p<0.0001, n=11). Analysis of female mice separately
indicated again that there was a significant interaction between genotype and
novelty [F(1,32)=19.85, p<0.0001], in addition to a main effect of novel object
preference [F(1,32)=23.47, p<0.0001], with the E2F1+/+ females exhibiting
significant novel object preference (p<0.0001, n=10) and the E2F1-/- females
exhibiting no novel object preference (p=0.9937, n=8) (Fig. 2.8D). Two-way
ANOVA of discrimination indices at the 5-minute time point in male and female
mice also indicated that there was an interaction between sex and genotype
[F(1,33)=11.19, p=0021] and a trend toward a genotype effect [F(1,33)=3.573,
p=0.0675]. There were no significant differences between the male mice, but the
discrimination index was significantly different between the E2F1+/+ and E2F1-/females (p=0.0046) (Fig. 2.8G). Two-way ANOVA of data combined from both
sexes indicated that there was a significant interaction between genotype and
novelty [F(1,70)=5.887, p=0.0178] and a significant effect of novel object
preference [F(1,70)=57.25, P<0.0001], but no gene effect [F(1,70)=1.217e-030,
p>0.9999]. Tukey’s post hoc analysis indicated that the E2F1+/+ mice exhibited
significant preference for the novel object (p<0.001, n=18), as did E2F1-/- mice
(p=0.0025, n=19) (Fig. 2.8J). There was no significant difference in novel object
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preference (p=0.3234) or discrimination index (p=0.5088) between genotypes,
suggesting that only the female E2F1-/- mice exhibited impaired novel object
recognition during the first 5-minute bin of the object recognition test.

At the 10-minute timepoint, we excluded one E2F1+/+ and one E2F1-/- male that
did not fulfill the novel object recognition analysis requirements. Three-way
ANOVA indicated that there was a significant three-way interaction among gene,
sex, and novel object preference [F(1,80)=5.919, p=0.01721] and a significant
effect of novel object preference [F(1,80)=52.56, p<0.0001]. No other main
effects or interactions were observed. Using two-way ANOVA to analyze male
mouse behavior separately indicated that there was an interaction between
genotype and novel object preference [F(1,40) = 4.753, p=0.0352] in addition to a
main effect of novel object preference [F(1,40)=21.41, p<0.0001]. The E2F1+/+
males no longer exhibited novel object preference (p=0.3701, n=10), whereas
the E2F1-/- males did (p<0.0001, n=12). Separate analysis of female mice
indicated that there was no longer a significant interaction between genotype and
novelty [F(1,40)=1.782, p=0.1895] although there was still a main effect of novel
object preference [F(1,40)=31.48, p<0.0001]. Both the E2F1+/+ and E2F1-/females exhibited novel object preference (p<0.0001, p=0.0217, respectively;
n=11 for each group) (Fig. 2.8E). Two-way ANOVA of the male and female
discrimination indices from the 10-minute time point indicated that there was a
trend toward an interaction between sex and genotype [F(1,40)=2.956,
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p=0.0933], and no main effect of sex or genotype. There were no significant
differences in discrimination indices between the genotypes in male (p=0.4951)
or female (p=0.7437) mice (Fig. 2.8H). Two-way ANOVA of the combined data
from both sexes indicated that there was an effect of novelty [F(1,84)=52.32,
p<0.0001], but no interaction between genotype and novel object preference
[F(1,84)=0.1164, p=0.7338] and no effect of genotype [F(1,84)=0.000, p>0.9999].
Tukey’s post hoc analysis indicated that the E2F1+/+ mice exhibited a significant
preference for the novel object (p<0.001, n=21), as did the E2F1-/- mice
(p=0.0025, n=23) (Fig. 2.8K). There was no significant difference in novelty
preference (p=0.9950) or discrimination index (p=0.8089) between the
genotypes.

At 15 minutes, three-way ANOVA indicated that there was a significant three-way
interaction among gene, sex, and novel object preference [F(1,82)=4.177,
p=0.0442] and a significant effect of novelty [F(1,82)=41.49, p<0.0001]. No other
main effects were observed. Using two-way ANOVA to analyze male mouse
behavior separately indicated that there was an interaction between genotype
and novel object preference [F(1,42)=5.212, p=0.0276] and a main effect of novel
object preference [F(1,42)=12.79=p<0.0009] but no effect of genotype alone. The
E2F1+/+ males did not exhibit novel object preference (p=0.8250, n=10), whereas
E2F1-/- males did (p=0.0004, n=13). Separate analysis of the female mice
indicated that there was no significant interaction between genotype and novel
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object preference [F(1,40)=0.4768, p=0.4939] but there was still a main effect of
novel object preference [F(1,40)=29.50, p<0.0001], with both the E2F1+/+ and
E2F1-/- females exhibiting significant novel object preference (p=0.0005,
p=0.0092, respectively; n=11 for each group) (Fig. 2.8F). Two-way ANOVA of
male and female mouse discrimination indices from the 15-minute time point
indicated that there was no interaction between sex and genotype
[F(1,41)=2.089, p=0.1560] and no effect of genotype or sex. There was no
significant difference in discrimination indices between the genotypes among
male (p=0.4235) or female (p=0.9561) mice (Fig. 2.8I). Two-way ANOVA of the
combined data from both sexes indicated that there was an effect of novelty
[F(1,86)=41.82, p<0.0001] but no interaction between genotype and novel object
preference [F(1,86)=0.8699, p=0.3536] and no effect of genotype [F(1,86)=0.000,
p>0.9999]. Tukey’s post hoc analysis indicated that the E2F1+/+ mice exhibited
significant preference for the novel object (p<0.0016, n=21) similar to that
observed in the E2F1-/- mice (p<0.0001, n=24) (Fig. 8L). There was no significant
difference in novelty preference (p=0.9119) or discrimination index (p=0.5131)
between the genotypes.

Olfaction: Since E2F1tm1/tm1 mice exhibit anosmia at P365+ [321], we assessed
olfaction in E2F1-/- mice using the habituation/dishabituation assay. We analyzed
data per odor condition (odor habituation or odor dishabituation) for each
genotype. Fig. 2.9A shows the time that the E2F1+/+ and E2F1-/- mice spent
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investigating each scent during the habituation/dishabituation assay for (i) males
only, (ii) females only, (iii) males and females combined. Three-way ANOVA
indicated that mice habituated to water [F(1.530,39.02)=29.06, p<0.0001],
almond [F(1.245,31.14)=28.61, p<0.0001], vanilla [F(1.025, 26.64)=29.90,
p<0.0001], same sex odor [F(1.111,26.66)=39.82, p<0.0001], and opposite sex
odor [F(1.994,51.85)=13.78, p<0.0001]. There was an interaction between sex
and gene for habituation to water [F(1,26)=4.3, p=0.0481] and vanilla
[F(1,26)=4.928, p=0.0354]. There was also a trend toward a three-way
interaction among sex, gene, and vanilla [F(2,52)=2.693, p=0.0771].

Among the male mice, there was a significant effect of habituation to water
[F(1.698,23.77)=9.698, p=0.0013], almond [F(1.171,16.39)=15.07, p=0.0009],
vanilla [F(1.025,26.64)=29.90], same sex odor [F(1.111,26.66)=39.82, p<0.0001],
and opposite sex odor [F(1.994,51.85)=13.78, p<0.0001], as determined by twoway ANOVA. No interactions were present, but there was a significant gene
effect on water and vanilla presentation [F(1,14)=8.431, p=0.0116,
F(1,26)=4.928, p=0.0354]. Tukey’s post hoc test indicated that all E2F1+/+ males
(n=8) habituated to almond, vanilla, same sex, and opposite sex scents whereas
the E2F1-/- males (n=8) habituated to vanilla and same sex scents; there was a
trend toward habituating to almond and opposite sex scents (see Fig. 2.9B for a
summary of p values associated with habituation).
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The males also exhibited dishabituation to all scents [almond: F(1,14)=10.61,
p=0057; vanilla: F(1,14)=20.72, p=0.0005; same sex: F(1,13)=29.08, p=0.0001;
opposite sex: F(1,14)=15.63, p=0.0014]. Sidak’s post hoc tests indicate that the
E2F1+/+ males exhibited significantly increased investigation of the same sex and
opposite sex odors and trended toward increased investigation of the almond
scent. The E2F1-/- males increased their exploration of vanilla, same sex, and
opposite sex odors, while exhibiting a trend toward increased investigation of the
almond scent (see Fig. 2.9C for a summary of p values associated with
dishabituation).

Within the female mice, there was a significant effect of habituation to water
[F(1.236, 14.21=22.35, p=0.002], almond [F(1.361,14.97)=14.40, p=0.0009],
vanilla [F(2,24)=1.038, p=0.3694], same sex [F(1.124, 11.80)=14.10, p<0.0023],
and opposite sex [F(1.678, 20.13)=11.25, p=0.0009] by two-way ANOVA. There
were no interactions or gene effects. Tukey’s post hoc test indicated that all
E2F1+/+ females (n=7) trended toward habituating to vanilla and opposite sex
odors but not to almond or same sex odors. The E2F1-/- females (n=7) also
habituated to almond and trended toward habituating to the same sex odor. The
E2F1-/- females did not significantly habituate to vanilla or opposite sex odors
(see Fig. 2.9B for a summary of p values associated with habituation).
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The females also exhibit dishabituation to all scents [almond: F(1,11)=15.38,
p=0.0024; vanilla: F(1,10)=10.24, p=0.0095; same sex: F(1,13)=29.08, p=0.0001;
opposite sex: F(1,10)=11.10, p=0.0076], with no interactions or gene effects.
Sidak’s post-hoc tests indicate that the E2F1+/+ females exhibited significant
increased investigation of almond, vanilla, and same sex odors. The E2F1+/+
females also trended toward increased investigation of the opposite sex odor.
The E2F1-/- females did not exhibit increased exploration of any of the odors but
trended toward increased exploration of the almond and same sex odors. The
E2F1-/- females did not exhibit significantly increased interaction with vanilla
scent or opposite sex odors (see Fig. 9C for a summary of p values associated
with dishabituation).

Combining the olfaction test results of both sexes indicated that there was a
significant effect of habituation to water [F(1.536, 42.23)=27.04, p<0.0001],
almond [F(1.249, 33.71)=31.04, p<0.0001], vanilla [F(1.029, 28.81)=29.38,
p<0.0001], same sex [F(1.114, 28.95)=42.23, p<0.0001], and opposite sex
[F(1.972, 55.23)=13.94, p<0.0001]. There were no interactions or gene effects.
Tukey’s post hoc test indicated that all genotypes habituated to all scents: water,
almond, vanilla, same sex, and opposite sex (see Fig. 2.9B for a summary of p
values associated with habituation). There was also a significant effect of
dishabituation to almond [F(1,27)=24.89, p<0.0001], vanilla [F(1,26)=28.77,
p<0.0001], same sex [F(1,27)=48.46, p<0.0001] and opposite sex
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[F(1,26)=27.91, p<0.0001] odors. Sidak’s post hoc test indicated that all
genotypes recognized all scents as novel: water, almond, vanilla, same sex, and
opposite sex (see Fig. 2.9C for a summary of p-values associated with
dishabituation). Sidak’s post hoc test also indicated that there were no significant
differences in time spent investigating any scent between genotypes.

Perturbation in synaptic proteins in E2F1tm1/tm1 is not present in E2F1-/- mice
Ting et al. reported that P365+ E2F1tm1/tm1 mice exhibited synaptic protein
perturbations along with novel object impairment and anosmia [321]. Therefore,
we characterized the expression of the synaptic proteins that were reported to be
altered in E2F1tm1/tm1 mice in our 1-year-old E2F1-/- mice. We compared the
expression levels of the N-methyl-D-aspartate receptor subunits (NR1, NR2A,
NR2B), the AMPA receptor subunit 2 (GluR2), postsynaptic density protein
(PSD-95), synapsin, synaptophysin, and synaptic Ras GTPase activating protein
(Syngap) between the E2F1+/+ (n=8) and E2F1-/- mice (n=8) in both the cortex
and hippocampus. We found that there were no changes in the expression levels
of any of these proteins caused by the loss of E2F1 (Fig. 2.10). There was also
no indication that there was a sex difference in expression levels, even though
sex differences were detected by novel object recognition at the 5-minute time
point.

69

E2F1tm1/tm1-associated aberrant expression of cerebellar PCNA expression
is not present in E2F1-/- mice
Wang et al. previously reported that P365+ E2F1tm1/tm1 mice exhibited aberrant
cell cycle reentry, evidenced by increased PCNA expression in cerebellar
neurons [339]. Therefore, we evaluated PCNA expression in the cerebellum of
our 14-month-old E2F1-/- mice. We found no difference in PCNA expression in
cerebellar neurons by both immunoblotting (n=8) and immunofluorescence (n=3)
(Fig. 2.11).

A subset of histopathological changes in E2F1tm1/tm1 is not present in aged
E2F1-/- mice
Since the E2F1-/- mice did not recapitulate the previous reported findings in
E2F1tm1/tm1 mice, including alterations in body and brain weight, novel object
recognition, anosmia, and expression of synaptic proteins and PCNA [62, 95,
321, 339], we proceeded to characterize E2F1-/- mice for pathologies that were
reported in aged E2F1tm1/tm1 and other models of E2F1 deficiency [95, 361]. The
histopathological changes we evaluated included testicular atrophy, altered
proliferation of thymocytes within the thymic cortex, exocrine tissue abnormalities
(salivary gland and pancreas), and tumors of varying origins [95, 361]. Therefore,
we assessed a variety of E2F1-/- organs for pathologies, in an effort to determine
if any of the reported E2F1tm1/tm1 pathologies could be a result of model design. A
summary of the relevant findings is shown in Fig. 2.12A.
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As previously reported, E2F1 loss caused pathological changes in testes and
exocrine glands. The mean testicular weight (±SD) of the E2F1-/- males were
42.18% ± 7.65% of that of the E2F1+/+ males (Fig. 2.12B). Histologically, the
testes in E2F1-/- males exhibited multifocal seminiferous tubular atrophy with
tubules lacking germinal cells and exhibiting abnormal germinal cell maturation
and overall decreased spermatogenesis. All E2F1-/- mice had histologically
abnormal salivary glands, which exhibited moderate/severe acinar cell
karyomegaly and cell multinucleation. Similar observations were noted in the
E2F1-/- pancreas. All E2F1-/- males exhibited pancreatic acinar cell karyomegaly
and multinucleation, while three and two of the four E2F1-/- females exhibited
acinar cell karyomegaly and multinucleation, respectively. Increased mitotic
activity in the pancreas was detected in all E2F1-/- males while not noted in E2F1/-

females. Pancreatic atrophy and zymogen cell loss were observed in one of the

four E2F1-/- males and two of the four female E2F1-/- mice. In mice with
pancreatic atrophy, adipose tissue was noted to have replaced pancreatic cells
(Fig. 2.12C).

We found no abnormalities associated with genotype in liver, gall bladder,
kidney, lung, heart, larynx, trachea, esophagus, thyroid, skeletal muscle, spleen,
lymph nodes, skin, prepubertal glands, penis, seminal vesicles, prostate, ovaries,
uterus, ureter, urinary bladder, urethra, stomach, small intestine, large intestine,

71

oral cavity, nasal cavity, eyes, brain, spinal cord, or thymus. The lack of a
genotype effect on thymic pathology (Fig. 2.12C) was interesting, given that the
most dramatic finding in aged E2F1 tm1/tm1 mice was found in the thymus
according to Field et al. [95]. We were also unable to confirm that E2F1 loss
increased tumor prevalence. Two mice, one from each genotype, exhibited
atypical round-cell proliferations infiltrating and expanding to the splenic red pulp.
It was possible that these were indicative of an early manifestation of histiocytic
sarcoma; however, it was more likely the result of a reactive process. Only one
mouse, an E2F1+/+ female, had a confirmed neoplastic process in the spleen and
liver, comprising large atypical cells reminiscent of histiocytes. Given the
morphology and distribution of the neoplastic cells, this mouse most likely had a
histiocytic sarcoma. However, with a small n (n=6-8 for each genotype), we could
not be certain that E2F1 loss in this model would not increase tumor prevalence.
In the cohort of animals used in the present study, however, none of the E2F1-/mice had cancerous tumors in any of the retrieved organs.

While confirming E2F1tm1/tm1-associated phenotypes, we also discovered that
bone marrow from the E2F1-/- mice frequently contained an increased number of
megakaryocyte precursor cells. Three of the four male and one of the four female
E2F1-/- mice exhibited bone marrow megakaryocytic hyperplasia, whereas none
of the E2F1+/+ mice exhibited this phenotype (Fig. 2.13).
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Discussion

We have developed a conditional E2F1 mouse that, when bred with a Cre
mouse, lacks not only the DNA-binding and dimerization domains but also the
cyclin A-binding and transactivation domains of E2F1, including the Rb-binding
domain. The constitutive E2F1 knockout generated from our conditional mouse
lacks the PGK-neocassette transgene unlike the two currently available E2F1
mouse models [95, 360], the consequences of which are yet to be determined.
These E2F1-/- mice, albeit viable and fertile similar to other E2F1 mutant and
knockout mice, exhibited muted or absent phenotypes compared to those
previously reported in the E2F1tm1/tm1 mouse. Body weight of the E2F1-/- mice
was reduced only by 3%-6% compared to the E2F1+/+ mice between 6 weeks
and 12 months of age, and the E2F1-/- males did not exhibit anxiety-like behavior,
novel object recognition impairment, or anosmia. The E2F1-/- females exhibited
anxiety-like behavior in one of the two assays used and novel object recognition
impairment only at an early timepoint. However, the same E2F1 -/- females
exhibited novel object recognition at later time points. Our data suggest that
hyposmia may be present in the E2F1-/- females due to the less time spent
investigating novel scents; however, there were no significant differences in
interaction time with novel scents between the E2F1+/+ and E2F1-/- females and
no significant genotype and novel scent interaction, leaving us unable to
conclude that the E2F1-/- females had an impaired sense of smell compared to
the E2F1+/+ females. The sex difference in novel object recognition impairment
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was not supported by our immunoblotting results, as we observed no
perturbations in the expression levels of synaptic proteins (NR2A, NR2B, NR1,
GluR2, PSD-95, synaptophysin, synapsin, syngap) in either sex. Additionally, the
E2F1-/- mice did not exhibit differences in cerebellar PCNA expression or adult
brain weight, two additional CNS-phenotypes present in the E2F1tm1/tm1 mice [62,
339]. In agreement with previous reports, the E2F1-/- mice exhibited reduced
testicular weight and spermatogenesis, testicular atrophy, and endocrine gland
dysplasia [95, 360]. However, the E2F1-/- mice did not exhibit thymic hyperplasia,
a phenotype that was present in all aged E2F1tm1/tm1 mice assessed by Field et
al. [95].

Furthermore, in our evaluations to determine whether E2F1tm1/tm1-related
phenotypes were present in our mice, we did not find any indication that E2F1-/mice exhibited a higher tumor prevalence, a result that contradicts the findings
observed in the other E2F1-/- model reported by Yamasaki et al. They found that
34% (35/102) of the necropsied E2F1-/- mice had tumors of varying origins, and
given that they necropsied more sick E2F1-/- mice than by random chance, the
authors estimated that the tumor prevalence in their mouse line was between
19%-34% [360]. Therefore, we had expected at least one of eight of the
necropsied E2F1-/- mice to exhibit tumorigenesis, instead of zero. However, the
evaluation of tumor prevalence in our mice could be subject to error due to the
lack of statistical power. We also discovered that 50% of our E2F1-/- mice
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exhibited megakaryocytic hyperplasia, a phenotype that was not previously
reported in any of the E2F1 knockout models. E2F1 is recognized to play a role
in myeloid differentiation in bone marrow [326], but an effect on megakaryocytic
differentiation has not been previously described. Megakaryocytic hyperplasia is
often related to conditions where increased consumption or destruction of
platelets occurs [325]. Since not all E2F1-/- mice exhibited this phenotype, it likely
reflects a reactive process to which E2F1-/- mice are more prone. However,
without further investigation, causality cannot be determined.

Overall, our results indicate that E2F1 may not be necessary for novel object
recognition memory, synapse maintenance, or neuronal cell cycle suppression.
Previous reports in E2F1tm1/tm1 mice established on a F2 B6x129 background
may be confounded by off-target effects of the neocassette or leaky expression
of a mutant E2F1. However, confounding factors such as stress caused by
experimenter sex or handling could have contributed to an absence in an
anxiety-like phenotype in our E2F1-/- male mice. Experimenter sex can influence
stress; male experimenters led to stress-induced analgesia in male mice
whereas female experimenters did not [300]. A male experimenter evaluated the
E2F1tm1/tm1 mice for anxiety-like behavior reported by our group [321], whereas a
female experimenter evaluated all E2F1-/- mice in our experiments. Therefore, it
is possible that the presence of a male experimenter caused additional stress
that allowed for the detection of an anxiety-like phenotype in the E2F1-/- males by
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the light/dark box test whereas the use of a female experimenter in the present
study reduced the likelihood of detecting this phenotype. Alternatively, the
anxiety-like phenotype may actually be weaker in our mouse model, and not
robust enough to detect in both sexes or the assays we chose.

The novel object recognition assay can also be confounded by anxiety-like
behavior by reducing locomotor activity, exploration time, or interest in novelty
[201]. We did not see a significant difference between locomotor activity or total
exploration time in the E2F1-/- mice; however, we did not perform additional tests
to assess whether the E2F1-/- females exhibited higher latency to explore novelty
or to confirm that the elimination of anxiety-like behavior, using a
pharmacological method, rescued the novel object recognition deficit. However,
the E2F1-/- females exhibited novel object recognition and no preference for
object location at 15 minutes; therefore, we predict that another yet undefined
factor confounded the novel object recognition deficit at the 5-minute time point.
Since Ting et al. used a more demanding protocol that relied on a 5-minute
timepoint for both training and testing phases, it is possible that the total
exploration time of the objects was different given that Ting et al. detected an
anxiety-like phenotype in the E2F1tm1/tm1 mice [321]. Since the total exploration
time was not published, we cannot determine if anxiety-like behavior in their
experiments might have served as a confounding factor. However, since our
dishabituation/habituation assay revealed no olfactory deficits in the E2F1-/- male
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mice, we conclude that stress or anxiety caused by experimental conditions or
differences in assay design cannot explain all phenotypic differences between
the E2F1tm1/tm1 and E2F1-/- mice. Furthermore, the lack of four previously
reported E2F1tm1/tm1 phenotypes — synaptic protein perturbation [321], aberrant
PCNA expression [339], reduced brain weight [62], and thymic hyperplasia [95]
— in our E2F1-/- mice implies that there is something different at a molecular
level between the two E2F1 mouse models.

Lopez-Sanchez et al. reported that E2F1tm1/tm1 mice on a B6 background
exhibited better memory in a stringent novel object recognition protocol and
Morris water maze at one year of age [198]; their findings weaken the argument
that a mouse model design difference, such as the expression of neocassette or
a mutant E2F1-like protein, contributes to CNS-related pathology. However, one
study showed that expression of a tetracycline transactivator (TTA), theoretically
an inert temporal control element, in mice caused neuronal loss in the dentate
gyrus in hybrid strain backgrounds but not in congenic B6 mice. While the
tetracycline transactivator-expressing mice on a B6/FVB/129 background
exhibited overt dentate degeneration, backcrossing these mice with B6 mice for
5-6 generations rescued the phenotype [121]. In the study by Lopez-Sanchez et
al, E2F1tm1/tm1 mice purchased from Jackson on a hybrid background were
backcrossed for 9 generations onto a B6 background [198], making the change
of background a possible reason for the absence of E2F1tm1/tm1 CNS-related
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phenotypes observed in the hybrid strain [321]. Since our experiments were not
designed to measure improved novel object recognition in our E2F1-/- mice, we
cannot discount the Lopez-Sanchez et al’s finding that the E2F1tm1/tm1 mice had
improved memory compared to wildtype mice and that this may be mediated by
E2F1 loss [198]. Using their protocol, Wildtype mice on a B6 background did not
spend more time investigating the novel object. Since our E2F1 +/+ mice did
investigate the novel object more than the familiar object in our less stringent
novel object recognition assay, it is possible that ceiling effects may have
obscured any novel object recognition improvement caused by the E2F1
knockout. We did see a trend toward an influence of genotype on intersession
habituation, wherein the E2F1-/- mice habituated earlier than the E2F1+/+ mice
when both sexes were analyzed together. Since habituation is one of the
simplest, most common forms of learning, earlier intersession habituation may be
considered a surrogate measure for long-term memory [38] and in this case, it is
possible that the E2F1-/- might have improved long-term memory.

We did not address whether the phenotypic differences between the E2F1tm1/tm1
and E2F1-/- mice were due to insertion/expression of a neocassette or the
expression of residual E2F1 C-terminal RNA. However, the two most studied
E2F1 mouse models both retain a PGK-neocassette in their genome [95, 361].
While there is substantial evidence that an inserted neocassette can alter
phenotypes depending on the location of insertion by altering the expression of
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nearby genes up to 100 kb away [257, 287], it is interesting to note that there is
at least one phenotype that is different between the E2F1tm1/tm1 mice and the
E2F1-/- mice by Yamasaki et al.. While the E2F1tm1/tm1 mice exhibit reduced body
weight by 17% for at least the first eight months of life [95], the Yamasaki group
noted that there was no perceptible difference in weight between their E2F1-/mice and age-matched E2F1+/+ mice between 6.7 and 8.7 months of age. The
weight differences became perceptible between 12 and 15 months of age, with a
number of E2F1-/- mice necropsied noted to have lost weight compared to their
weights at 8.7 months [361]. While it is not clear if the E2F1-/- mice by Yamasaki
et al. express neocassette RNA, this finding raises the possibility that the
neocassette may not be the only factor contributing to the differences in
phenotypes observed between our E2F1-/- mice and the E2F1tm1/tm1 mice.
Additionally, similar to our E2F1-/- mice, the E2F1-/- mice by Yamasaki et al. do
not appear to express C-terminal E2F1 [361], and we also did not observe a
“perceptible” decrease in body weight up to one year of age. These suggest that
the residual C-terminal E2F1 expression in E2F1tm1/tm1 mice might have resulted
in a dominant negative phenotype.

Theoretically, while the mutated E2F1 lacks DNA-binding activity, the expression
of a functional Rb-binding domain, a domain shared by E2F1-5 [187], might have
adversely affected the activities of other E2F family members. Compensatory
activities of E2F1-3 are well-studied, and upregulation of E2F3 in response to the

79

loss of E2F1 is not uncommon [134, 169, 322]. While E2F1 has several specific
activities that are not regulated by E2F2 or E2F3 [69, 345], E2F1-3 often regulate
similar functions by binding to E2F promoters to induce or repress transcription
depending on the context [327]. For all three E2Fs, pRb binding inhibits
transcriptional activity of activator E2Fs in cycling cells and represses activator
E2F activity in postmitotic cells [58]. Expression of a mutant E2F1 without DNAbinding activity could still sequester pRb from E2F2 and E2F3, detrimentally
affecting functions within a cell that is regulated by all three transcription factors,
serving as a dominant negative for other E2Fs that share significant C-terminal
homology.

Increased levels of unbound E2F2 or E2F3 and/or reduced availability of pRb for
binding may result in increased proliferation in cycling cells or reduced repression
of E2F promoters in postmitotic cells. Limiting the amount of Rb-bound E2F2 or
E2F3 can also reduce the ability of histone deacetylases to cooperatively repress
E2F-responsive genes, resulting in impaired cell cycle exit or aberrant cell cycle
reentry in postmitotic neurons [41, 203]. In fact, E2F3 has been implicated in a
variety of necessary neuronal processes including neurogenesis, neuronal
migration, and cortical health [158, 212]. Like E2F1, PCNA is a target gene for
E2F3 [140, 186]. It is possible that the expression of C-terminal E2F1 in
E2F1tm1/tm1 mice alters pRb-dependent and E2F3-dependent functions, resulting
in CNS phenotypes reported in other studies. The disruption of E2F1 alone may
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not be enough to elicit CNS phenotypes, but the additional disruption of pRb and
E2F3 may reach a threshold that results in aberrant cell cycle reentry,
neurogenesis, and synaptic integrity, leading to anosmia, accentuation of
anxiety-like behavior, and novel object recognition impairment.

Therefore, it is also possible that other E2F1-associated pathologies reported in
the E2F1tm1/tm1 mouse may be muted or absent in a mouse model that does not
express C-terminal RNA, since the characteristic E2F1tm1/tm1 thymic pathology
was also absent in our E2F1-/- mice. In addition to the alterations in cell cycle,
disrupting the interaction of E2F3 with pRb can also alter the expression of genes
involved in metabolism, inflammation, immunity, and stress response [186].
Therefore, additional E2F3 activity may confound the interpretation that E2F1
hinders wound healing [84], regulates oxidative metabolism [35], and has dual
pro-inflammatory and anti-inflammatory functions [343], findings primarily
observed in the E2F1tm1/tm1 mice. Our E2F1-/- mouse model and the conditional
mouse this model was based on may be useful in evaluating whether these and
other reported phenotypes are dependent on E2F1, are a result of compensatory
upregulation and increased activity of E2F3, or are specific to the E2F1tm1/tm1
mouse model.

While acknowledging the potential unintended effects that mouse model design
could have on evaluating endogenous gene-mediated phenotypes, we also
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investigated whether there were any off-target effects of our targeting strategy in
our E2F1-/- mice. We acknowledge that the excision of approximately 5.3 kb
genomic DNA, might have contributed to altered expression of nearby genes. We
found that the closest 3’ gene, Necab3, was altered in a tissue-specific manner in
our E2F1-/- mice. However, given that the gene was altered in liver, and not brain,
we do not think that this model difference contributed to the absence of CNS
phenotypes observed in our studies. This however does not discount that
another nearby gene might be altered to effectively attenuate E2F1-dependant
phenotypes. But, since E2F1 is increased in progressive neurodegenerative
diseases such as Alzheimer’s disease [154], Parkinson’s disease [133], and
Huntington’s disease [251] and as it can contribute to aberrant cell cycle reentry
and apoptosis in vitro, we believe that further studies of E2F1 excision as a
therapeutic strategy may be warranted if approached in a tissue-specific manner,
assuming E2F1 is dispensable in for learning and memory.

In summary, our results suggest that E2F1-specific roles that have been
identified using the E2F1tm1/tm1 mouse may be confounded by model design. This
is especially true for CNS-related pathologies. The lack of thymic hyperplasia and
the novel finding of megakaryocytic hyperplasia in our E2F1-/- mice suggest that
the roles of E2F1 in inflammatory processes may also be different than that
observed in the E2F1tm1/tm1 mouse model. Further evaluation of the reported
pathologies mediated by E2F1 loss may require the use of E2F1-/- mice that do
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not express residual E2F1 RNA or a neocassette. Use of our novel conditional
E2F1 mouse, from which our E2F1-/- mouse was derived, would be a useful tool
to clarify the role of E2F1 in various cellular processes and pathologies, identify
the roles of E2F1 that avoid detection in E2F1 knockout models due to
compensation by other E2F family members, and identify the value of cell-type
specific E2F1-targetting therapies.
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Figure 2.1. Development of conditional E2F1 mice. A) Targeting vector was constructed with
the loxp site located 208bp upsteam of exon (E) 2, a flippase recombinant target (FRT)-flanked
neocassette (neo) 315bp downstream of the 3’ untranslated region, and the second loxp site
located 18bp downstream of it, and electroporated into V6.5 ES cells. Neo-positive clones were
screened by Southern blotting using a probe located downstream of the targeting vector. B)
Probe was used for Southern analysis of KpnI-cut genomic DNA from male chimera. Positive
clones yielded the expected 14kb length wildtype band and 16kb length mutant band. A wildtype
sample is used as control. C) Genotyping by PCR of genomic DNA (wildtype band: 336bp;
mutant band: 434bp) showing no DNA control (X), wildtype (+/+), heterozygous floxed (+/fx), and
homozygous floxed (fx/fx) mouse tail samples.
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Figure 2.2. Development and validation of constitutive E2F1 knockout mice. A) Breeding
scheme for knockout generation. Breeding of homozygous floxed E2F1 mice (E2F1fx/fx) with
homozygous tamoxifen-inducible ubiquitous Cre (CreERT2++) produced mice double
homozygous for floxed E2F1 and tamoxifen-inducible Cre (E2F1fx/fx; CreERT2++) after 2
generations. F2 E2F1fx/fx; CreERT2++ males were injected for five consecutive days with 75mg/kg
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CreERT2++ females were injected with 1.5mg tamoxifen to induce cre recombination in F3
E2F1fx/fx; CreERT2++ embryos. F3 adults exposed to tamoxifen in utero were bred with each
other, and again 12 dpc females were injected with 1.5mg tamoxifen. One F4 male was bred with
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heterozygotes were bred with WT mice to remove the final Cre allele. Breeding of F6 mice
produced the experimental mice in this study. Created with BioRender.com. B) Diagram showing
genomic recombination expected by inducing Cre in E2F1fx/fx mice. Cre-induced excision of
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~7.5kb of the genome, cooresponding to exon 2 through 3’UTR of E2F1 and the flippaserecognition target (FRT)-flanked neocassette. Sanger sequencing of PCR-amplified F6 E2F1-/DNA confirm that recombination happened as expected. C) qPCR for quantification of E2F1
mRNA in mouse tissues showing that E2F1-/- mice do not express E2F1 mRNA. GAPDH was
used as a housekeeping gene (n=3-5). N.d., not detected. D) Genotyping by PCR of genomic
DNA (wildtype band: 336bp; mutant band: 425bp) showing no DNA control (X), wildtype (+/+),
heterozygous null (+/-), and homozygous null (-/-) mouse tail samples E) Immunoprecipitation (IP)
of E2F1 from mouse brain lysates. A specific signal for E2F1 was not detected in input lysate.
E2F1 was immunoprecipitated from E2F1+/+ and not E2F1-/- brain extracts. Normal Rabbit IgG
antibody was used as a control.
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Figure 2.3. E2F1 RNA is not detected in the newly generated E2F1 knockout but persists in
previously reported E2F1 mutant mice. A) RNAscope probe (red) labeling of hippocampal
sections from wildtype (E2F1+/+) and E2F1 knockout (E2F1-/-) mouse brain. No E2F1 is detected
in E2F1-/- mice. Positive PPIB labeling (red) in tissue indicates that the lack of E2F1 signal in
E2F1-/- brain is not a result of poor tissue integrity. B) E2F1 RNAscope probe (red) labeling of
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hippocampal sections from wildtype (F2 B6x129) and E2F1 mutant (E2F1tm1/tm1) mice. Both
sections are positive for E2F1 RNA. Probe detects RNA spanning nucleotides 631 to 1513,
corresponding to regions that if translated in frame could produce an intact transactivation
domain. Scale bars: 25m. Hematoxylin counter stain (blue).
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wildtype (E2F1+/+) and E2F1 knockout (E2F1-/-) mice at 6 weeks, 3 months and 12 months (n=1112 per group). B) Body weight of male and female E2F1-/- mice as a percent of sex-matched
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(n=15 per genotype). No genotype comparisons were statistically significant (p<0.05) by Tukey
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Figure 2.6. Locomotor Activity in 1-year-old E2F1 knockout mice. A) Total beam break
counts in open field for wildtype (E2F1+/+) and E2F1 knockout (E2F1-/-) mice divided by sex. B)
Total beam break counts in open field for E2F1+/+ and E2F1-/- mice ignoring sex as a variable. C)
Horizontal beam break counts in open field for E2F1+/+ and E2F1-/- mice divided by sex. D)
Horizonal beam break counts in open field for E2F1+/+ and E2F1-/- mice ignoring sex as a
variable. E) Vertical beam break counts in open field for E2F1+/+ and E2F1-/- mice divided by sex.
Vertical activity, or rearing, is significantly different between male and female E2F1-/- mice
(Tukey’s post hoc * p<0.05, n=11-13 per group). F) Vertical beam break counts in open field for
E2F1+/+ and E2F1-/- mice ignoring sex as a variable. All graph data are represented as mean 
SEM, with E2F1+/+ mice represented by filled circles and E2F1-/- mice represented by open
circles.
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Figure 2.7. Habituation to the novel object recognition test arena of experimental mice
across five days. Intersession habituation to the novel object recognition test arena in 1year-old E2F1 knockout mice. Distance traveled across five preexposures (PE) during
habituation to the arena for A) wildtype (E2F1+/+) males, B) E2F1+/+ females, E2F1+/+ females
(n=12), C) all E2F1+/+ mice, combining sexes (n=22), D) E2F1-/- males (n=12), E) E2F1-/- females
(n=10), F) E2F1-/-(n=22). E2F1-/- females (E) habituated earlier than E2F1+/+ females (panel B)
E2F1-/- exhibited reduced distance traveled by PE3 compared with E2F1+/+ (C vs F). However,
distance traveled between E2F1+/+ and E2F1-/- mice was not significantly different from each other
for any PE. Tukey’s post hoc * p<0.05, *** p<0.001 for PE1 vs PE5, PE1 vs PE4 and PE1 vs PE3.
E2F1+/+ mice [female and combined sex (panel B-C)] continued to reduce activity following PE3
(Tukey’s post hoc $ p<0.05, $$$ p<0.001 for PE3 vs PE5 and PE3 vs PE4) in contrast to E2F1-/mice [female and combined sex (panel E-F)]. All graph data are represented as mean  SEM,
with E2F1+/+ mice represented by filled circles and E2F1-/- mice represented by open circles.
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Figure 2.8. 1-year-old E2F1 knockout females exhibit time-dependent novel object
recognition impairment. A-C) Experimental mice do not exhibit object location preference
during object familiarization in the novel object recognition assay at (A) 5 minutes, (B) 10 minutes
and (C) 15 minutes. Object 1 (filled circle) and object 2 (open circle) are identical objects; object 2
was replaced by the novel object during testing. Data are represented as a percent of time spent
interacting with either object, mean  SEM, stratified by sex. D-F) Novel object interaction after
(D) 5 minutes, (E) 10 minutes and (F) 15 minutes. At 5 minutes, only E2F1-/- females failed to
interact more with the novel object. At 10 and 15 minutes, only E2F1+/+ males failed to interact
more with the novel object. Data are represented as a percent of time spent interacting with
familiar (filled circle) and novel (open circle) objects, mean  SEM, stratified by sex. G-I) Novel
object discrimination at (G) 5 minutes, (H) 10 minutes and (I) 15mins. Novel object discrimination
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is impaired in E2F1-/- females compared to E2F1+/+ females at 5 minutes. Discrimination index is
not different between genotypes at 10 or 15 minutes. Data are represented as discrimination
indices [(novel object interaction time – familiar object interaction time) / (novel object interaction
time + familiar object interaction time)] from E2F1+/+ (filled circles) and E2F1-/- mice (open circles),
mean  SEM, stratified by sex. 5 minute: n=8-11 per sex per genotype, 10 minute: n=10-12 per
sex per genotype, 15 minute: n=10-12 per sex per genotype. Tukey’s post hoc * p<0.05, **
p<0.01, *** p<0.001, **** p<0.0001. J-L) Novel object interaction after (J) 5 minutes, (K) 10
minutes, and (L) 15 minutes. For all timepoints, both E2F1+/+ and E2F1-/- mice interact more with
the novel object when sexes are combined. Data are represented as a percent of time spent
interacting with familiar (closed circle) and novel (open circle) objects, mean  SEM. 5 minute:
n=18-19 per genotype, 10 minute: n=21-23 per sex per genotype, 15 minute: n=21-24 per
genotype. Tukey’s post hoc *** p<0.001, **** p<0.0001.
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Figure 2.9. Habituation/dishabituation to nonsocial and social odors is not affected in 1year-old E2F1 knockout mice Mice were subjected to 3 consecutive presentations (2 seconds
each, 1-3) with 1 second break between for water (W), 1:100 almond extract (A), 1:100 vanilla
extract (V), same sex odor (SS) and opposite sex odor (OS). A) Time spent interacting with the
scented cue for each scent and presentation are shown for (i.) male E2F1+/+ and E2F1-/- mice
(n=), (ii.) female E2F1+/+ and E2F1-/- mice (n=), and iii) E2F1+/+ and E2F1-/- mice, sex data
combined (n=7-8 per sex per genotype, n=15 per genotype). No genotype comparisons for time
interacting with any scent at any presentation were significantly different by Sidak’s post hoc.
Data are represented as mean  SEM, with E2F1+/+ mice indicated by filled circles and E2F1-/-
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mice indicated by open circles. B) Table showing Tukey post-hoc p-values indicating significant
habituation to any scent, comparison between first and third presentation, separated by genotype
and sex. Lack of significant differences for habituation in sex-separated analyses may indicate
that sex-separated analyses are underpowered (n=7-8 per sex per genotype). When sexes were
combines, both genotypes habituated to all presentations. Significant Tukey’s post hoc p-values
are in bold (n=15). C) Table showing Sidak’s post-hoc p-values for dishabituation at presentation
to a novel scent, comparison between immediately preceding scent presentation and first
presentation of novel scent, separated by sex and genotype. Sex-differences may be present in
E2F1+/+ and E2F1-/- mice for dishabituation, however, all E2F1+/+ and E2F1-/- mice exhibited
significant dishabituation to all presented scents. Significant Sidak’s post hoc p-values are in bold
(n=7-8 per sex per genotype, n=15 per genotype).
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Figure 2.10. Prominent synaptic proteins associated with learning and memory are not
altered in 14-month-old E2F1 knockout mice. A) Representative immunoblots of various
synaptic proteins from cortices and hippocampi of male and female wildtype (E2F1 +/+) and E2F1
knockout (E2F1-/-) mice: i) NR2A, NR1, Synapsin, ii) NR2B, GluR2, PSD95, Synaptophysin, and
iii) syngap. Immunoblots for actin and fast green protein stain are shown as loading controls. B)
Quantification of band densitometry associated with synaptic markers in the cortex of E2F1+/+
(filled circle) and E2F1-/- (open circle) mice. Data were normalized to fast green loading control
and represented as fold change from E2F1 +/+ with mean  SEM. C) Quantification of band
densitometry associated with synaptic markers in the hippocampus of E2F1 +/+ (filled circle) and
E2F1-/- (open circle) mice. Data were normalized to fast green loading control and represented as
fold change from E2F1+/+ with mean  SEM. For all western blot analyses, n=8 for each
genotype. Sexes were divided evenly within each genotype.
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Figure 2.11. PCNA expression is not aberrantly induced in the cerebellum of 14-month-old
E2F1 knockout mice. A) Representative immunoblot of PCNA expressed in cerebellum from
wildtype (E2F1+/+) and E2F1 knockout (E2F1-/-) mice. Immunoblots for actin and fast green
protein stain are shown as loading controls. B) Quantification of PCNA expression in the
cerebellum of E2F1+/+ (closed circle) and E2F1-/- (open circle) through normalization of band
densitometry with fast green loading control, mean  SEM, n=8 per genotype. C) PCNA
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expression is not detected by immunofluorescence in the cerebellum of E2F1-/- mice. (i) PCNA
(Cy3-red) is not detected in the cerebellum (CERE). PCNA positive cells are detectable in the
ventricular-subventricular zone (SVZ) indicating that the antibody is working. (ii) serial section
showing that PCNA positive region of the SVZ is located in a similar area as doublecortin (DCX)
positive cells (Cy3-red). GFAP (FITC-green) was used to help locate the subventricular zone and
rostral migratory stream. DAPI (blue) was used to label nuclei. Scale=50m, n=3.
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Figure 2.12. Aged E2F1 knockout mice share a subset of reported E2F1 mutant mouse
histopathologies. Tissues were collected from 15- to 18-month-old mice, sectioned and
evaluated for histopathologies using hematoxylin & eosin (H&E) staining A). Heat map identifying
frequencies of specific pathologies observed in wildtype (E2F1+/+) and E2F1 knockout (E2F1-/-)
mice. NA indicates evaluations that are not applicable. Color code represents relative level of
pathology observed in tissue assessed, blue being no pathology and pink, red and dark red
representing mild, moderate severe pathology respectively. B) Testicular weight is reduced in
E2F1-/- mice. Data are represented at mean  SEM, n=3-4. C) Representative images of H&Estained sections for identification of pathologies in testes, parotid salivary glands, pancreas, and
thymus. E2F1-/- mice exhibit abnormal seminiferous tubules characterized by seminiferous tubule
atrophy with empty tubules lacking germinal cells, as well as tubule exhibiting abnormal germinal
cell maturation (n=3-4 for each genotype). E2F1-/- parotid salivary glands exhibit frequent acinar
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cell karyomegaly and multinucleation (n=6-8 for each genotype). E2F1-/- pancreas exhibit
frequent acinar cell karyomegaly and multinucleation (n=6-8 for each genotype). White arrows
indicate acinar cells with karyomegaly. Green arrows indicate acinar cells that are multinucleated.
No thymic hyperplasia was observed in E2F1-/- thymus (n=6-8 for each genotype). Scale bar =
60m.
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Figure 2.13. Megakaryocytic hyperplasia is observed in aged E2F1 knockout mice. Bone
marrow was collected and decalcified from 15-18 mth old wildtype (E2F1+/+) and E2F1 knockout
(E2F1-/-) mice, sectioned and stained with hematoxylin & eosin for pathological analysis. A) Heat
map showing frequency of bone marrow megakaryocytic hyperplasia (BMMH) in E2F1 +/+ and
E2F1-/- mice. Color code represents relative level of pathology observed, blue being no pathology
and pink or red representing mild or moderate pathology respectively. B) Representative images
of H&E-stained bone marrow sections from E2F1+/+ and E2F1-/- mice. E2F1-/- sternum sections
have more megakaryocyte precursors, n=6-8 for each group. Scale bar = 60m.
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CHAPTER 3: INVESTIGATING PRO- AND ANTI-INFLAMMATORY
ROLES OF E2F1 IN BONE-MARROW-DERIVED MACROPHAGES

Introduction
Inflammation is the body’s method of defending against damaged tissue and
foreign bodies. Acute inflammation results in the elimination of noxious agents,
including microbes and dead cells, and inflammation abates following their
elimination. Prolonged inflammation can be damaging, but inflammatory
mechanisms can activate repair or regenerative processes [228]. Macrophages
are key cells involved in inflammatory responses as they modulate cytokine
release, clear pathogens through phagocytosis, and control angiogenesis and
extracellular matrix remodeling. While essential for initiating acute inflammation,
macrophages also play a role in promoting repair and recovery [237]. In cases of
inadequate initiation of anti-inflammatory pathways, a skewed and low-grade
induction of proinflammatory mediators may contribute to chronic inflammation or
pathological priming and exaggerated proinflammatory mediator release, which
can occur in response to subclinical levels of lipopolysaccharide (LPS), a
bacterial component observed in adverse health conditions including obesity, HIV
infection, and aging [74, 206]. Unresolved inflammation or dysregulated repair
mechanisms can contribute to the development of fibrosis, atherosclerosis,
cancer, and neurodegeneration [228].

103

Cytokines, chemokines, and growth factors are key mediators that act to
coordinate inflammation and repair. The prototypical proinflammatory cytokines
released during the initial inflammatory phase include IL-6 and TNF- [122].
Additionally, IL-10 is a cytokine responsible for the pro-resolution and
regeneration phases. IL-10 downregulates proinflammatory cytokine release and
initiates metabolic changes in proinflammatory macrophages that lead to a
phenotypic switch toward repair and regeneration, along with IL-4 and IL-13 [209,
304], which is not expressed in response to subclinical concentrations of LPS in
cell culture [206, 237]. Although overly simplistic, macrophages can be divided
into classically activated (M1) or alternatively activated (M2) macrophages. M1like macrophages are considered to be induced by proinflammatory cytokines,
such as IL-6 and TNF-, as well as bacterial components such as LPS, while the
M2-like macrophages are induced by anti-inflammatory cytokines including IL-10,
IL-4, and IL-13 [151, 209, 237, 304]. M1-like macrophages are characterized by
(1) production of reactive nitrogen intermediates and ROS, (2) release of proinflammatory cytokines, and (3) surface expression of markers involved in
antigen presentation to T cells, highlighting their essential role in pathogen
elimination. M2-like macrophages are characterized by expression of arginase 1,
an enzyme responsible for hydrolysis of L-arginine to L-ornithine, which in turn is
necessary for cell survival, production of collagen, and repair of tissue damage.
M2-like macrophages also express high surface levels of scavenger, mannose-,
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and galactose-type receptors involved in the clearance of debris [222]. Together,
M2-like macrophages are considered to be involved in long-term tissue repair,
fibrosis, and promotion of tumor growth [40]. Although chemokine release is
associated with both M1- and M2-like phenotypes, alternative M2 activation often
leads to the secretion of growth factors with reparative functions in addition to the
release of anti-inflammatory cytokines [178, 302].

E2F1 is a multifunctional transcription factor recognized for its role in cell cycle
regulation [70, 259, 319, 355], apoptosis [69, 110], DNA damage [56, 306],
energy metabolism [35, 71], and inflammation [10, 138, 343] whose activity can
be modulated by a large number of growth factors and cytokines [91]. However,
the role of E2F1 in inflammatory response is complex. Studies show that E2F1
can promote an inflammatory response specifically through its interaction with
the RelA/p65 subunit of the NF-B complex. Specifically, following LPS binding
to the toll-like receptor 4 (TLR4) and subsequent activation of the NF-B system,
E2F1 is recruited to promoters of several inflammatory genes, including CCL-3,
IL-23A, TNF-, and IL-1 by RelA/p65, thereby enhancing NF-B-mediated
transcription and potentiating LPS-induced inflammatory responses [189]. In
addition, E2F1 mutant mice injected with LPS exhibit reduced release of TNF-,
IL-6, and IL-1 three hours after treatment in vivo; however, these mice are still
more susceptible to LPS-induced mortality [343]. In contrast, Tanaka et al.
showed that the expression of E2F1 was capable of inhibiting NF-B activity by
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binding to p65, indicating that the role of E2F1 in NF-B-mediated inflammation
is more complex [313]. Albeit in dendritic cells, another study showed that E2F1
shRNA knockdown led to increased LPS-induced TNF- release from 6 hours
through 24 hours poststimulation, suggesting that E2F1 may interfere with NF-B
signaling more than inhibit it in dendritic cells [92]. The role of E2F1 in
macrophage polarization is also unclear. In vitro studies indicate that E2F1 may
inhibit MHCII and CD86 expression and M1-like polarization [92, 136, 371].
However, in vivo studies from E2F1 mutant mice indicate that loss of E2F1
activity promotes M2-like polarization during wound healing based on the
detection of more M2-like macrophages at the site of injury [356]. Taken
together, these studies suggest that E2F1 has both pro- and anti-inflammatory
roles that may differ based on the cell type or the context of the inflammatory
event.

In the current study, we aimed to characterize the release of cytokines,
chemokines, and growth factors and macrophage polarization in macrophages
treated with 50 pg/ml LPS (high end of the subclinical range) and 100 ng/ml LPS
(septic range), in an effort to better understand the role of E2F1 in inflammation
through a broad discovery-based approach. Using bone-marrow derived
macrophages from E2F1 heterozygotes (E2F1+/-), homozygotes (E2F1-/-), and
littermate controls (E2F1+/+), we show that E2F1 knockout alters TNF-, IL-6, and
CCL-2 release in a dose-dependent manner and the endogenous release of IGF-
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1 and Osteopontin independent of the LPS treatment. At 4 hours, IL-6 and TNF-
expression levels and/or release appeared reduced in E2F1-/- cultures in
response to both LPS doses, indicating that the dose-dependent effects of E2F1/-

appeared later during the inflammatory process and might depend on the late-

phase induction of an anti-inflammatory response caused by high-dose LPS
treatment. Finally, E2F1 knockout inhibited the primed release of IL-6 and TNF-.
Taken together, these data demonstrate that the abrogation of E2F1 expression
might inhibit proinflammatory responses associated with subclinical LPS doses
and the early proinflammatory phase of the inflammatory response while altering
the regulation or delaying the induction of anti-inflammatory mechanisms induced
by high-dose LPS.

Methods

Animals
B6.129 E2F1 knockout mice (E2F1-/-) were generated and housed at the
University of Pennsylvania, as previously described (Chapter 2). In brief, since
E2F1-/- mice were the product of Cre-lox breeding, they retained one loxp-site
situated near the 3’ end of intron 1, with the rest of the E2F1 genomic sequence
(approximately 5.3kb) excised through Cre-mediated recombination. After
confirming inheritance of the Cre-recombined allele, the Cre gene was bred out.
Heterozygote breeding was used to generate littermate-matched E2F1+/+, E2F1+/-
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, and E2F1-/- mice. All mice were kept on a 12-hour light/dark cycle, and food
and water were provided ad libitum. 10- to 12-week-old male mice were used for
in vitro macrophage generation. Middle-aged 14-month-old male mice were used
for blood collection and plasma isolation.

Monocyte isolation and macrophage cultures
Bone marrow cell progenitors were obtained by flushing femurs from 10- to 12week-old male adult mice, as described previously [344]. The cells obtained were
plated at a density of 1.25 x 106 cells/ml and cultured in RPMI-1640 medium
supplemented with 25mM HEPES and glutamine (Thermo Fisher Scientific), 10%
heat-inactivated fetal bovine serum (Thermo Fisher Scientific), and 20 ng/ml
gentamicin (Thermo Fisher Scientific) containing 30ng/ml M-CSF (R&D Systems)
at 37oC in a 5% CO2 incubator. The day of plating was defined as 0 days in vitro
(DIV0). On DIV3 and DIV5, the medium was removed and the plates were
washed two times with 1x PBS pH 7.4 before adding fresh M-CSF-containing
medium. On DIV7, the medium was replaced with M-CSF-free medium for 24
hours before treatment with 50 pg/ml or 100 ng/ml LPS from Salmonella enterica
serotype typhimurium (Sigma Aldrich) treatments.

LPS-mediated priming of macrophages
At the time of experiments, cultures containing M-CSF-free medium (RPMI 1640
plus 25 mM HEPES and glutamine, 10% heat-inactivated fetal bovine serum, and
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20 ng/ml gentamicin) were either mock-treated or treated with 50 pg/ml LPS.
Four hours later, the medium was removed, the cells were washed twice with
macrophage medium, and the medium was replaced with fresh medium with or
without 100 ng/ml LPS. Four hours later, the medium was collected for Luminex.

Semiquantitative and Quantitative reverse transcription-polymerase chain
reaction
RNA was isolated using Qiazol reagent and spin columns, according to the
manufacturer’s instructions (Qiagen), and RNA was quantified by Nanodrop.
Next, 250 ng total RNA was reverse transcribed to cDNA using RT2 First Strand
Kit (Qiagen). Semiquantitative and Quantitative reverse transcription-polymerase
chain reaction (PCR and qPCR respectively) was performed with gene-specific
primer sets for mouse IL-6 (forward: 5’-AGCCAGAGTCCTTCAGAGA-3’; reverse:
5’-TCCTTAGCCACTCCTTCTGT-3’), mouse TNF- (forward: 5’AGACCCTCACACACTCAGATCA-3’; reverse: 5’TCTTTGAGATCCATGCCGTTG), and mouse GAPDH (forward 5’AATGGTGAAGGTCGGTGTG-3’; reverse 5’GTGGAGTCATACTGGAACATGTAG-3’). Samples were diluted 1:5 to allow for
PCR amplification in a semiquantitative range. Quantitative PCR was performed
with Fast SYBR Green® Master mix (Thermo Fisher Scientific) using the 7300
Real-Time PCR system (Thermo Fisher Scientific). Data were presented as fold

109

changes from controls using the comparative Ct (Ct) method. GAPDH was
used as the reference gene that did not change with treatment.

Measurement of cytokines and chemokines
Cell culture supernatants were collected at specified time points and stored at
−80oC until analysis. Blood from mice was isolated using cardiac puncture and
deposited in K2 EDTA Minicollect tubes for plasma preparation. Following
several inversions to ensure adequate exposure to the anticoagulant EDTA,
samples were centrifuged at 1000 g for 10 minutes at 4oC. The plasma layer was
removed and stored at −80oC. Concentrations of cytokines and chemokines were
measured in plasma sampled diluted 1:2 dilutions using Luminex multiplex assay
(R&D Systems) according to the manufacturer’s instructions. Analytes included
GM-CSF, CXCL-1, CXCL-2, CXCL-12a, TNF-, IL-6, IL-1, IL-1, IL-10, IL-13,
IFN-, CCL-2, CCL-3 CCL-5, Osteopontin, VEGF, IGF-1, MMP-3, and TIMP1).

Flow cytometry
Following trypsinization, 1 x 106 cells were blocked with CD16/CD32 monoclonal
Antibody (93, eBioscience) for 30 minutes. After spinning down cells at 300 g for
5 min, the cells were incubated with the following monoclonal antibodies: APC
conjugated F4/80 (BM8), FITC conjugated CD11b (M1/70), PE-cyanine5
conjugated CD86 (GL1), and PE conjugated MHC class II (M5/114.15.2). The
following isotype controls were used to identify nonspecific staining: APC
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conjugated rat IgG2a kappa Isotype Control (eBR2a); FITC conjugated rat IgG2b
kappa Isotype Control (eB149/10H5), PE-Cyanine5 conjugated rat IgG2a kappa
Isotype Control (eBR2a); PE conjugated rat IgG2b kappa Isotype Control
(eB149/10H5). The cells were then incubated with LIVE/DEAD™ Fixable Aqua
Dead cell stain (excitation, 405 nm) for 30 minutes at room temperature
according to the manufacturer’s instructions following antibody removal by
centrifugation. Cells were fixed using fixation medium A, and marker expression
was measured using an LSR Fortessa. All antibodies were diluted 1:400, and all
reagents were purchased from Thermo Fisher Scientific. Double labeling using
CD11b-FITC and F4/80-APC was used to ensure the high purity of macrophage
cultures (92% ± 3%). Within gated macrophages, the percentage of cells that
were double-labeled for MHCII and CD86 was determined to evaluate the
percentage of M1-like macrophages induced by LPS and the amount of total
MHCII and CD86 expression. 10,000 events were recorded for each sample, and
median florescence intensity was measured using FCS Express 7. Live/Dead
Fixable Aqua dye was used to confirm that only live cells were analyzed for
fluorescent markers.

Statistical analysis
All data were analyzed using GraphPad Prism 9. All data were represented as
mean ± SEM unless otherwise indicated. The analysis of three groups with only
one independent variable was performed using one-way ANOVA and Dunnett’s
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post hoc test, unless variances were not equal among groups. In those cases,
the Brown-Forsythe ANOVA test was used with Dunnett’s T3 multiple
comparisons test. Randomized-block two-way ANOVA with Tukey’s post hoc (to
compare treatment effects) or Sidak’s post hoc (to compare genotype effects)
was used for the comparison of two independent variables. On occasion, a t-test
was used to evaluate differences in cytokine expression when the heterozygote
genotype condition was excluded from the analysis.

Results

E2F1 knockout alters chemokine, cytokine and growth factor release in
response to low- and high-dose LPS
To explore the proinflammatory and anti-inflammatory impact of E2F1 loss, we
treated E2F1+/+, E2F1+/-, and E2F1-/- macrophages with LPS at low dose (50
pg/ml) or high dose (100 ng/ml) for 24 hours. Using Luminex assay, we screened
for differences in the secreted levels of GM-CSF, CXCL-1, CXCL-2, CXCL12a,
TNF-, IL-6, IL-1, IL-1, IL-10, IL-13, IFN-, CCL-2, CCL-3 CCL-5, Osteopontin,
VEGF, IGF-1, MMP-3, and TIMP1 and found that there was a significant effect of
genotype on Osteopontin (F=4.014, p=0.0373) and IGF-1 (F=8.147, p=0.0033)
release. We found a positive linear trend between E2F1 allele loss and
Osteopontin (p=0.0115) and IGF-1 (p=0.0014), with the E2F1-/- macrophages
releasing significantly more Osteopontin (p=0.0211) and IGF-1 (p=0.0031) than
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the E2F1+/+ macrophages. While not statistically significant by ANOVA, the E2F1/-

macrophages released lower levels of IL-6 and TNF- over a 24-hour time

period. The independent comparison of E2F1+/+ and E2F1-/- macrophage
supernatants by independent t test revealed a statistically significant trend toward
a reduction in IL-6 and TNF- release from the E2F1-/- macrophages. The mean
(±SEM) reductions in IL-6 and TNF- released from E2F1-/- macrophages were
49.7%  9.8% (p=0.0793) and 27%  7.3% (p=0.0903), respectively. Additionally,
there was no significant difference in the released MMP-3 levels among the three
genotypes, but the E2F1+/- and E2F1-/- macrophages inconsistently produced
more MMP-3 than the E2F1+/+ macrophages, indicating that this effect may
represent a degree of vulnerability caused by the loss of E2F1 that may not be
direct. (Fig. 3.1).

Similarly, in macrophages treated with high-dose LPS, we observed a significant
genotype effect on Osteopontin [F*(2, 12.12)=5.623, p=0.0187] and IGF-1
[F(2,17)=7.702, p=0.0042] release (Fig. 2). Additionally, the E2F1-/- macrophage
supernatants contained significantly higher levels of Osteopontin (p=0.0203) and
IGF-1 (p=0.044) than the E2F1+/+ macrophage supernatants. CCL-2 was also
significantly altered by genotype [F(2,17)=6.727, p=0.0070], with the E2F1-/macrophages releasing significantly higher levels of CCL-2 compared to the
E2F1+/+ macrophages (p=0.0097). In contrast, the levels of IL-6 or TNF- in
macrophage supernatants were not altered by genotype. While the MMP-3 levels
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were not significantly different, the median MMP-3 amount released from the
E2F1-/- macrophages was two times higher than that released from the E2F1+/+
macrophages, suggesting the possibility that the E2F1 loss had an effect on
MMP-3 release from macrophages. (Fig. 3.2).

E2F1 knockout results in increased basal cytokine, chemokine and growth
factor secretion
Since E2F1 loss altered Osteopontin and IGF-1 release in response to both lowand high-dose LPS, we next compared the levels of Osteopontin and IGF-1 in
macrophage supernatants at baseline. We detected a genotype effect on
Osteopontin [F(2,17)=3.849, p=0.0418] and IGF-1 [F(2,17)=7.184, p=0.0055]
release at baseline (Fig. 3). The E2F1-/- macrophage supernatants contained
significantly higher levels of Osteopontin (p=0.0262) and IGF-1 (p=0.0091) as
baseline. We also found a significant effect of genotype on CCL-2
[F(2,17)=4.234, p=0.0322] at baseline, whereas there was a trend toward a
significant increase in CCL-2 levels in the E2F1-/- macrophage supernatants
compared to the E2F1+/+ macrophage supernatants (p=0.0751) (Fig.3.3).

Low- and high-dose LPS produce different treatment-dependent effects
Evaluating LPS dose-dependent effects on inflammatory mediator release:
Randomized-block two-way ANOVA to examine the changes in the levels of IL-6,
TNF-, MMP-3, CCL-2, Osteopontin and IGF-1 in macrophage supernatants
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identified an effect of treatment for all examined inflammatory mediators
[F(1.000, 11.00)=102.4, p<0.0001; F(1.014, 11.16)=163.5, p<0.0001; F(1.579,
17.37)=5.290, p=0.0215; F(1.053, 11.58)=187.0, p<0.0001; F(1.711,
18.82)=9.880, p=0.0017; F(1.070, 11.76)=16.28, p=0.0015, respectively].
Tukey’s post hoc tests indicated that both low-and high-dose LPS treatment led
to significant increases in IL-6, TNF-, and CCL-2 release in macrophage
supernatants, with significant differences observed among all dose conditions
within each genotype. High-dose LPS treatment led to a significant increase in
the levels of MMP-3 in E2F1+/+ macrophage supernatants, whereas the increase
in MMP-3 levels in E2F1-/- macrophage supernatants in response to high-dose
LPS treatment only exhibited a trend toward significance. There was a trend
toward a significant decrease in the release of IGF-1 from E2F1+/+ macrophages
in response to both low- and high-dose LPS. Within the E2F1-/- macrophage
supernatants, we detected a trend toward a significant decrease in IGF-1 release
in response to low-dose LPS treatment and a significant decrease in IGF-1
release in response to high-dose LPS treatment; the levels of IGF-1 were
significantly different between the E2F1-/- macrophages treated with low- and
high-dose LPS. Tukey's post hoc tests identified no significant differences in
Osteopontin levels between the low- and high-dose LPS treatments in E2F1+/+
macrophage supernatants; however, there was a significant difference in
Osteopontin release between the low- and high-dose LPS treatments in E2F1-/macrophages. Fig. 3.4A-G includes graphical summaries of inflammatory factor
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release in response to different LPS doses and a table summarizing p values for
all comparisons.

Reevaluating genotype effects on inflammatory mediator release using more
robust statistical tests: Similar to the previous analyses of inflammatory mediator
release, where treatment conditions were analyzed separately, when all
treatment conditions were evaluated together, we detected a main genotype
effect on CCL-2, IGF-1 and Osteopontin by randomized block two-way ANOVA
[F(1, 11)=187.0, p<0.0001; F(1,11)=14.58, p=0.0028; F(1,11)=9.361, p=0.0109].
There was also a significant interaction between genotype and treatment for
CCL-2 [F(2,22)=8.698, p=0.0016] and a trend toward an interaction for IGF-1
[F(2,22)=2.892, p=0.0767]. There was no interaction observed between genotype
and treatment for Osteopontin. Sidak’s post hoc test to compare differences
between E2F1+/+ and E2F1-/- macrophages for each treatment condition found
that, similar to our earlier analysis, CCL-2 was significantly increased in the
E2F1-/- macrophage supernatants compared to the E2F1+/+ macrophage
supernatants with high-dose LPS dose (p=0.0349) whereas IGF-1 was
significantly increased in the E2F1-/- macrophage supernatants compared to the
E2F1+/+ macrophage supernatants for all conditions (0: p=0.0375, 50 pg/ml LPS:
p=0.0054, 100 ng/ml LPS: p=0.0067). By Sidak’s post hoc analysis, the increase
in Osteopontin was significant only in the E2F1-/- macrophage supernatants with
low- and high-dose LPS treatments (p=0.0255, p=0.0323) compared to the
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E2F1+/+ macrophage supernatants; however, there was also a trend toward
significance for the increase in baseline Osteopontin levels in E2F1-/macrophage supernatants compared to that in the E2F1+/+ macrophage
supernatants (p=0.0703). (Fig. 3.4H-J).

Temporal dynamics of key pro-inflammatory and anti-inflammatory cytokines,
and markers for M1- and M2-like macrophages: Based on our observation of
different treatment-dependent effects on inflammatory mediator release from
macrophages, we next characterized the temporal RNA expression of IL-6, TNF, and IL-10 in E2F1+/+ macrophages to further elucidate the opposing patterns
observed in E2F1-/- macrophages responding to treatment with low- and highdose LPS and to clarify whether low-dose LPS would fail to induce certain antiinflammatory cytokines such as IL-10, which was reported in previous studies
[206]. Our preliminary data in E2F1+/+ macrophages indicated that the IL-10
expression, which was not detectable 48 hours after the treatment of with lowdose LPS, was detectable as early as 4 hours after treatment with high-dose
LPS. Interestingly, in E2F1+/+ macrophages, the increases in IL-6 and TNF-
expression, which were resolved by 48 hours after treatment with low-dose LPS,
remained elevated in cultures treated with high-dose LPS (Fig. 3.5A, n=1). The
observation that IL-10 RNA was not expressed in the low-dose LPS condition
coincides with our observation that IL-10 release was only detectable by Luminex
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in supernatants from E2F1+/+ and E2F1-/- macrophages treated with high-dose
LPS at 24 hours (Fig. 3.5B, n=6-7 per genotype).

We also examined the expression levels of common M1-like and M2-like
macrophage markers at multiple timepoints over 48 hours after treatment of
E2F1+/+ macrophages with low- or high-dose LPS. Similar to our observations
regarding changes in IL-6 and TNF- expression, the M1-like macrophage
markers Nos2, MHCII and CD86 exhibited a treatment-specific difference in
induction and/or time course, with all three markers exhibiting either higher or
prolonged expression in response to high-dose LPS. Additionally, the M2-like
macrophage markers CD206 and arginase-1 exhibit altered expression in
response to low- and high-dose LPS treatments. CD206 expression was below
detection at 24 hours and 48 hours in response to high-dose LPS treatment,
while it was still detectable and appeared to recover by 48 hours in response to
low-dose LPS treatment. Arginase-1, while previously below detection without
treatment, was detected at 24 hours in response to high-dose LPS treatment,
while remaining below detection in response to low-dose LPS treatment for all
timepoints measured (Fig. 3.5C, n=1). This suggests that low- and high-dose
LPS differed in the activation or induction of both pro-inflammatory and antiinflammatory pathways.
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Flow cytometry for differences in M1 markers at 24 hours: Based on our
observation of different treatment-dependent effects in characteristic
macrophage polarization markers, we utilized flow cytometry to compare the
activation status among E2F1+/+, E2F1+/-, and E2F1-/- macrophages treated with
low- or high-dose LPS treatment for 24 hours based on the expression of M1-like
markers MHCII and CD86. We focused on these M1-like markers since in vitro
studies on E2F1 deficiency suggest that E2F1 regulates the expression of M1like marker expression [92, 136]. After gating for live cells and macrophage
populations using F4/80 and CD11b, respectively, we determined the percentage
of M1-like macrophages (MHCII and CD86 double-labeled cells) and the
expression level of MHCII and CD86 in our cultures. The changes in the
expression of these M1-like macrophage markers were similar between the
E2F1+/- and E2F1+/+ macrophages. Therefore, we herein focus on the E2F1+/+
and E2F1-/- macrophages. As shown in Fig. 3.6, there was a main effect of
treatment on the levels of CD86 and MHCII and the percentage of M1-like
macrophages induced by LPS treatment [F(1.073,6.435)=18.81, p<0.0039;
F(1.598,9.587)=38.31, p<0.0001; F(1.140,6.842)=81.21, p<0.0001]. Specifically,
LPS treatment led to increases in CD86 and MHCII expression and the
percentage of M1-like macrophages, as expected. There was no genotype effect
or interaction between treatment and genotype. For both E2F1+/- and E2F1+/+
macrophages, Tukey’s post hoc test indicated that there was a significant
increase in MHCII expression in response to low-dose LPS (E2F1+/+: p=0.0415,
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E2F1-/-: p=0.0020). In response to high-dose LPS treatment, the increase in
MHCII expression exhibited a trend towards significance in E2F1+/+ macrophages
(p=0.0644) and was significant in E2F1-/- macrophages (p=0.0079). Interestingly,
the E2F1+/+ macrophages exhibited significantly lower MHCII expression in
response to high-dose LPS compared to those responding to low-dose LPS
(p=0.0378), whereas there was no decrease in MHC-II expression in E2F1-/macrophages treated with low- or high-dose LPS (p=0.9935). However, there
was no significant difference in the MHCII expression between E2F1+/+ and
E2F1-/- macrophages in any treatment condition. Examination of the treatment
effect on CD86 expression by Tukey’s post hoc analysis revealed that there was
a trend toward significance in the increase of CD86 expression in E2F1+/+
macrophages treated with low-dose LPS compared to the untreated E2F1+/+
macrophages (p=0.0855); however, a significant change in CD86 expression
after high-dose LPS treatment was not observed. In E2F1-/- macrophages, there
was a significant increase in CD86 expression in response to low- and high-dose
LPS treatment (p=0.0026, p=0.0275, respectively). There was also a trend for
reduced CD86 expression in E2F1-/- macrophages at baseline compared to
E2F1+/+ macrophages (p=0.0897). However, without additional samples, E2F1 +/+
in particular, whether the reduced detection of MHCII expression levels in
macrophages treated with high-dose LPS, in comparison to low-dose LPS in
E2F1+/+ macrophages, an effect that was not observed in E2F1-/- macrophages
remains unclear. Additionally, without additional samples, it is unclear whether
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the lower CD86 expression in E2F1-/- macrophages at baseline compared to
E2F1+/+ macrophages is meaningful. For both the E2F1+/+ and E2F1-/- genotypes,
low and high LPS doses increased the number of M1-like macrophages (UT vs
50 pg/ml LPS: E2F1+/+ p<0.0001, E2F1-/- p=0.0004; UT vs 100 ng/ml LPS:
E2F1+/+ p=0.0180, E2F1-/- p=0.0045), with no significant difference in the number
of double-labeled cells between the two genotypes at any treatment condition
(Fig. 3.6).

E2F1 knockout reduces IL-6 and TNF- release in low-dose LPS-primed
macrophages
Based on our observation of a non-significant reduction in IL-6 release at 24
hours, we next evaluated whether low-dose LPS-induced priming of
macrophages prior to treatment with high-dose LPS could alter IL-6 release and
whether this change would be different among the E2F1 +/+, E2F1+/-, and E2F1-/macrophages. By randomized-block two-way ANOVA, we found a significant
treatment effect [F(1,8)=153.6, p<0.0001], a significant genotype effect
[F(2,8)=7.931, p=0.0126], and significant interaction between genotype and
treatment [F(2,8)=6.121, p=0.0244]. Tukey’s post hoc analysis indicated that lowdose LPS pretreatment was effective at significantly increasing IL-6 release in
E2F1+/+, E2F1+/-, and E2F1-/- macrophages (p=0.0001, p<0.0001, p=0.0051), with
the E2F1-/- macrophages releasing significantly lower levels of IL-6 compared to
the E2F1+/+ macrophages after priming with low-dose LPS (p=0.0004). To
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determine whether this effect was dependent on priming, we evaluated IL-6
release in response to high-dose LPS treatment and found that there was a
significant effect of genotype [F*(2, 4.796)=14.33, p=0.0095] and significantly
reduced IL-6 release from the E2F1-/- macrophages compared to E2F1+/+
macrophages by Brown-Forsythe ANOVA. In contrast, two-way ANOVA
indicated that there was a significant effect of treatment on TNF- [F(1,8)=348.7,
p<0.0001] but that there was no genotype effect or interaction. The increased
TNF- release as a result of low-dose LPS-induced priming was evident in all
genotypes (p<0.0001). We also found a significant difference in primed TNF-
release following low-dose LPS priming between the E2F1+/+ and E2F1-/macrophages (p=0.0495). Again, we evaluated TNF- release in response to
high-dose LPS treatment to determine if the observed genotype effect in E2F1-/macrophages was dependent on priming. By one-way ANOVA, there was a
pattern toward reduced TNF- release in E2F1-/- macrophages (p=0.1153). While
additional replicates are necessary, we predicted that TNF- release, similar to
that observed for IL-6 release, may also be significantly reduced with high-dose
LPS treatment. To test this hypothesis, we examined differences in IL-6 and
TNF- RNA expression among the genotypes and treatments by qPCR. IL-6
expression in E2F1-/- macrophages was significantly lower in response to lowdose LPS (p=0.0003) and lower with a trend toward significance in response to
high-dose LPS (p=0.07) compared to that in E2F1+/+ macrophages. TNF- RNA
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expression was not significantly lower in E2F1-/- macrophages treated with lowor high-dose LPS compared to E2F1+/+ (Fig. 3.7).

Assessing changes in the expression of CCL-2, Osteopontin, IGF-1 and
other inflammatory mediators in 1-year-old E2F1 knockout mice
Since our in vitro experiments identified treatment-independent as well as
treatment-dependent differences in CCL-2, Osteopontin, IGF-1, IL-6 and TNF-,
we determined if any of these mediators were altered in the peripheral blood of
middle-aged, i.e., 14-mth-old, E2F1-/- mice using the previously described
Luminex panel. Specifically, low-dose LPS, which is equivalent to the high end of
the spectrum for subclinical LPS doses, might have induced lower levels of IL-6
and TNF- in E2F1-/- macrophages than E2F1+/+ macrophages, we examined the
differences in these mediators based on our hypothesis that endogenous
circulating endotoxins would alter the release of IL-6 and TNF- in circulation.
Surprisingly, we found that the circulating levels of IL-6 and TNF- were not
significantly altered in E2F1-/- mice and, on average, were not lower than those
measured in the circulation of E2F1+/+ mice. There were also no significant
differences in plasma Osteopontin and IGF-1 levels between the E2F1+/+ and
E2F1-/- mice. However, we found a trend toward significant increase in CCL-2
(p=0.0673) and IL-13 (p=0.0533) levels in E2F1-/- plasma compared to the
E2F1+/+ plasma. There were no notable differences between E2F1+/+ and E2F1-/plasma levels of any of the other analytes in our panel (Fig. 3.8).
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Discussion

Previous reports indicate a role for E2F1 in macrophage polarization and
cytokine release. However, whether E2F1 loss yields a proinflammatory or antiinflammatory phenotype has not been clear. We found that the loss of E2F1 was
primarily associated with an anti-inflammatory phenotype during the initiation of
the LPS-mediated inflammatory response; however, this anti-inflammatory effect
of E2F1 loss might be overcome depending on the strength of the inflammatory
stimulus. Since the inflammatory response can be divided into at least two
phases, a proinflammatory initiation phase and an anti-inflammatory resolution
phase [163], we used one low dose and one high dose of LPS to tease out the
contribution of E2F1 to these two phases. Since subclinical LPS doses cause a
proinflammatory response without the induction of late-phase anti-inflammatory
mediators commonly observed with high-dose LPS treatment [206], we evaluated
the cytokine profile of supernatants of E2F1-/- macrophages treated with low- and
high-dose LPS. Low-dose LPS-treated E2F1-/- macrophages exhibited a trend
toward a significant reduction in IL-6 and TNF- release at 24 hours compared to
low-dose LPS-treated E2F1+/+ macrophages, a potential difference that was
absent in cultures treated with high-dose LPS. However, high-dose LPS
treatment produced no difference in IL-6 and TNF- release at 24 hours,
suggesting that E2F1 may play dual roles in both the initiation/proinflammatory
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and resolution/anti-inflammatory phases. In response to high-dose LPS, CCL-2
was significantly increased in E2F1-/- macrophages without an observable effect
in low-dose LPS-treated E2F1-/- macrophages. Albeit not significant, there was
also an approximately two-fold increase in MMP-3 release from the E2F1-/macrophages based on the comparison of median values. Similar to that
observed for IL-6 and TNF-, both CCL-2 and MMP-3 are responsive to IL-10
treatment and the observed differences in the expression of these cytokines may
be explained by the dysregulation of an anti-inflammatory mechanistic response
specific to high-dose LPS. In fact, we did not observe IL-10 induction with lowdose LPS treatment. Since the aberrant expression or activity of CCL-2 or MMP3 may be associated with the further induction of proinflammatory cytokine
release, fibrosis, extravasation, and leukocyte recruitment [96, 107, 119, 351], it
appears that loss of E2F1 may be detrimental in response to high-dose LPS
treatment. We found no difference in M1-like macrophage polarization between
E2F1+/+ and E2F1-/- macrophages at any treatment condition; however, there was
a trend toward a significant reduction in CD86 expression in E2F1-/macrophages at baseline. This is in direct contrast to a previous observation that
homozygous E2F1 mutant mouse dendritic cells express higher levels of CD86
as well as MHCII at baseline [92]. This difference may be due to cell-type specific
effects or different in vitro culturing conditions.
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We also found that, at both baseline and in response to low- or high-dose LPS,
E2F1-/- macrophages released more Osteopontin and IGF-1 than E2F1+/+
controls, implying that the loss of E2F1 may constitutively alter the release of
IGF-1 and Osteopontin. Both IGF-1 and Osteopontin can facilitate M2-like
macrophage activation programs [290, 302] and promote tumor development
[190, 347]. Furthermore, some studies report that Osteopontin has additional
mixed pro- and anti-inflammatory roles independent of polarization, including the
inhibition of IL-10, promotion of immune cell chemotaxis and reduction of
inducible nitric oxide synthase (iNOS) [202]. Therefore, increased IGF-1 and
Osteopontin levels in E2F1-/- macrophage supernatants cannot be considered
strictly beneficial or detrimental. Further, it remains unknown if the increased
levels of these mediators are sufficient to produce any of the abovementioned
effects. Specifically, although Osteopontin inhibits IL-10 expression [15], the lack
of a difference in IL-10 release from the E2F1-/- macrophages compared to the
E2F1+/+ macrophages implies that increased Osteopontin levels may have not
been sufficient to produce a measurable effect.

Based on studies indicating that E2F1 loss reduces proinflammatory cytokine
release by inhibiting NF-B mediated transcription [189], and our results showing
that E2F1 may inhibit the release of proinflammatory cytokines 24 hours after
treatment with low-dose LPS, we also evaluated the RNA expression of TNF-
and IL-6 for both LPS doses at 4 hours and cytokine release in response to high-
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dose LPS at 4 hours, as cytokine release for low-dose LPS at 4 hours was under
the limit of detection for the Luminex assay. Similar to that reported by Warg et
al., we found reduced expression of IL-6 in response to both low-and high-dose
LPS treatments [343]. IL-6 release was also reduced in low-dose LPS-primed
and high-dose LPS treated E2F1-/- macrophages. Although we did not detect
significant changes in TNF- transcription or its release in response to either LPS
dose, the pattern toward reduced TNF- release from high-dose LPS-treated
E2F1-/- macrophages and the significant reduction of TNF- in low-dose LPSprimed E2F1-/- macrophages after 4 hours suggests that, with additional
statistical power, these results might be in accordance with the findings of Lim et
al [189]. Together, these results offer further support for our conclusion that E2F1
plays an important role in initiation of the inflammatory response in macrophages.

In vivo, entry of endotoxins increases with age [114, 206]. Since E2F1-/macrophages exhibited a significant trend toward releasing lower levels of TNF-
and IL-6 than the E2F1+/+ macrophages at 24 hours in response to subclinical
doses of LPS, we examined the circulating levels of cytokines and chemokines in
middle-aged E2F1+/+ and E2F1-/- mice. Although macrophages likely would not be
responsible for any observed differences in cytokine levels in circulation, if E2F1
loss was able to alter TNF- and IL-6 release in macrophages, the same effect
may have been observed in monocytes. We were surprised to find no difference
in TNF- or IL-6 levels but did notice that Osteopontin and IGF-1 levels were
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increased albeit without statistical significance. Interestingly, plasma CCL-2
levels were increased in E2F1-/- mice, a finding that was only observed in
response to high-dose LPS. This could indicate that middle-aged E2F1-/- mice
were suffering from some unknown trauma that induced CCL-2 release, which
requires further examination. We also observed an increase in IL-13, which is
interesting given its role as an anti-inflammatory cytokine; we did not detect
significant differences in IL-13 levels among genotypes in our in vitro
macrophage experiments. However, IL-13 promotes an M2-like phenotype in
macrophages and may explain why Xiao et al. observed more macrophages
exhibiting M2-like surface markers in E2F1 mutant mice compared to wildtype
mice as part of the wound healing process [356]. Therefore, it is possible that, in
these earlier studies, the loss of E2F1 promoted an M2-like phenotype due to the
altered secretion of IL-13 by another cell type.

The observed baseline differences in E2F1-/- macrophages are potentially due to
altered macrophage numbers at the start or end of the experiment, and this
represents a major caveat in our interpretations. While the same number of
progenitor cells isolated from the bone marrow were plated at the start of the
experiment, we do not know if there were differences in the effect of macrophage
culture stimulating factor (M-CSF), which we used for differentiation of
progenitors to macrophages, on proliferation of cells between the E2F1-/- and
E2F1+/+ cultures. Examination of the cultures under transmitted light did not
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suggest an overt difference in the number of cells in each plate; however, it
remains possible that E2F1-/- macrophages proliferated faster. Previous studies
reported that E2F1 knockout in various cell types slowed, hastened, or had no
effect on proliferation [95, 144, 223]; therefore, the increased proliferation would
have to be specific to M-CSF treatment and cell type. Iglesias-Ara et al. noted
that E2F1 knockout was not sufficient to increase proliferation in differentiating
macrophages but suggested that it produced a non-significant “intermediate
effect” compared to the increased proliferation caused by dual E2F1 and E2F2
knockout [144]. Therefore, it is possible that baseline levels of E2F1-/macrophages are slightly increased and this mild increase in proliferation may
have produced significant increases in basal secretion of Osteopontin or IGF-1.
On the other hand, since E2F1 plays a prominent role in apoptosis [70], the
number of cells might be higher in E2F1-/- cultures due to a reduction in cell death
following the removal of M-CSF before the experiments, since apoptosis has
been observed as a result of M-CSF deprivation for 24 hours [240]. We did not
observe increased cell death caused by LPS treatment using flow cytometry;
however, dead cells could have been detached and lost before their collection for
analysis. Even with these caveats, the interpretation that E2F1 loss plays an antiinflammatory role during initiation and that E2F1 loss does not induce an M1-like
phenotype does not change. Yet, differentiating macrophages using GM-CSF
instead of M-CSF may alter these results, given that M-CSF promotes M2-like
differentiation whereas GM-CSF promotes M1-like differentiation [120]. A final

129

alternative rationale for the different responses to LPS observed between the
E2F1+/+ and E2F1-/- macrophages may be alterations in TLR4 levels. The TLR4
promoter contains putative E2F1 binding sites [324]. E2F1 may repress TLR4
receptor expression and therefore reduce the number of receptors available for
LPS to interact with at later timepoints [324], causing cytokine expression and
secretion to be elevated in macrophages lacking E2F1 compared to the wildtype
controls at later timepoints.

Overall, these data indicate that contradictory reports for E2F1’s role in the
inflammatory process may depend on the model system (in vivo vs in vitro), the
timepoint evaluated (early vs late), the method of gene delivery (knockdown vs
knockout), and the cell type. Since we did not detect an anti-inflammatory
phenotype in E2F1+/- mice, it is possible that pro-inflammatory phenotype
dominates when E2F1 expression is not reduced below a certain threshold;
however, we did not detect any statistically significant increase in
proinflammatory markers in E2F1+/- macrophages at 24 hours after treatment
compared to E2F1+/+ macrophages either. A variety of factors may explain the
contribution of E2F1 loss to a proinflammatory phenotype at later time points. In
addition to the altered expression of TLR4 due to the absence of E2F1 binding to
its promoter [324], it is possible that E2F1 loss may affect IL-10-dependent
STAT3-mediated responses. STAT3 can be recruited to sites with prebound
E2F1 in macrophages. The role E2F1 plays in these cases was not studied;
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however, it was suggested that E2F1 drives quick response of STAT3-mediated
transcription of anti-inflammatory factors [142]. Interestingly, IGF-1 also activates
STAT3 [376], and activated STAT3 can lead to increased Osteopontin
transcription [116]. Therefore, any role E2F1 would play in STAT3-mediated antiinflammatory responses may result in increased activation in STAT3-mediated
anti-inflammatory signals where E2F1 is not required and reduced antiinflammatory signals where E2F1 is required — the latter may be responsible for
reducing the secretion of proinflammatory cytokines such as TNF-, IL-6, and
CCL-2. Future studies should focus on how E2F1 loss affects STAT3-mediated
anti-inflammatory mechanisms to clarify the anti-inflammatory roles of E2F1
during the resolution of inflammation.
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Figure 3.1. Cytokine, chemokine and growth factor release 24 hours after low-dose LPS
treatment is altered in macrophages lacking E2F1. Wildtype (E2F1+/+), E2F1 heterozygous
(E2F1+/-) and E2F1 knockout (E2F1-/-) macrophages were treated with 50pg/ml LPS. 24 hours
later, macrophage supernatants were collected and analyzed for production of: (A) IL-6, (B) TNF, (C) MMP-3, (D) CCL-2, (E) Osteopontin, and (F) IGF-1 from each genotype (mean  SEM,
n=6-7 per group). Tukey’s post hoc * p<0.05, **p<0.01. G) Summary of inflammatory mediators
altered by low-dose LPS treatment represented as fold change from E2F1+/+ (mean  SEM). H)
Summary of inflammatory mediators altered by low-dose LPS treatment represented as median
fold change from E2F1+/+. In response to low-dose LPS, E2F1-/- cytokine release (significant trend
toward reduced IL-6 and TNF- release) may indicate an overall reduced proinflammatory profile.
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Figure 3.2. Cytokine, chemokine and growth factor release 24 hours after exposure to
high-dose LPS treatment is altered in macrophages lacking E2F1. Wildtype (E2F1+/+), E2F1
heterozygous (E2F1+/-) and E2F1 knockout (E2F1-/-) macrophages were treated with 100ng/ml
LPS. 24 hours later, macrophage supernatants were collected and analyzed for production of: (A)
IL-6, (B) TNF-, (C) MMP-3, (D) CCL-2, (E) Osteopontin, and (F) IGF-1 from each genotype
(mean  SEM, n=6-7 per group). Tukey’s post hoc **p<0.01. G) Summary of inflammatory
mediators altered by high-dose LPS treatment represented as fold change from E2F1 +/+ (mean 
SEM). H) Summary of inflammatory mediators altered by high-dose LPS treatment represented
as median fold change from E2F1+/+. In response to high-dose LPS, increased CCL-2 (and
potentially MMP-3) production from E2F1-/- macrophages may represent a dysregulated proinflammatory response.
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Figure 3.3. Macrophages lacking E2F1 exhibit altered levels of baseline cytokine,
chemokine and growth factor release without LPS treatment. Supernatants were collected
from wildtype (E2F1+/+), E2F1 heterozygous (E2F1+/-) and E2F1 knockout (E2F1-/-) macrophages
48hrs after M-CSF removal and used for measurement of inflammatory factors with a customized
R&D Luminex Assay. Production of (A) CCL-2, (B) Osteopontin, and (C) IGF-1 from each
genotype are shown (n=6-7 per group). Tukey’s post hoc * p<0.05, **p<0.01. G) Summary of
inflammatory mediators altered at baseline represented as fold change from E2F1+/+ (mean 
SEM). H) Summary of inflammatory mediators altered at baseline represented as median fold
change from E2F1+/+. Summary data indicate that there may be a mixed pro- and antiinflammatory phenotype at baseline.
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Figure 3.4. Dose-dependent effects of LPS treatment on IL-6, TNF-, MMP-3, CCL-2,
Osteopontin, and IGF-1 release at 24 hours. Wildtype (E2F1+/+), E2F1 heterozygous (E2F1+/-)
and E2F1 knockout (E2F1-/-) macrophages were mock-treated or treated with 50pg/ml or
100ng/ml LPS. 24 hours later, macrophage supernatants were collected and used for
measurement of inflammatory factors with a customized R&D Luminex Assay. Production of (A)
IL-6, (B) TNF-, (C) MMP-3, (D) CCL-2, (E) Osteopontin, and (F) IGF-1 from each genotype are
shown (mean  SEM, n=6-7 per group). Tukey’s post hoc * p<0.05, ** p<0.01, *** p<0.001, ****
p<0.0001. G) Table showing Tukey’s post hoc p-values for each treatment comparison for all
inflammatory mediators shown. Significant p-values are in bold. Significant genotype
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comparisons at (H) 100pg/ml LPS for CCL-2, (I) 50pg/ml and 100ng/ml LPS for Osteopontin, and
(J) baseline, 50pg/ml and 100ng/ml for IGF-1 confirm previous treatment associated differences
determined by separate analyses in Figures 3.1-3.3. Only the absence of baseline differences in
Osteopontin is not congruent with earlier statistical tests.
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Figure 3.5. Compared to high dose LPS, low-dose LPS fails to induce late phase antiinflammatory responses by 48 hours. A) Semi-quantitative PCR gel showing differences in IL6, TNF-, and IL-10 RNA expression between low- and high-dose LPS treatments in wildtype
macrophages treated with 50pg/ml LPS or 100ng/ml LPS for the indicated time in wildtype
(E2F1+/+) macrophages (hours). GAPDH is included as a loading control. IL-10 was only detected
in the high dose condition (n=1). No cDNA control (X). B) IL-10 was not reliably detected by
Luminex assay only in response to 24-hour treatment of 50pg/ml LPS. 24-hour treatment of
100ng/ml LPS induced IL-10 release in supernatants of both E2F1+/+ and E2F1 knockout (E2F1-/-)
macrophage supernatants. Dashed line represents the detection limit (DL) (n=6-7 per group). C)
Semi-quantitative PCR gel showing differences in M1 like markers (Nos2, H2-Ab1, and CD86)
and M2-like markers (CD206, and Arg1) RNA expression between low- and high-dose LPS
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treatments in E2F1+/+ macrophages treated with 50pg/ml LPS or 100ng/ml LPS for the indicated
time (hours). GAPDH is included as a loading control. Arginase 1 (Arg1) is only induced in the
high dose condition starting between 12 and 24 hours (n=1). No cDNA control (X).
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Figure 3.6. Phenotypic M1 markers are unaltered by E2F1 deficiency with and without LPS
treatment after 24 hours. Wildtype (E2F1+/+), E2F1 heterozygous (E2F1+/-) and E2F1 knockout
(E2F1-/-) macrophages were mock-treated or treated with 50pg/ml or 100ng/ml LPS. 24 hours
later, cells were fixed and analyzed for M1-like markers using flow cytometry. A) Gating-strategy.
Cells were gated using forward scatter, side scatter and live-dead dye to identify viable, single
cell events. All cells that were not double-positive for macrophage markers F4/80-APC and
CD11b-FITC were excluded from analysis. Isotype controls (gray) were used to determine the
positive detection range for antibody signals of interest. Positive signal range is represented by
the maroon line. Representative MHCII-PE and CD86-PECy5 positive signals for untreated
(green), 50pg/ml LPS (blue) and 100ng/ml LPS (purple) conditions are shown. B) Representative
counts for E2F1+/+ (black), E2F1+/- (orange), and E2F1-/- (red) of MHCII-PE, CD86-PECy5, and
double positive MHCII and CD86 cells by treatment condition. No genotype differences are
evident. C) Treatment-dependent differences in MHCII expression. D) Treatment-dependent
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differences in CD86 expression. E) Treatment-dependent differences in percentage of double
positive MHCII and CD86 macrophages, indicative of an M1-like phenotype. F) Number of live
cells detected in samples measured before dead cell exclusion for analysis. All graphed data are
represented at median florescence intensity  SEM, n=3-5 per group. Tukey’s post hoc * p<0.05,
** p<0.01, *** p<0.001, **** p<0.0001.
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Figure 3.7. E2F1 knockout inhibits low dose LPS-primed IL-6 and TNF- release and LPSinduced IL-6 transcription. Wildtype (E2F1+/+), E2F1 heterozygous (E2F1+/-) and E2F1 knockout
(E2F1-/-) macrophages were mock-treated or treated with 50pg/ml LPS to prime macrophages. 4
hours after treatment, media was replaced and macrophages were treated with 100ng/ml LPS.
Supernatants were collected 4 hours later and analyzed by a customized R&D Luminex assay. A)
IL-6 release from unprimed and low-dose LPS primed E2F1+/+, E2F1+/-, and E2F1-/- macrophages
(n=3-4 per group). (i) IL-6 release from low-dose primed E2F1-/- macrophages is reduced
compared to E2F1+/+ and E2F1+/- macrophages 4 hours after high dose LPS treatment. (ii) IL-6
release from unprimed E2F1-/- macrophages is reduced compared to E2F1+/+ macrophages 4
hours after high dose LPS treatment. B) TNF- release from unprimed and low-dose LPS primed
E2F1+/+, E2F1+/-, and E2F1-/- macrophages (n=3-4 per group). (i) TNF- release from low-dose
primed E2F1-/- macrophages is reduced compared to E2F1+/+ and E2F1+/- macrophages 4 hours
after high dose LPS treatment. (ii) TNF- release from unprimed E2F1-/- macrophages 4 hours
after high dose LPS treatment. C) QPCR for RNA expression of IL-6 in response to mock,
50pg/ml or 100ng/ml LPS at 4hrs without priming in E2F1 +/+ and E2F1-/- mice. IL-6 RNA
expression is significantly reduced in response to low dose LPS treatment and trending toward
being reduced in response to high dose LPS treatment (n=3 per group). D) QPCR for RNA
expression of TNF- in response to mock, 50pg/ml or 100ng/ml LPS at 4hrs without priming in
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E2F1+/+ and E2F1-/- mice. TNF- RNA expression is not significantly reduced in response to low
dose or high dose LPS treatment (n=3-4 per group). Tukey’s post hoc * p<0.05, **p<0.01,
***p<0.001.
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Figure 3.8: Differences in circulating pro- and anti-inflammatory factors in middle-aged
E2F1 knockout mice. Plasma was obtained from 14-month-old male wildtype (E2F1+/+) and
E2F1 knockout (E2F1-/-) mice for inflammatory mediator analysis by R&D Luminex assay. Plasma
levels of (A) IL-6, (B) TNF-, (C) MMP-3, (D) CCL-2, (E) Osteopontin, and (F) IGF-1 from each
genotype are shown (mean  SEM, n=5 per group). Since IL-6, TNF- and IL-13 level bordered
the line of detection, these results are represented as mean fluorescence intensity instead of
pg/ml. CCL-2 and IL-13 trended toward significant increases in E2F1-/- plasma, Tukey post-hoc pvalues are shown.
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CHAPTER 4: DISCUSSION

Results from Chapter 2 question the belief that E2F1 is integral to mature neuron
health [321, 339] and results from Chapter 3 suggests that E2F1 promotes proinflammatory responses and anti-inflammatory responses in macrophages.
Whether E2F1 is necessary for anti-inflammatory responses has not been clear
due to the role of pro-inflammatory cytokines in inducing anti-inflammatory
responses [193, 292, 310]. Yet, E2F1 has been reported to associate with key
proteins or promoters of genes involved in anti-inflammatory cascades [142,
163]. In this chapter, we will discuss the implications of our findings in detail and
propose future studies that should further our understanding of E2F1 in neurons
and inflammatory processes in both health and disease.

Role of E2F1 in neuronal health and synaptic maintenance
In contrast to the transcription-deficient E2F1tm1/tm1 mice, we found that E2F1
knockout in mice did not reduce adult brain weight or the expression of a subset
of post-synaptic proteins associated with synaptic plasticity. Additionally, the
E2F1-/- mice did not exhibit increased PCNA expression associated with cell cycle
reentry or alter novel object recognition memory. Outside of the CNS, our E2F1 -/mice recapitulated some of the E2F1tm1/tm1-related phenotypes, including
testicular atrophy and exocrine gland dysplasia. However, two other phenotypes
associated with the E2F1tm1/tm1 were absent: reduced body weight and thalamic
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hyperplasia. Some of the reasons which may account for these differences are
differential involvement of E2F family members, effects of the retained
neocassette, and expression of the remaining E2F1 gene products. The
E2F1tm1/tm1 mice retain exons 1, 5, 6, and 7, the latter of which encodes the Rb
binding domain [232], and expression of the residual E2F1 protein may alter
E2F3 activity by sequestering pRb from E2F3, thereby increasing its basal
activity. Alternatively, retention of the neocassette in E2F1tm1/tm1 mice may lead to
a neurotoxic phenotype independent of E2F1. There may also be compensatory
changes in the expression of E2F1 family members that compensate for the loss
of E2F1, which has been previously described in other tissues [169, 322, 355]. In
any case, phenotypes initially attributed to E2F1-dependant functions may be
inaccurate, and may actually represent phenotypes associated with the loss of
E2F1 transcriptional activity in addition to the dysregulation of E2F-specific
activity and/or the expression of the neocassette (Chapter 2).

The initial goal of this thesis was to identify the roles of E2F1 in synapse health
and maintenance and learning and memory. Although our data suggest that
E2F1 is dispensable for novel object recognition memory, E2F1 may still play a
role in synapse maintenance and other forms of memory. High homology
between E2F domains may allow another E2F family member to compensate for
the loss of E2F1 [134, 169, 187, 322]. Compensatory mechanisms, which often
occur between proteins that share similar structure or function, can establish
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during germline maturation or embryonic development, resulting in adaption to
mutations [88]. Some studies indicate that, in contrast to conditional knockouts,
germline/constitutive mutants exhibit reduced or absent phenotypes [88, 282].
One such example includes studies in pRb, which showed that pRb-deficient
mouse embryonic fibroblasts (MEFs) isolated from a germline mutant exhibited
mild resistance to G0 arrest whereas the acute knockout of pRb in conditional
MEFs displayed higher resistance to G0 arrest, with more than twice as many
conditional pRb-mutant MEFs synthesizing DNA compared to the MEFs from the
germline mutant [282]. The pRb-family protein p107 was upregulated in pRb
germline mutants compared to the pRb conditional knockouts, suggesting that
this compensatory upregulation was sufficient to prevent cell cycle reentry and
mute the phenotype observed in pRb germline MEFs [282]. However,
compensation sometimes occurs regardless of whether the mutation happens in
the germline [276]. Therefore, the conditional E2F1 mouse line that our E2F1
knockout was based on can be a useful comparative tool to evaluate E2F1specific functions that escape compensatory mechanisms in different cell types.

Our initial attempts at developing a neuron-specific knockout by breeding B6.CgTg(Syn1-Cre)671Jxm/J (Syn1-Cre+) mice with our conditional E2F1 mice did not
meet our expectations for behavioral studies. Although other studies indicated
that Syn1-cre should express in enough neurons to result in a 30%-70%
reduction in the targeted gene’s protein of interest [7, 49, 328], our results
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suggest that synapsin-driven Cre is not as universally expressed and/or that Cremediated knockout was not as efficient as expected in older mice (Fig. 4.1). As
Cre efficiency can depend on the size of the gene that is excised [66, 192, 372],
future studies will attempt to minimize the size of the excised gene by first
excising the FRT-flanked neocassette, which will be accomplished by breeding
E2F1fx/fx mice with flippase-expressing mice. Excision of the neocassette would
shorten the loxp-flanked gene by approximately 2 kb, a little more than 25% of its
original length, and would prevent the development of neocassette-related
phenotypes in E2F1fx/fx mice. However, other factors such as chromosomal
location and epigenetic modification might have also contributed to differences in
recombination rates [192, 196]. Therefore, future studies will focus on identifying
a Cre-based strategy that maximizes E2F1 knockout in a brain region of interest,
such as the hippocampus. One such strategy is using adenovirus associated
viral (AAV) vectors to deliver green fluorescent protein (GFP) or Cre to excise
floxed genes in specific brain regions through stereotaxic injection [161].
Breeding E2F1fx/fx mice with a ROSA26 reporter mouse will allow us to observe
the rate of Cre recombination in response to AAV-Cre injection at a known Creresponsive locus [301] and to compare it to the rate of E2F1 excision in our
E2F1fx/fx mice. We can test a variety of AAV-Cre constructs under the control of
different promoters to find a suitable neuron-specific/selective strategy [149,
161]. Following the successful development of a neuron-specific knockout, the
evaluation of synaptic protein expression will determine if conditional and
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temporally restricted knockout in neurons produce the effects that we have
observed in our knockout mouse. Evaluating conditional E2F1 knockout in the
cerebellum will also aid in determining if E2F1 is necessary to maintain the
quiescent state of cerebellar neurons. Both studies will clarify the role of E2F1 in
mature neurons.

Regardless of whether compensation accounts for the absence of synaptic
protein perturbation in our E2F1-/- mice, we could focus on identifying a
mechanism that E2Fs share in the regulation of synaptic protein expression. As
mentioned previously, the E2F DNA-binding domain can also bind RNA [147].
Given that RNA-binding proteins contribute to local protein synthesis required for
rapid synaptic membrane organization and surface receptor distribution [291], it
is possible that E2Fs may stabilize RNAs involved in synapse formation. RNA
immunoprecipitation using E2F antibodies in combination with RNA-seq may
provide insights into the non-cell-cycle-related roles of E2Fs in synaptic
regulation. Alternatively, E2Fs may regulate calcium-dependent signaling that
could influence LTP. The cytoplasmic overexpression of an E2F1-like protein
without transcriptional activity but an intact C-terminal domain is able to induce
calpain activation in HEK293 cells [308], and E2F1 interacts with necdin [315],
which is involved in calcium regulation through its interaction with NEFA [314].
Therefore, E2F1 may regulate the association of necdin with NEFA to alter
calcium-dependent signaling. Whether necdin binds to other E2Fs has not been
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studied; however, necdin binds to the same location as pRb in E2F1 [315], and
other E2Fs may also play a role in necdin-NEFA regulation of calcium efflux from
the endoplasmic reticulum (ER) [314]. Future studies should aim to identify
interactions between necdin-NEFA and E2F family members and explore the
impact of overexpression of E2F mutants on cytosolic calcium levels in the
presence of compounds that alter ER calcium efflux, such as caffeine [314].

E2F1 in inflammation

Given the conflicting evidence on E2F1’s role in inflammation, we set out to
determine if E2F1 loss might contribute to the development of cognitive
impairment in E2F1tm1/tm1 mice. Since we did not detect cognitive impairment in
our new E2F1-/- mouse model, we are unable to establish if our results can be
used to interpret the role immune cells might play in the development of the
neurocognitive phenotype observed in the E2F1tm1/tm1 mice. However, using our
mouse model, we found that E2F1 loss in macrophages reduced early
proinflammatory cytokine expression in response to LPS. In E2F1-/macrophages, the IL-6 RNA expression was reduced in response to low-dose
LPS and trended toward being reduced in response to high-dose LPS, and IL-6
release was reduced in unprimed and low dose-primed E2F1-/- macrophages
treated with high-dose LPS. On the other hand, the cytokine profile of aging
E2F1-/- mice suggests that circulating levels of TNF- and IL-6 are unaltered and
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that CCL-2 and IL-13 levels are increased with a trend toward significance.
These alternations could be due to other cell types in circulation or due to an
unknown inflammatory condition (Chapter 3). The aging cytokine profile suggests
that an inflammatory process may be occurring more frequently in the E2F1-/mice. Therefore, to eliminate the potential contribution of macrophageindependent E2F1-/--related pathologies, such as exocrine dysplasia, on immune
responses including E2F1-/- macrophage polarization and inflammatory activity, it
may be more prudent to study in vivo macrophage polarization and
proinflammatory activity in the context of a cell-type specific model. However,
Cre-drivers targeting macrophage populations often target dendritic cells, mast
cells, and monocytes as well [295]. Future studies using our conditional E2F1
mouse model and the tamoxifen-inducible CXC3R1-Cre mouse model will
evaluate whether E2F1-/- macrophages are activated to a lesser extent in aged
mice by examining different tissue-resident macrophage populations in tandem
with the evaluation of whether dendritic cells, mast cells, or monocytes with E2F1
deletion contribute to CCL-2 or IL-13 production observed in circulation.

Since E2F1tm1/tm1 mice injected with LPS exhibited reduced proinflammatory
cytokine release at three hours [343] and given that E2F1 loss impairs
transcription of proinflammatory cytokines regulated by NF-B [189], further
investigation into E2F1’s role in neuroimmune cells may be warranted. Microglia
have been suggested to contribute to neurodegeneration through activation by
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neurodegenerative disease-associated protein aggregates and dying neurons,
leading to NF-B-mediated transcription of proinflammatory cytokines that further
activate astrocytes and result in additional neuronal damage [20, 39, 188]. This
process can lead to excitotoxicity since (1) activated microglia release glutamate
[23], (2) activated astrocytes release more glutamate [123], (3) proinflammatory
cytokines inhibit astrocyte-mediated glutamate reuptake [137], and (4) excess
glutamate further inhibits astrocytic glutamate metabolism, thereby propagating
glutamate receptor mediated excitotoxicity [145, 249]. Microglial priming by LPS
has also been shown to worsen A accumulation in an AD mouse model [346].
Therefore, future studies evaluating whether E2F1 loss in microglia alters
cytokine release associated with A treatment may provide a new potential
avenue for cell type-specific treatment in AD.

However, we also found treatment-dependent effects of low-dose and high-dose
LPS on the proinflammatory profiles of macrophages. The E2F1-/- macrophages
appeared to release lower levels of proinflammatory cytokines IL-6 and TNF- in
response to low-dose LPS throughout the 24-hour treatment course, which was
not observed in E2F1-/- macrophages in response to high-dose LPS at the 24hour time point. In fact, CCL-2 was increased at 24 hours in E2F1-/macrophages, with a potential increase in MMP-3 levels as well. The induction of
IL-10 by high-dose LPS, but not low-dose LPS, may indicate that E2F1 plays
dual roles in macrophages and macrophage-like cell inflammation by inhibiting
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the proinflammatory as well as the anti-inflammatory response. A delayed antiinflammatory response by E2F1 knockout might be due to reduced
proinflammatory cytokine release at an early timepoint or due to reduced
response of anti-inflammatory pathways dependent on E2F1 (Chapter 3). One
such pathway that might be regulated by E2F1 involves STAT3 [142]. E2F1
associates with several STAT3-responsive genes. Although the role of E2F1 in
regulation of STAT3 genes was not studied, E2F1 associates with several
STAT3-responsive genes and has been suggested to be required for the quick
transcription of select STAT3-dependant genes in IL-10-treated macrophages.
These genes include STAT3, SOCS3, TCF4, PTPN1, JUNB, CMTM6, EIF1A,
FOXK1, NFKBIZ, PIH1D1, SETMAR, SKAP2, AND SMARCD2 [142]. The
quantification of the expression of these genes in IL-10-treated E2F1+/+ and
E2F1-/- macrophages by qPCR together with the examination of the expression of
STAT3-dependent genes lacking E2F binding sites may identify a novel
mechanism by which E2F1 is necessary for anti-inflammatory response.

Impaired IL-6 release, which we observed at an early timepoint after LPS
exposure, and impaired STAT3 activation can reduce the development of
tolerance [54, 374]. Microglia tolerance, i.e., suppressed immune activation in
response to subsequent stimulus, may also be required for reducing Apathology. In an AD mouse model, LPS priming of microglia led to increased A
accumulation and astrocyte activation; however, induction of tolerance was able
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to reduce A accumulation and astrocyte activation [346]. The analysis of H3K27
acetylation peaks revealed that E2F motifs were acetylated significantly more in
the tolerance condition than in the priming condition in the AD mouse model
[346]. Therefore, although E2F1 loss inhibited LPS-primed macrophage release
of proinflammatory cytokines with the subsequent high-dose LPS treatment, it
may also be possible that E2F1 is necessary for the development of tolerance.
Further examination of the mechanism by which E2F1 mediates priming and
tolerance-associated cytokine release should provide more information on the
role of E2F1 in innate immune memory. Examination of these processes in a
mouse model will provide better information on the effect of E2F1 loss
specifically in microglia given that the CNS microenvironment is essential for
maintaining physiologically relevant microglial identity [28]. Generating and using
microglia-specific E2F1-/- mice to address the question of how E2F1 loss in
microglia affects neuroinflammation and A accumulation, both with and without
tolerance induction, should yield insight into whether E2F1 loss in microglia can
alter the progression of AD pathology.

Finally, we found that 50% of the E2F1-/- mice exhibited bone marrow
megakaryocytic hyperplasia. This phenotype appeared in three of the four male
E2F1-/- mice and in one of the four female E2F1-/- mice (Chapter 2). The cause of
this phenotype is not clear; however, increased megakaryocyte differentiation in
bone marrow suggests and increased platelet demand, which can result from
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increased platelet destruction and sequestration or from simply an increased
need due to tissue damage [325]. There was no evidence that the observed
megakaryocytic hyperplasia was a result of cancer or autoimmune disease;
therefore, this finding might indicate that E2F1 loss is a risk factor for the
development of a platelet disorder. Additionally, the lack of splenomegaly in
E2F1-/- mice suggests that increased platelet demand was not due to platelet
sequestration (Chapter 2). 6–8-week-old E2F1tm1/tm1 mice exhibited reduced
transcription of coagulation cascade genes and increased prothrombin, activated
partial thrombin, and fibrin-split products in response to LPS; however, no
differences were observed in saline-treated animals [343]. Although there were
no differences in young saline-treated E2F1tm1/tm1 mice, it does not mean that a
defect in the clotting system does not exist in older mice lacking E2F1. Further
investigation of platelet dynamics in male and female E2F1-/- mice as they age
should clarify if and how E2F1 loss alters clotting and the coagulation cascade
with age and if the phenotype is more prevalent in male mice. If E2F1 loss alters
the coagulation cascade with age, identification of cell types and/or related agingassociated physiological processes should highlight new pathways that inform
therapeutic development to prevent aberrant clot formation.

E2F1 in cell cycle reentry-mediated neurodegeneration
A secondary aim of this thesis was to determine whether neuron-specific
knockout of E2F1 could be considered a therapeutic option for the treatment of
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neurodegenerative disease. The overwhelming evidence on neuronal cell cycle
reactivation during neurodegeneration comes from studies investigating the
pathology of AD. Cell cycle protein expression is detected early during the course
of disease wherein some neurons reenter the cell cycle and survive as tetraploid
neurons [198, 220]. The neurological outcome of tetraploid neurons is not entirely
understood; however, studies indicate that these neurons are more sensitive to
toxic stimuli than diploid neurons and that reducing their incidence may improve
long-term memory in aging rodents [13, 24, 99, 198]. Furthermore, cell cycle
reactivation in neurons by overexpression of oncogenes causes A and tau
pathology [214, 248].

As a regulator of the G1/S transition during cell cycle, E2F1 ablation may be able
to prevent cell cycle reentry and limit A pathology [1]. However, whether E2F1
loss is sufficient to prevent cell cycle reentry, given that E2F2 and E2F3 can also
contribute to cell cycle activation [52, 53, 186, 277] is unknown. Given that our
E2F1-/- mice did not exhibit any overt pathology in mature neurons, it is worth
considering whether E2F1 knockout can prevent cell cycle re-entry and A and
tau pathology in the context of a cell cycle activator. A first step would be to
mimic a study by McShea et al. [214] and use adenoviruses expressing RAS (HRAS61L) to induce cell cycle reentry in wildtype and E2F1-deficient primary
neuronal cultures, both from constitutive knockouts and shRNA-mediated
knockdown to account for any differences due to compensation by other E2F
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family members. If reduced DNA replication is observed in E2F1 deficient
neurons, tau pathology can be quantified as the next step. If E2F1 loss is able to
reduce both measures, the next step can be to evaluate whether E2F1 loss
prevents adenovirus (H-RAS1L)-induced cell cycle activation in vivo. These
experiments can clarify whether E2F1 prevents one of the pathologies observed
in AD and whether it is worth identifying an AD mouse model where we can
determine how our neuron-specific knockout affects learning and memory.

Technical challenges associated with examining E2F1
While attempting to show that our E2F1-/- mice did not express E2F1 using
immunoblotting, we discovered that the 60-kd immunoreactive band detected by
the E2F1 antibody (KH95) was not E2F1. The protein detected by this antibody
was expressed at similar levels in the E2F1+/+ and E2F1-/- mice. This
immunoreactive band exhibited a predominantly cytoplasmic localization by
immunoblotting, indicating that it is possible that reports of cytoplasmic
localization [321, 342, 354], and perhaps synaptosomal localization [321] of E2F1
may be false assumptions (Fig. 4.2A). Further, the immunohistochemistry of
formalin-fixed, paraffin-embedded brain tissue samples failed to identify a
specific E2F1 signal; however, it is unclear whether this is also true in frozenfixed tissue. Although the KH95 antibody can recognize transfected E2F1, it
appears that this antibody strongly binds another protein that has yet to be
identified. Future experiments will aim to identify a specific E2F1 antibody for
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brain tissue, and localization analyses will need to be repeated to determine if
E2F1 is primarily cytoplasmic in the brain and if it is located in synaptosomes.

Since the 60-kd band was not specific to E2F1, we tested whether the stable
calpain-cleavage product of E2F1, that is associated with excitotoxicity-mediated
neuronal death and is detected in the brains of HIV-infected patients with
neurocognitive impairment [377], was indeed E2F1. Since the KH95immunoreactive calpain cleavage product was detected in the E2F1-/- mice, we
concluded that the previously reported calpain-cleaved E2F1 was actually
another calpain cleavage product (Fig. 4.2B). While it is clear that E2F1 is
cleaved by calpain in cells overexpressing E2F1, the formerly identified “calpaincleaved E2F1” may not be associated with E2F1 or an alternate mode of E2F1mediated cell death. We could not consistently immunoprecipitate the 60-kd
nonspecific band or the calpain cleavage product using KH95-conjugated
columns from any neuronal fraction (Fig 4.3B). The BLAST analysis of the KH95
antigen sequence indicates that it is most likely another E2F family member.
Therefore, we will test whether other E2F antibodies can recognize the 60-kd
protein and it’s calpain-cleaved product. If E2F antibodies targeting the DNAbinding domain, a domain shared by all E2Fs [91, 218, 327], are unable to detect
either protein, we may try to identify the protein using 2D-DIGE in combination
with mass spectrometry. These studies are aimed to identify the potential novel
roles for other E2F family members, novel calpain cleavage products, and novel
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functions of non-E2F proteins in neurodegeneration, excitotoxicity, and neuronal
death.

In summary, a thorough understanding of the roles that E2F1 plays in neurons
should start with reevaluating its localization. Since protein localization
determines function [141], confirming whether E2F1 is predominantly cytoplasmic
or nuclear or is otherwise located in synaptosomes [296, 321, 342, 354] will
dictate approaches to identify E2F1’s role in mature neurons. Although we did
not observe any neuronal pathologies in our E2F1-/- knockout mice,
compensation by E2F family members may have complicated the identification of
E2F1-specific roles [169, 355]. Conditional knockouts or shRNA are vital tools for
the identification of E2F1-dependant functions before compensatory mechanisms
can be established [88, 276]. Further investigation of E2F1 as a cell type-specific
therapy depends on both the lack of development of a phenotype in its absence
and the ability to demonstrate significant improvement in a disease model [139].
Studies that can demonstrate that E2F1 knockout reduces cell cycle reentry in
the presence of a cell cycle inducer or moderates the release of pro-inflammatory
cytokines from microglia in neuroinflammatory disease models may yield novel or
adjunctive treatment approaches in a field with clear unmet needs [312, 367].
Based on published studies [84, 92, 142, 324, 343, 346] and our preliminary data
(Chapter 3), it is evident that the role of E2F1 in inflammation remains unclear.
Yet undiscovered roles of E2F1 in priming and tolerance and the inability to
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target E2F1 in a specific immune cell type may impinge on successful outcomes
during these attempts.
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Figure 4.1. Technical difficulties in validating the neuron-specific E2F1 mouse model
(E2F1fx/fx;Syn1-Cre+). A) Variable staining for Cre in 14-month-old neuron-specific E2F1 knockout
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mice and E2F1. Sections from 2 different mice (Bio Rep 1 and Bio Rep 2) that were Cre positive
were stained with Cre antibody (D7L7L) to identify cre positive (brown) neurons. Sections that
were stained from Cre negative mice indicate that the antibody sometimes lightly labels
cytoplasms in neurons (data not shown). Staining from Bio Rep 1 shows that Cre positive
neurons are infrequent in the cortex and even less frequent in the hippocampus. Staining from
Bio Rep 2 shows vastly more Cre positive neurons in the cortex, and few in the hippocampus.
Images were taken from cortical areas showing highest Cre-positive staining, other areas of the
cortex have fewer Cre positive neurons. These data suggest that any behavioral evaluations that
produce no results would be difficult to interpret due to the low level and variability of Cre
expression among mice. B) Variable detection of E2F1 RNA in neuron-specific knockout mice.
Attempts to detect differences in E2F1 RNA expression in 2 biological replicates (Bio Rep 1 and
Bio Rep 2) between neuron-specific knockout mice (E2F1fx/fx; Syn1-cre+) and floxed E2F1
(E2F1fx/fx) littermates using E2F1 RNAscope probe (red) suggests that quantification of E2F1
RNA expression may be complicated by low Cre expression, Cre efficiency or variability of the
assay itself. Some floxed neurons aren’t positive, even without Cre, indicating that absence of
E2F1 RNA expression in neurons in neuron-specific knockouts may not necessarily imply
successful Cre recombination. Neuron-specific knockout Bio Rep 1 does not appear to have
reduced E2F1 RNA expression, while neuron-specific knockout Bio Rep 2 doe appear to have
reduced E2F1 RNA expression. This implies that the model may be working but as the reduced
expression far extends the number of Cre positive neurons observed in Bio Rep 2 in panel A,
these results may be a combination of successful Cre recombination and sensitivity of the assay.
So far, it appears that dual ISH/IHC with the Cre antibody is incompatible. All tissue sections were
counterstained with hematoxylin (blue).
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A)

B)

C)

Figure 4.2. E2F1(KH95) antibody binds a protein that is not E2F1 in brain, and features
qualities reported to be associated with E2F1: Cytoplasmic localization and cleavage by
calpain. Whole brains from wildtype (E2F1+/+), and E2F1 knockout (E2F1-/-) mice were
homogenized and separated into cytosolic (Cyto), membrane bound (Memb) and nuclear (Nuc)
fractions. Equal amounts of protein (5g) were loaded from each fraction. A) Representative blot
showing that KH95 detects a protein in E2F1-/- mice that is predominantly cytoplasmic, suggesting
that these bands are not specific to E2F1 (n=3). E2F1 has been reported to be 70kd, 60kd, 53kd,
or 47kd by a variety of western blot antibody manufacturers, and it appears that nonspecific
bands are present at all these sizes. GAPDH was used to confirm cytoplasmic localization. Lamin
B1 was used to confirm nuclear extraction. Fast green protein stain was used as a loading
control. B) Equal amounts of protein from E2F1+/+ and E2F1-/- brain cytosolic, membrane, and
nuclear fractions were incubated with and without recombinant calpain-1 for four hours at 37oC. In
all E2F1-/- fractions, a stabilized calpain cleaved product was present, indicating that the
previously reported calpain-cleaved E2F1 may not be E2F1, but is cleaved by calpain (n=3). spectrin is a well-recognized calpain substrate and was included as a positive control for calpain
activity. Incomplete digestion occurred in the cytosolic fraction (as detected by residual GAPDH),
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showing an intermediate cleavage product detected by KH95. Zyskind et al. reported that two
cleavage events were required to produce the stabilized calpain-cleaved E2F1, suggesting that
these KH95-immunoreactive bands (~60kd, ~57, ~55kd) bands are the same as what was
previously understood to be E2F1 or lower-molecular-weight (LMW)-E2F1 in brain. Lamin B1 was
used to identify nuclear fractions. Fast green stain was used as a loading control for untreated
fractions, but also serves to show how total protein changes between ~65kd and ~55kd with
calpain cleavage. C) Immunoprecipitation of E2F1 from HEK293 (HEK), the cytosolic fraction
from E2F1+/+ brain (B.C) and the membrane bound fraction of E2F1 +/+ brain (B.M.). Normal Mouse
IgG control and E2F1(KH95) antibody were conjugated to immunoprecipitation columns using
and Epoxy dynabeads coupling kit (Thermofisher). Following 24-hour incubation with HEK, B.C.
and B.M. at 4oC, columns were washed and bound samples were eluted with acidic elution buffer.
Samples were loaded in gels for immunoblotting using the same KH95 antibody. Conjugated
antibodies should have remained bound but antibody leakage did occur (faint band in all samples
around 55kd). No KH95 positive signal was detected in Brain Cytoplasmic fractions. KH-95
immunoreactive proteins (53kd and 47kd) were identified in elute from HEK293 columns, and we
have no reason to suspect that they are not E2F1. Thermofisher KH95 validation data suggest
that E2F1 is ~53kd. This suggests that the E2F1 (KH95) antibody recognizes E2F1, but also
other unknown proteins in the brain. Non-specific binding of KH95 may only occur in immunoblot,
or at an extremely low frequency with immunoprecipitation.
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